Effects of Cognitive Functioning on Diabetes Self-Care in Adults with Type 2 Diabetes Mellitus by Monette, Michelle
University of Windsor 
Scholarship at UWindsor 
Electronic Theses and Dissertations Theses, Dissertations, and Major Papers 
3-25-2018 
Effects of Cognitive Functioning on Diabetes Self-Care in Adults 
with Type 2 Diabetes Mellitus 
Michelle Monette 
University of Windsor 
Follow this and additional works at: https://scholar.uwindsor.ca/etd 
 Part of the Psychology Commons 
Recommended Citation 
Monette, Michelle, "Effects of Cognitive Functioning on Diabetes Self-Care in Adults with Type 2 Diabetes 
Mellitus" (2018). Electronic Theses and Dissertations. 7465. 
https://scholar.uwindsor.ca/etd/7465 
This online database contains the full-text of PhD dissertations and Masters’ theses of University of Windsor 
students from 1954 forward. These documents are made available for personal study and research purposes only, 
in accordance with the Canadian Copyright Act and the Creative Commons license—CC BY-NC-ND (Attribution, 
Non-Commercial, No Derivative Works). Under this license, works must always be attributed to the copyright holder 
(original author), cannot be used for any commercial purposes, and may not be altered. Any other use would 
require the permission of the copyright holder. Students may inquire about withdrawing their dissertation and/or 
thesis from this database. For additional inquiries, please contact the repository administrator via email 
(scholarship@uwindsor.ca) or by telephone at 519-253-3000ext. 3208. 
 
 
 
Effects of Cognitive Functioning on Diabetes Self-Care in Adults with Type 2 Diabetes 
Mellitus 
By 
Michelle (Mich) C. E. Monette 
 
A Dissertation  
Submitted to the Faculty of Graduate Studies  
through the Department of Psychology 
in Partial Fulfillment of the Requirements for 
the Degree of Doctor of Philosophy 
 at the University of Windsor 
 
 
Windsor, Ontario, Canada 
2018 
© 2018 Michelle C. E. Monette 
 
  
Effects of Cognitive Functioning on Diabetes Self-Care in Adults with Type 2 Diabetes 
Mellitus 
By 
Michelle (Mich) C. E. Monette 
APPROVED BY: 
 
__________________________________________________ 
N. Anderson, External Examiner 
University of Toronto 
 
__________________________________________________ 
L. Patrick 
Department of Nursing 
 
__________________________________________________ 
L. Buchanan 
Department of Psychology  
 
__________________________________________________ 
A. Baird 
Department of Psychology  
 
__________________________________________________ 
D. Jackson, Advisor 
Department of Psychology  
 
 
        February 9, 2018 
 iii 
 
DECLARATION OF ORIGINALITY 
 
I hereby certify that I am the sole author of this dissertation and that no part 
of this dissertation has been published or submitted for publication. 
I certify that, to the best of my knowledge, my dissertation does not 
infringe upon anyone’s copyright nor violate any proprietary rights and that any 
ideas, techniques, quotations, or any other material from the work of other people 
included in my dissertation, published or otherwise, are fully acknowledged in 
accordance with the standard referencing practices. Furthermore, to the extent that 
I have included copyrighted material that surpasses the bounds of fair dealing 
within the meaning of the Canada Copyright Act, I certify that I have obtained a 
written permission from the copyright owner(s) to include such material(s) in my 
dissertation and have included copies of such copyright clearances to my appendix.  
I declare that this is a true copy of my dissertation, including any final 
revisions, as approved by my dissertation committee and the Graduate Studies 
office, and that this dissertation has not been submitted for a higher degree to any 
other University or Institution. 
 
  
 iv 
 
 
ABSTRACT 
The present investigation comprised exploratory prospective and 
retrospective studies of the relationships between cognitive functioning, Diabetes 
Self-Management Behaviour (DSMB) completion, and diabetes-related and 
general Quality of Life (QoL). A prospective study explored the relationships 
among these variables in a sample of 26 adults over the age of 40 with Type 2 
Diabetes Mellitus (T2DM). Measures used included validated neuropsychological 
tests assessing multiple cognitive domains and abilities, three self-report measures 
of DSMB, and the Audit of Diabetes Dependent Quality of Life (ADDQoL). 
Increased performance on a phonemic verbal fluency task was significantly related 
to better DSMB behaviour completion (r = .577, p = .002, r
2 
= .333). There were 
many significant relationships between a self-report measure of executive 
functioning and DSMB completion. Processing speed and objective and self-report 
measures of executive functioning correlated significantly with general QoL. An 
archival study investigated these relationships using data from the Health and 
Retirement Study (HRS). The Telephone Interview for Cognitive Status (TICS) 
assessed cognitive functioning, and measures of DSMB completion and impact of 
diabetes on life from the 2003 HRS diabetes survey were used to assess DSMB 
completion and QoL outcome variables in a sample of 776 community dwelling 
adults with T2DM. Cognitive functioning as measured by the TICS did not 
account for significantly more variance and did not significantly predict DSMB 
completion over and above demographic and health-related variables for any of the 
domains of DSMB completion. Cognitive functioning and a total score of 
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difficulty with DSMB completion accounted for significantly more variance in 
diabetes impact over and above demographic and health-related variables when 
A1C was (F(2, 503) = 9.846, p < .001) and was not (F(2, 700) = 13.282, p < .001) 
included in the model. However, cognitive functioning was not a significant 
predictor of diabetes impact in either model. Difficulty with DSMB completion 
was a significant predictor in both models and thus accounted for most of the 
increase in variance explained above and beyond that explained by the 
demographic and health-related variables. The implications of the results for future 
studies of the relationships between cognitive functioning, DSMB completion, and 
QoL are discussed, as well as the strengths and limitations of the prospective and 
archival studies. 
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CHAPTER I 
INTRODUCTION AND REVIEW OF THE LITERATURE 
 Type 2 Diabetes Mellitus (T2DM) is a chronic disease affecting primarily adults 
and older adults (Government of Canada, 2011). Given the chronicity of the disease and 
the daily management required to stave off the complications of the disease, T2DM 
treatment regimens include a number of Diabetes Self-Management Behaviours (DSMB). 
These DSMB need to be completed independently by the individual with T2DM while 
under the supervision of a physician and ideally, but not always, a diabetes treatment 
team (Bailey & Kodack, 2011). The DSMB include taking medication (pills and/or 
insulin), blood glucose monitoring, following a healthy diet, maintaining physical 
activity, executing regular foot care, and attending follow-up appointments. The goal of 
these behaviours is to achieve good control of the disease as measured by A1C levels (the 
three month average measure of blood glucose levels) and the postponement or 
prevention of disease complications (Mulcahy et al., 2003).  
Adherence to T2DM treatment regimens is notoriously poor (Ahola & Groop, 
2013; Bailey & Kodack, 2011; Gillani, 2012) due to the many barriers to adherence, for 
instance medication costs, diabetes knowledge and health literacy levels, and mental 
health (Emery et al., 2010). A new barrier that has emerged in the past decade that has 
not received the same level of empirical investigation as other barriers is poor cognitive 
functioning (Primozic et al., 2012). It is now known that, on average, groups of 
individuals with T2DM have small to moderate deficits in all studied cognitive abilities 
and domains when they are compared to groups of individuals without T2DM (Monette 
et al., 2014; Palta et al., 2014; van den Berg et al., 2009). 
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 The first goal of the present investigation was to determine the relationship 
between cognitive functioning and DSMB completion. The second goal of the current 
study was to determine the impact of cognitive functioning and DSMB completion on 
diabetes-related quality of life (QoL). The answers to these questions from the current 
investigation and from the research literature can be used to improve T2DM management 
and improve QoL in individuals with T2DM.  
The following sections review the previous literature that is most relevant to these 
two questions. The review of the literature will encompass a brief description of T2DM, a 
review of the most up to date findings on cognitive functioning in T2DM, definitions and 
descriptions of adherence and barriers to the completion of DSMB, previous work on the 
relation between cognitive functioning and DSMB completion and between DSMB 
completion and QoL, and will conclude with a description of the present study.  
Description of T2DM 
T2DM is a chronic metabolic disorder characterized by hyperglycemia (elevated 
blood glucose levels, Codario, 2010). Hyperglycemia results from a gradual process in 
which the body becomes incapable of absorbing glucose due to body tissues becoming 
insulin resistant. At first, the body can maintain fasting blood glucose levels in the normal 
or non-diabetes range (4.0 to 6.0 mmol/l) by producing insulin in excess 
(hyperinsulinemia). When the pancreatic cells become exhausted and die and can no 
longer produce insulin in excess, glucose intolerance (pre-diabetes) develops. At this 
point fasting blood glucose ranges from 6.1 to 7.9 mmol/l. T2DM is diagnosed when 
fasting blood glucose levels surpass 7.9 mmol/l (Codario, 2010).  
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The development of T2DM is related to increasing age, poor diet, physical 
inactivity, and obesity (Pradhan, 2007). There is also evidence for a genetic 
predisposition towards T2DM (Moore & Florez, 2008). However, a complete 
understanding of the gene-environment and gene-gene interactions does not yet exist 
(Herder & Roden, 2011). At least 36 diabetes-associated genes have been identified; yet, 
only ~10% of the heritability of T2DM can be explained (Herder & Roden, 2011). 
Prevalence rates of diabetes across ethnicities (gene-environment interaction) vary with 
some as low as 1% in rural Asian populations and some as high as 30-50% in Pima 
Indian and Polynesian populations (Moore & Florez, 2008). The child of a parent with 
diabetes has a 40% chance of developing diabetes compared to a population risk of 
approximately 7%; if both parents have diabetes the chances increase to 70% (Moore & 
Florez, 2008).  
T2DM is a progressive chronic disease that leads to complications resulting in end 
organ damage, such as peripheral and central neuropathy often resulting in amputation of 
the lower limbs due to infection; nephropathy (kidney damage); retinopathy, in which the 
small blood vessels of the retina become damaged, leading to visual impairment and 
blindness; and cerebrovascular and cardiovascular disease, including atherosclerosis, 
heart attack, and stroke (Brands et al., 2007, Emery-Tiburcio et al., 2015). T2DM is often 
comorbid with obesity, dyslipidemia, and hypertension and it leads to excess disability 
and early mortality (Palta et al., 2014).  
The purpose of the treatment of T2DM is to keep blood glucose levels within the 
optimal range to prevent or slow down the complications of diabetes through the 
completion of DSMB. At first, T2DM can be managed with lifestyle modifications, 
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namely, changing diet, increasing physical activity, and reducing or eliminating 
unhealthy behaviours such as smoking. As the disease progresses, oral hypoglycemic 
medications and eventually insulin injections may be required to maintain target blood 
glucose levels and stave off complications (Brands et al., 2007).  
Throughout the world, approximately 366 million people have been diagnosed 
with diabetes; estimates put this number at 552 million by 2030 (Whiting et al., 2011). In 
Canada the prevalence of diabetes in adults over the age of 20 is 8.7%, representing 1 in 
11 Canadians (Government of Canada, 2011). The greatest increase in the prevalence of 
diabetes occurs after the age of 40; with prevalence rates of at least 20% for every age 
group older than 65 years of age (Government of Canada, 2011). Approximately 90% of 
individuals with diabetes have T2DM, and this percentage increases in older age groups. 
Ontario has the third highest prevalence of diabetes compared to all other provinces and 
territories and is surpassed only by Nova Scotia and Newfoundland. In addition, more 
than 50% of individuals living with diabetes in Canada are of working age (between 25 
and 64 years of age, Government of Canada, 2011).     
Cognitive Functioning in T2DM   
 T2DM is associated with increased risk of vascular dementia, Alzheimer’s 
Disease (AD), and accelerated rate of cognitive decline in older adults (Palta et al., 2014). 
Munshi and colleagues (2006) reported that cognitive dysfunction (poor performance on 
neuropsychological measures when compared to normative samples with similar 
demographic characteristics) is present in 30-40% of individuals who have diabetes and 
are more than 70 years of age. Estimates indicate that 6 to 13% of all cases of dementia 
can be attributed to diabetes (Biessels et al., 2008; Koekkoek et al., 2015). An early 
 5 
 
systematic review showed a 1.2 to 2.3 times greater risk for AD and a 2.2 to 3.4 times 
greater risk for vascular dementia in individuals with diabetes when compared to 
individuals without diabetes (Cukierman et al., 2005). A more recent meta-analysis 
confirmed these rates showing a 1.46 (95% CI: 1.20-1.77) times greater risk of 
developing AD and a 2.48 (95% CI: 2.08-2.96) times greater risk of developing vascular 
dementia in individuals with diabetes when compared to individuals without diabetes 
(Cheng et al., 2012).  
Vascular Cognitive Impairment and T2DM. Cognitive dysfunction that is 
associated with or caused by vascular risk factors has been called vascular cognitive 
impairment (VCI, Hachinski et al., 2006; Vasquez & Zakzanis, 2015). VCI ranges in 
severity from unnoticed cognitive changes, to mild cognitive impairment, to dementia, 
and can occur in isolation or along with AD pathology (Hachinski et al., 2006; Vasquez 
& Zakzanis, 2015). Vascular risk factors include T2DM, hypertension, dyslipidemia, 
obesity, and cerebrovascular incidents (Hachinski et al., 2006; van den Berg et al., 2009). 
Some vascular risk factors (including T2DM) are treatable; treatment of vascular risk 
factors is thought to prevent or postpone VCI and exacerbation of AD pathology by VCI 
comorbidity (Hachinski et al., 2006). The numerous vascular risk factors often co-occur 
and have overlapping consequences such as atherosclerosis; however, these risk factors 
also show differences in the end organ damage caused, age of onset, and initial damage at 
time of diagnosis (van den Berg et al., 2009)  
 A review by van den Berg and colleagues (2009) looked at the effects of T2DM, 
impaired glucose metabolism, hypertension, dyslipidemia, and obesity on cognitive 
functioning. T2DM and hypertension were the vascular risk factors with the most 
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consistent associations with cognitive dysfunction, with 67% of studies reviewed for 
T2DM and 71% of studies reviewed for hypertension showing cognitive dysfunction in 
groups of individuals with each condition (van den Berg et al., 2009). Results were less 
consistent for other risk factors with individuals with impaired glucose metabolism 
showing decline in 12.5% of studies, individuals with obesity showing decline in 50% of 
studies, and those with dyslipidemia showing decline in 40% of studies reviewed (van 
den Berg et al., 2009). The most commonly affected cognitive domains across vascular 
risk factors were memory, processing speed, and cognitive flexibility; however, the most 
commonly affected domains were also the most commonly assessed domains, suggesting 
a broader sampling a cognitive domains assessed is likely required (van den Berg et al., 
2009). Importantly, studies controlling for the effects of individual vascular risk factors 
(e.g., dyslipidemia, obesity, and hypertension) on each of the studied risk factors (e.g., 
T2DM) did not produce statistically significant differences in affected cognitive domains 
from studies that did not control for the effects of individual risk factors and effect sizes 
for impairment remained similar across risk factors (van den Berg et al., 2009).  
VCI as a whole causes impairment in all cognitive domains; however, the greatest 
impairments are seen in executive functioning and processing speed (Vasquez & 
Zakzanis, 2015) and more specifically with shifting abilities (Hachinski et al., 2006). The 
work of Hachinski and colleagues and of Vasquez and Zakzanis shows some overlap 
with the findings of van den Berg and colleagues (2009) in the areas of processing speed, 
cognitive flexibility/shifting, and executive functioning.  
Metabolic syndrome is the name given to the presence of three or more of the 
following vascular risk factors: abdominal obesity, elevated diastolic blood pressure, 
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elevated systolic blood pressure, elevated glucose levels, elevated cholesterol levels, and 
elevated triglyceride levels (Falkowski et al., 2014). A study investigating the effects of 
metabolic syndrome status on executive functioning abilities found that metabolic 
syndrome was significantly associated with worse executive functions; however, this 
association only accounted for 1% of variance after controlling for age, education, 
gender, and ethnicity (Falkowski et al., 2014). Most importantly, this study only found 
that the presence (≥3 components) or absence (≤2 components) of metabolic syndrome 
predicted executive functioning abilities and the authors did not find additive effects of 
more metabolic syndrome components being associated with worse executive functioning 
as they had hypothesized (Falkowski et al., 2014). These findings fit with the findings of 
van den Berg and colleagues (2009), who concluded that having diagnoses of multiple 
risk factors does not necessarily lead to greater cognitive impairment overall than does 
having a diagnosis of a single risk factor.  
Neuropsychological findings in T2DM. Neuropsychological findings specific to 
T2DM will be reviewed within the context of the above discussion. A review (van den 
Berg et al., 2009) and meta-analyses (Kinga & Szamosközi, 2014; Monette et al., 2014; 
Palta et al., 2014; Vincent & Hall, 2015) have provided good summaries of the 
neuropsychological effects of T2DM.   
In the van den Berg and colleagues (2009) review, cognitive functioning was 
classified by cognitive domains. Studies reviewed assessing these domains showed 
impairments in individuals with T2DM in 63% of studies assessing processing speed, 
50% assessing attention, 44% assessing memory, 38% assessing cognitive flexibility, 
33% assessing language, 31% assessing general intelligence, and 22% assessing 
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perception and construction. Median Cohen’s d for the most commonly affected domains 
were -0.4 for processing speed, -0.5 for attention, and -0.3 for memory (van den Berg et 
al., 2009).  
These authors noted that cross sectional studies with older adults tended to have 
larger effect sizes (van den Berg et al., 2009). On the other hand, adjusting for risk factors 
other than age did not significantly change the findings. A recent longitudinal study 
showed that cognitive decline was 19% greater over the 20 years of the study in those 
with T2DM compared to those without T2DM (Rawlings et al., 2014).  T2DM on 
average sped cognitive aging  by five years; in other words, a person who was 65 years-
old with T2DM would be expected to have the same level of cognitive functioning as a 
person who was 70 years-old without T2DM (Rawlings et al., 2014).  
 In their meta-analysis Palta and colleagues (2014) included 24 studies published 
between 1995 and 2013 and these authors also classified cognitive functioning by 
cognitive domains. Small to moderate statistically significant deficits were found in every 
classified cognitive domain in individuals with T2DM when compared to controls 
without T2DM. Specifically, using the author’s cognitive classification, the largest 
deficits in mean effect sizes were found in motor functions (d = -0.36), followed by 
processing speed (d = -0.33), executive functions (d = -0.33), verbal memory (d = -0.28), 
visual memory (d = -0.26), and attention/concentration (d = -0.19).  
 Monette and colleagues (2014) included 25 studies published between 2000 and 
2013 in their meta-analysis and classified cognitive functioning more specifically by 
cognitive abilities. Results were similar to Palta and colleagues (2014) in that all 
classified cognitive abilities showed statistically significant small to moderate deficits in 
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individuals with T2DM compared to controls without T2DM. The largest mean effect 
sizes were reported for processing speed measured with tasks with motor demands (-
0.37), and for divided attention/shifting (-0.36, Monette et al., 2014). Median effect sizes 
equivalent to those reported by van den Berg and colleagues (2009) were calculated for 
cognitive domains and yielded Cohen’s ds of -0.42 for processing speed, -0.36 for 
attention, and -0.28 for memory (Monette et al., 2014).   
 Vincent and Hall (2015) completed a meta-analysis specifically of executive 
functioning in individuals with and without T2DM. The authors included 60 studies 
published between 1984 and 2013. Again, all effect sizes were statistically significant and 
small to moderate in magnitude (Vincent & Hall, 2015). The executive functioning 
composite had a small effect size (d = -0.25). Effect sizes were calculated for individual 
components of executive functioning as classified by the authors. The letter fluency (d = -
0.38), attention (d = -0.38), shifting (d = -0.36), and inhibition (d = -0.32) effect sizes 
were larger than the executive functioning composite effect size and the categorical 
fluency (d = -0.16) and working memory (d = -0.13) effect sizes were smaller in 
magnitude than the executive functioning composite.    
 A fourth meta-analysis by Kinga and Szamosközi (2014) reviewed nine studies 
published between 1993 and 2009. The magnitude of effect sizes for this meta-analysis 
ranged from small to large for classified cognitive domains. However, this meta-analysis 
was of adults age 18-65 and included studies with individuals with T1DM and T2DM. 
Thus, the results of this meta-analysis are not directly comparable to the other three meta-
analyses reviewed above.  
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Effect sizes for memory and processing speed were similar across all studies 
where these were reported (Monette et al., 2014, Palta et al., 2014; van den Berg et al., 
2009). Attention showed a larger median effect size in the van den Berg et al. (2009) 
study (-0.5), a smaller mean effect size in the Palta et al. (2014) study (-0.19), an 
intermediate median effect size in the Monette et al. (2014) study (-0.36), and an 
intermediate mean effect size in the Vincent and Hall (2015) study (-0.38). This 
difference in effect sizes for attention has two potential sources. First, the van den Berg et 
al. study only reported median effect sizes, the Palta et al. and the Vincent and Hall 
studies only reported mean effect sizes, and the Monette et al. study reported both mean 
and median effect sizes. The different statistics used could have contributed to the 
difference in attention effect sizes across these three studies and are not directly 
comparable values.  
Second, the three studies differed in terms of whether tests were classified by 
domain or by ability. In the Monette et al. (2014) study the mean effect size for the 
attention domain was -0.29 as compared to the mean effect size for the same domain 
from Palta and colleagues (2014, d = -0.19) and from Vincent and Hall (2015, d = -0.38). 
However, differences in mean effect sizes emerged among attention abilities in the 
Monette et al. study (divided attention/shifting d = -0.36, focused attention d = -0.15, and 
selective attention d = -0.33). Divided attention/shifting, often considered to be part of the 
executive functioning domain (Falkowski et al., 2014), had an effect size close to that 
reported for the entire executive functioning domain in the Palta et al. study (d = -0.33) 
and was identical to the shifting effect size reported by Vincent and Hall (d = -0.36). 
Further, the attention effect size from Vincent and Hall was likely inflated due to the 
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inclusion of the Digit Symbol Substitution Test (DSST) in the calculation of this effect 
size. The DSST is a processing speed measure with high motor demands that measures 
divided attention (Strauss et al., 2006). Thus, divided attention/shifting is the most 
consistently reported impaired component of executive functioning in individuals with 
diabetes as it is in individuals with other vascular risk factors (van den Berg et al., 2009) 
and in VCI (Hachinski et al., 2006). As such, in the present study the cognitive abilities 
of processing speed and shifting/cognitive flexibility were measured by more than one 
neuropsychological test and the other cognitive abilities were measured by at least one 
measure.   
The American Diabetes Association standards of medical care for diabetes 
recommend that cognitive screening should be done for all individuals diagnosed with 
diabetes and that there should be ongoing cognitive assessment in individuals with poor 
glycemic control and poor diabetes self-management (ADA, 2013). This is recommended 
as it is not T2DM itself that causes cognitive decline but the quality of glycemic control, 
the duration of diabetes, and the presence of complications (all indicators of a more 
advanced disease process) that lead to cognitive decline in T2DM (Rawlings et al., 2014). 
Therefore, better glycemic control achieved through performing DSMB should minimize 
cognitive functioning deficits and decline in individuals with T2DM. Unfortunately, 
adherence and self-care in T2DM as related to performing DSMB is generally poor as 
will be reviewed in the following section.  
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Adherence, Self-Care, and DSMB 
 Definitions and Statistics. Adherence is typically defined by “the extent to which 
a person’s actions and behaviour coincides with advice or instruction from a health care 
provider intended to prevent, monitor, or ameliorate a disorder” (p. 3, Christensen, 2004). 
In the context of T2DM, adherence is measured by achieving target A1C levels (usually 
≤ 7%) and through the completion of DSMB (Bailey & Kodack, 2011).  
The above definition is too simplistic (Emery et al., 2010). Walker & Usher 
(2003) provide a more comprehensive definition of adherence by distinguishing 
conditions under which the behaviour recommended by a healthcare provider is 
completed by an individual with T2DM. First, the individual must be aware of the 
provider recommendation. If the individual fails to complete the behaviour because they 
are not aware of the provider recommendation this is a knowledge deficit that needs to be 
corrected as opposed to a failure to adhere to the provider recommendation. Second, if 
the individual is aware of the provider recommendation, does not agree with it, but still 
completes the behaviour, this is categorized as compliance, which is different than 
adherence because the individual is passively following the instructions of the healthcare 
provider. Lastly, if the individual is aware of the provider recommendation, agrees with 
it, and completes the behaviour this can be categorized as adherence; and similarly, if the 
individual is aware of the provider recommendation, agrees with it, but fails to complete 
the behaviour, then this can be categorized as non-adherence or failure to adhere (Walker 
& Usher, 2003). This model of adherence recognizes that the individual with T2DM has 
an active role in completing their recommended DSMB, and ideally there is a 
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collaborative relationship between the healthcare provider and the individual with T2DM 
(Emery et al., 2010). 
Self-care and self-management are often used interchangeably to refer to 
behaviours necessary for T2DM treatment adherence (Bailey & Kodack, 2011). 
However, self-care is a broader concept that includes DSMB along with self-monitoring 
and symptom management completed by the individual with T2DM (Caro-Bautista et al., 
2014). Self-care behaviours include DSMB (blood glucose monitoring, medication and/or 
insulin taking, physical activity, diet, foot care), but also problem solving when blood 
glucose is not in range, reducing diabetes complications, and living with diabetes 
(diabetes-related QoL); self-report can be utilized to measure all of these domains 
(Mulcahy et al., 2003). Good self-care helps protect against diabetes complications; the 
individual with T2DM must actively manage their diabetes through DSMB with the goal 
of achieving target blood glucose and A1C levels (Schmitt et al., 2013). Therefore, self-
care is the ongoing day-to-day management of T2DM that requires intact knowledge and 
skills, motivation, mood, and DSMB completion (Feil et al., 2012). 
Adherence in T2DM is notoriously poor with only slightly more than half of 
individuals achieving a target A1C of less than 7.0% (Bailey & Kodack, 2011; Hunter, 
2016). Only 7 to 25% of people with diabetes fully adhere to all aspects of their treatment 
regimen, i.e., complete all their DSMB (Gillani, 2012). Similarly, Ahola & Groop (2013) 
reported that only 39% of individuals with T2DM achieve “complete success” in at least 
2/3 of their self-management behaviour domains as per their provider recommendations. 
Failures to adhere to diet recommendations occur in 40-60% of individuals with diabetes, 
failures to complete recommended glucose monitoring occur in 30-80% of individuals 
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with diabetes, and failures to adhere to physical activity recommendations occur in 70-
80% of individuals with diabetes (Gillani, 2012). Adherence to medication 
recommendations is usually better than to diet and physical activity recommendations 
(Ahola & Groop, 2013). These poor rates of  DSMB completion can be better understood 
with the consideration that estimates place the total time required to execute all DSMB as 
directed by healthcare providers at up to 2 hours per day for the average adult with 
T2DM (Gonzalez et al., 2016). Overall, adherence in T2DM is found to be poorest for 
females, people with comorbid depression, those with negative attitudes towards insulin, 
and those with lower general and diabetes specific education (Emery et al., 2010).  
Barriers to the completion of DSMB. The major goal of diabetes education and 
the role of the healthcare provider are to facilitate the ability of individuals with T2DM to 
carry out their DSMB behaviours and empower them to take responsibility for their 
DSMB in order to complete them independently (Caro-Bautista et al., 2014; Compeán-
Ortiz et al., 2010). Barriers to diabetes self-care hinder the independent decision-making 
and independent execution of agreed upon DSMB and treatment goals and affect 
treatment adherence (Caro-Bautista et al., 2014). Barriers to completion of DSMB belong 
to three major categories: individual or patient factors, provider or treatment factors, and 
environmental or system level factors. 
Individual or patient level factors. Individual or patient level factors include 
knowledge and skill (Ahola & Groop, 2013; Bailey & Kodack, 2011; Emery et al., 2010). 
Lack of knowledge is seen as a barrier. However, good levels of knowledge do not in and 
of themselves guarantee adherence to DSMB as more knowledge has been shown to lead 
to more flexibility in performance of DSMB (Ahola & Groop, 2013). This greater 
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flexibility in performance of DSMB behaviours due to increased knowledge has been 
shown to sometimes lead to failures to reach A1C goals (Ahola & Groop, 2013).  Health 
beliefs, including feeling as though the disease is not severe or a lack of faith in the 
efficacy of the treatment regimen, lead to poor adherence (Ahola & Groop, 2013; Bailey 
& Kodack, 2011; Castellon et al., 2009; Emery et al., 2010; Gonzalez et al., 2016). Poor 
self-efficacy, coping, and problem solving skills, lack of empowerment, and an external 
health locus of control also lead to poor adherence (Ahola & Groop, 2013; Bailey & 
Kodack, 2011; Emery et al., 2010; Gonzalez et al., 2016). Poor health literacy leads to 
poorer adherence (Ahola & Groop, 2013; Bailey & Kodack, 2011; Castellon et al., 2009; 
Emery et al., 2010). Cultural factors including ethnicity and religious beliefs have 
differing effects on adherence (Emery et al., 2010; Gonzalez et al., 2016). Psychological 
factors such as depression, anxiety, substance abuse, or severe mental illness all hinder 
adherence (Ahola & Groop, 2013; Bailey & Kodack, 2011; Castellon et al., 2009, de 
Groot et al., 2016). Finally, cognitive impairment has been shown to be a barrier to 
DSMB completion (Ahola & Groop, 2013; Bailey & Kodack, 2011; Castellon et al., 
2009; Emery et al., 2010). These authors refer specifically to dementia as a barrier, but 
specific characterizations of the impact of cognitive abilities on DSMB are scarce in the 
literature. The few studies that have been completed will be discussed in the next section.  
 Provider or treatment factors. In addition to these factors at the individual level, 
a host of other factors can impact adherence. Treatment regimen factors that adversely 
affect adherence include more complex treatment regimens, more frequent medication 
dosages, and more severe medication side effects (Bailey & Kodack, 2011; Castellon et 
al., 2009). Provider factors that influence adherence include interaction and 
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communication style of the healthcare provider (Ahola & Groop, 2013; Castellon et al., 
2009; Emery et al., 2010). Ratings of quality of physician communication and their level 
of participatory decision making with patients were found to predict DSMB completion 
in individuals with diabetes after controlling for sociodemographic and disease variables 
(Heisler et al., 2002).  
Environmental or system level factors. Environmental or system level factors 
include cost of the medication, availability of care, distance to the physician’s office, 
interference of the treatment regimen with lifestyle and other duties, and access to social 
support (Ahola & Groop, 2013; Bailey & Kodack, 2011; Castellon et al., 2009; Emery et 
al., 2010; Gonzalez et al., 2016). Human factors can also become barriers, including poor 
labelling and packaging of medications and reading levels of instructions above the 
comprehension of the individual with T2DM (Castellon et al., 2009).  
 All three levels of barriers interact together and the same individual with T2DM 
can show difficulties with adherence for reasons that change across time (Castellon et al., 
2009). As the current investigation was an exploratory study most concerned with the 
relationship between DSMB completion and cognitive functioning, only individual level 
factors were considered in the present investigation. Individual level factors that are most 
likely to affect the relationship between DSMB completion and cognitive functioning 
were exclusion criteria in the present study where possible (e.g. diagnoses of dementia, 
severe mental illness, chronic diseases not typically comorbid with T2DM). When it was 
not possible to exclude individual level factors, these factors were analysed to determine 
their impact on DSMB completion.   
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DSMB and Cognitive Functioning  
 Due to the chronicity of T2DM, most of the DSMB are expected to be performed 
independently by the individual with T2DM, with the healthcare provider available to 
facilitate understanding on a limited basis. Therefore the impact of cognitive functioning 
on the daily management of T2DM must be known (Compeán-Ortiz et al., 2010). 
Conceptually, there is a reciprocal relationship between DSMB completion and cognitive 
functioning (Feil et al., 2012; Umegaki et al., 2013) wherein cognitive impairment (due 
to T2DM or some other disease process) can begin to interfere with the individual’s 
ability to complete their DSMB and adhere to their treatment regimen. Once this 
happens, there is likely to be poorer T2DM control, which would increase the risk of 
diabetes complications and further cognitive decline (Feil et al., 2012). This cycle would 
continue leading to more severe cognitive decline unless an intervention is carried out to 
compensate for the cognitive deficits (Compeán-Ortiz et al., 2010; Monette, 2012; 
Primozic et al., 2012).  
Completing DSMB is difficult for cognitively intact individuals (Feil et al., 2012) 
as seen by the statistics discussed above (Ahola & Groop, 2013; Gillani, 2012).  In 
addition, specific cognitive deficits predict DSMB completion over and above measures 
of health literacy typically used in the T2DM adherence literature (Ross et al., 2010). 
Most health behaviour models for the management of chronic illnesses do not incorporate 
the possible effects of cognitive deficits on performance of health behaviours (Hall et al., 
2006). Cognitive deficits can potentially influence the accuracy of health beliefs, the 
ability to assimilate new information to change beliefs, and the ability to problem solve 
situations according to one’s health beliefs (Castellon et al., 2009). As such, cognitive 
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deficits and decline, not only frank cognitive impairment or dementia, are barriers to the 
completion of DSMB (Feil et al., 2012). 
 The cognitive changes seen in normal aging can serve to inform the difficulties 
individuals with T2DM might have completing their DSMB due to the profile of 
cognitive deficits in T2DM being qualitatively similar to that of normal aging (van den 
Berg et al., 2009). The pattern of cognitive deficits seen in those with T2DM is often 
characterized as accelerated aging (Okereke et al., 2008). Normal aging generally leads to 
slowed processing speed, difficulty with divided attention, changes in working memory, 
executive function abilities, efficiency of information retrieval, and prospective memory 
(Castellon et al., 2009). Due to the changes in cognition that occur as humans age, older 
adults might not have the memory and organizational skills necessary for complex 
treatment regimens requiring multiple coordinated behaviours and goal management (i.e., 
DSMB, Emery et al., 2010). Retrospective memory for instructions on how to take 
medications and prospective memory for when to take them have been shown to affect 
treatment adherence in older adults, with poorer abilities in these areas leading to 
nonadherence (Castellon et al., 2009).    
Previous studies of the effect of cognitive functioning on DSMB completion. 
Few studies have investigated the relationship between DSMB and cognitive impairment 
(Feil et al., 2009; Feil et al., 2012; Sinclair et al., 2000) or the relationship between 
DSMB and cognitive abilities (Asimakopoulou & Hampson, 2002; Compeán-Ortiz et al., 
2010; Gatlin & Insel, 2015; Primozic et al., 2012; Rosen et al., 2003; Thabit et al., 2009); 
and existing studies also have found conflicting results. Each of these studies will be 
discussed in turn and were used to inform the design of the current investigation.  
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The first study identified on the subject looked at the capabilities of individuals 
with diabetes (most had T2DM) to complete DSMB and other related behaviours 
(Sinclair et al., 2000). The Mini-Mental State Exam (MMSE) was used to measure 
cognitive functioning. The MMSE is a measure of cognitive functioning used to screen 
for the presence of dementia; scores below 23 out of a possible 30 indicate the possibility 
of dementia (Folstein et al., 1975). In the Sinclair and colleagues study, 113 individuals 
with MMSE scores ≤ 23 were compared to 283 individuals with MMSE ≥24. Those with 
poorer cognitive functioning were statistically significantly less likely to be solely 
responsible for their medication intake and blood glucose monitoring, to attend a 
specialized diabetes clinic, to have adequate diabetes knowledge, and to complete their 
activities of daily living. They were also statistically significantly more likely than those 
with higher cognitive function to have been hospitalized in the last year, to have received 
help with personal care, to have had a needs assessment completed in the past year, and 
to be living in a long-term care home (Sinclair et al., 2000). This study did not evaluate 
the ability of individuals to complete their DSMB, only if they were completing them 
independently or not given their cognitive status. The study also used a cognitive 
screening measure to obtain an estimate of current cognitive status rather than evaluating 
multiple cognitive domains or abilities.   
 Asimakopoulou & Hampson (2002) reported selected findings from an 
unpublished study where they explored the relationships between measures of cognitive 
functioning and self-reported DSMB completion in 51 individuals with T2DM and no 
dementia. No data were reported; only a description of findings was provided. Multiple 
Regression Analysis (MRA) controlling for age, premorbid IQ, and depression found that 
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better completion of diet DSMB was predicted by better scores on the modified 
Wisconsin Card Sorting Test, a measure of executive functioning, and that better physical 
activity DSMB was predicted by better performance on a serial subtraction task, a 
measure of working memory. After reporting that above findings, these authors 
concluded that overall the cognitive deficits present in T2DM when there is no dementia 
present were unlikely to affect completion of DSMB (Asimakopoulou & Hampson, 
2002). It is difficult to know how the authors reached this conclusion given what was 
reported.   
Rosen and colleagues (2003) investigated the relationship between cognitive 
abilities and adherence to Metformin (the most commonly used oral hypoglycemic 
medication) in 79 individuals with T2DM attending a VA primary care clinic. 
Microelectronic Event Monitoring Systems were used to assess medication intake for a 4-
week period and the MMSE, Trail Making Test A & B, Stroop, Digit Span, Digit 
Symbol, and Grooved Pegboard cognitive tests were administered. Only the Stroop word 
score (a measure of processing speed), time to completion of Trails B (a measure of 
visual scanning, processing speed, and shifting), and age were significantly correlated 
with medication adherence. Stepwise Regression showed that age accounted for 9.8% of 
the variance in medication adherence and time to completion of Trails B accounted for an 
additional 9.1% of variance (R
2 
change from age only). A second Stepwise Regression 
showed that number of Stroop words read accounted for an additional 8% of variance (R
2 
change from age only, Rosen et al.). There were no significant correlations between 
neuropsychological measures and A1C, and MMSE score accounted for 13.3% of the 
variance in missed appointments (Rosen et al., 2003). This study provides some 
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indication that processing speed and shifting are important for medication adherence; 
however, medication taking was the only domain of DSMB included in the study.     
Thabit and colleagues (2009) assessed the relationship between executive 
dysfunction and DSMB completion in 50 older adults with T2DM. They assessed 
executive dysfunction using two measures, the Frontal Assessment Battery (FAB) and the 
Executive Interview 25 (EXIT25). They assessed global cognitive functioning using the 
MMSE, a measure wherein performance on memory and orientation items accounts for 
most of the score. A total score from a measure of DSMB correlated significantly with 
the EXIT25 (r = -0.3 p <.05) and the MMSE (r = 0.5 p<.05), but not with the FAB (r = 
0.2 p = 0.14). DSMB completion was significantly worse for those who scored below the 
cut-off for impairment on both the EXIT25 and the FAB. The correlation between 
MMSE and DSMB completion remained significant when the variance accounted for by 
FAB scores was removed (r = 0.36, p < 0.05), which suggests that overall cognitive 
functioning has an effect on DSMB completion greater than that caused by executive 
dysfunction alone (Thabit et al., 2009). Conversely, these authors also concluded that a 
MMSE score within normal limits does not preclude executive dysfunction that can 
impact DSMB completion and that executive deficits in individuals with T2DM can be 
missed if they are not assessed directly (Thabit et al., 2009).  
Compeán-Ortiz and colleagues (2010) investigated the relationship of memory 
abilities and DSMB completion in 105 younger Mexican adults ages 30 to 55 years with 
T2DM. They excluded individuals with an MMSE score under 23. They administered a 
Spanish measure of DSMB and the Spanish version of the Wechsler Memory Scale, 
yielding scores of immediate verbal and visual recall and delayed visual and verbal 
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recognition and recall. After accounting for diabetes education and knowledge, delayed 
verbal recognition, immediate visual recall, and delayed visual recall were significantly 
related to blood glucose monitoring accounting for 9.4%, 14.2%, and 11.1% of the 
variance, respectively.  Immediate visual recall and delayed visual recall were 
significantly related to diet DSMB accounting for 8.5% and 7.6% of the variance 
respectively. All other memory scores were reportedly not significantly related to blood 
glucose monitoring or diet, and none of the memory scores were significantly related to 
physical activity or medication DSMB after accounting for prior diabetes education and 
knowledge (Compeán-Ortiz et al., 2010). This study is important because the authors 
demonstrated that memory abilities are related to blood glucose monitoring and diet 
DSMB in younger adults who scored above the cut-off score for dementia on a cognitive 
screening measure.  
 Feil and colleagues (2012) investigated the relationship of cognitive functioning 
with diabetes comorbidity and DSMB in a community sample of 1398 older adults. 
Cognitive functioning was measured using the Telephone Interview for Cognitive Status 
(adapted from the MMSE). More severe cognitive impairment was significantly related to 
poorer DSMB completion and the relationship became stronger as diabetes comorbidities 
increased. Cognitive impairment affected physical activity DSMB most strongly followed 
by diet DSMB. These two domains were also the most affected when diabetes 
comorbidities increased (Feil et al., 2012). These findings remained significant after 
controlling for functional status, duration of diabetes, treatment modality, and 
demographic characteristics (Feil et al., 2012). This study was the first to show the 
relationship between cognitive functioning and DSMB in a large sample of community 
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dwelling older adults. A study by the same group also showed a significant relationship 
between cognitive impairment (measured using the Cognitive Abilities Screening 
Instrument) and poorer DSMB completion in 51 male veteran outpatients (Feil et al., 
2009).  
 Primozic and colleagues (2012) investigated the relationship between cognitive 
abilities and DSMB using the Repeatable Battery of the Assessment of 
Neuropsychological Status (RBANS) to measure immediate and delayed memory, 
attention, language, and visuospatial/constructional abilities; the Tower of London to 
measure the executive functions of planning, problem solving, and working memory, and 
the Stroop test to measure processing speed and cognitive flexibility in 98 adults with 
T2DM over the age of 40. Simple regression analysis showed a significant relationship 
between a total score for DSMB and body mass index (BMI), depression symptoms, total 
score on the RBANS, immediate memory, visuospatial/constructional abilities, attention, 
and planning and problem solving. There were no significant associations between the 
total score for DSMB and age, A1C, duration of diabetes, diabetes-related distress (proxy 
measure for QoL), working memory, processing speed, cognitive flexibility, language, 
and delayed memory (Primozic et al., 2012).  
Multiple regression analysis (MRA, Primozic et al., 2012) showed that better 
problem solving, lower BMI, female sex, and absence of depression predicted better total 
DSMB scores (R
2
 = 0.37, p < 0.001). The RBANS total (β = 0.33, p < 0.006, R2 = 0.40, p 
< 0.001) and attention domain (β = 0.28, p < 0.015, R2 = 0.39, p < 0.001) scores 
significantly predicted total DSMB scores when these scores were used in the regression 
model in place of planning and problem solving. Visuospatial/constructional abilities and 
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immediate memory scores did not significantly predict total DSMB when they were 
inserted into the model and delayed memory and language scores were not tested due to 
not being significant in the simple regression analyses (Primozic et al., 2012). This study 
is important because the relationships between DSMB and multiple cognitive abilities 
across all cognitive domains in relation to demographic and disease variables were 
analysed.  
Finally, Gatlin and Insel (2015) investigated the relationship between working 
memory as measured by the Working Memory Index of the WAIS-III and executive 
functioning as measured by the EXIT25 in a sample of 67 adults with T2DM. These 
authors assessed global cognitive functioning using the MMSE. Participants with a score 
≤ 23 on the MMSE were excluded from the study. Self-care was measured by the Self-
Care Inventory – Revised (SCI-R), a 25-item self-report measure, which included 
medication, blood glucose, diet, and exercise DSMB domains, along with question 
assessing preventative and routine aspects of self-care (Gatlin & Insel, 2015). Scores on 
the Exit25 and the SCI-R were significantly correlated (r = -0.31, p < .01). However, 
there was no significant correlation between the Working Memory Index and the SCI-R 
(r = 0.01, p > .05). 
 Overall significant relationships were found between DSMB completion and 
cognitive impairment in all three studies in which only global cognitive impairment was 
measured (Feil et al., 2009; Feil et al., 2012; Sinclair et al., 2000). Executive dysfunction 
in the presence of a normal range score on the MMSE was noted (Gatlin & Insel, 2015; 
Thabit et al., 2009) to impact DSMB completion and self-care. Immediate memory, 
visuospatial/constructional abilities, attention, and planning and problem solving 
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(Primozic et al., 2012) were significantly correlated with DSMB completion total scores, 
although immediate memory and visuospatial/constructional abilities were not 
independent predictors of DSMB completion in the MRA analyses.  
 For specific DSMB domains, previous studies indicated that diet DSMB 
completion is impacted by memory abilities (Compeán-Ortiz et al., 2010) and executive 
functioning (Asimakopoulou & Hampson, 2002). Memory abilities were also related to 
blood glucose monitoring DSMB completion (Compeán-Ortiz et al., 2010). Processing 
speed and shifting abilities were related to successful medication adherence (Rosen et al., 
2003). Physical activity DSMB completion was impacted by working memory abilities 
(Asimakopoulou & Hampson, 2002). However, all the studies investigating the impact of 
cognitive abilities on DSMB completion also have  reported nonsignificant associations 
with  many cognitive abilities (Asimakopoulou & Hampson, 2002; Compeán-Ortiz et al., 
2010; Primozic et al., 2012; Rosen et al, 2003; Thabit et al.,2009) and no clear pattern of 
deficits has emerged; therefore, the effects of cognitive abilities on the completion of 
DSMB remain to be fully determined.  
DSMB and QoL 
 Good quality of life (QoL) is an essential (Gonzalez et al., 2016) and sometimes 
overlooked (Cochran & Conn, 2008) treatment outcome in T2DM, even though it is a 
core outcome of DSMB education (Mulcahy et al., 2003). To aid in the development of a 
measure of QoL, the World Health Organization developed the following consensus 
definition of QoL by international expert review:  
individuals’ perception of their position in life in the context of the culture 
and value system in which they live and in relation to their goals, 
expectations, standards and concerns. It is a broad ranging concept 
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affected in a complex way by the persons’ physical health, psychological 
state, level of independence, social relationships and their relationship to 
salient features of their environment (The WHOQOL Group, 1995, p. 
1405). 
QoL in individuals with T2DM is often defined in relation to which aspects of 
well-being and life quality are being considered (Cochran & Conn, 2008). General QoL 
usually queries overall well-being across many psychosocial functioning domains. The 
construct of health QoL encompasses the impact of overall health status on QoL and 
well-being. Related to health QoL, diabetes specific QoL measures the impact of diabetes 
on QoL and well-being (Ostini et al., 2012). General QoL in T2DM is diminished when 
compared to those without T2DM (Cochran & Conn, 2008; Emery-Tiburcio et al., 2015). 
This is evidenced by the higher prevalence of Major Depressive Disorder (MDD) in 
individuals with T2DM (15-20%) compared to those in the general population (2-9%, 
Gonzalez et al., 2007). Untreated depression affects DSMB completion and has also been 
associated with higher risks of mortality and dementia in those with T2DM when 
compared to those with T2DM and no depression (Kirkman et al., 2012; Primozic et al., 
2012). In addition, treatment of depression symptoms alone does not usually lead to an 
increase in DSMB completion (Gonzalez et al., 2016; Hunter, 2016). Poor general and 
diabetes-related QoL have been shown to negatively impact DSMB completion (Cochran 
& Conn, 2008; Primozic et al., 2012). Likewise, learning how to complete DSMB and 
performing the behaviours increases QoL (Cochran & Conn, 2008), possibly because 
individuals with T2DM feel better physically when they exercise and follow a 
recommended healthy diet and do not experience the unpleasant physical side effects of 
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hyperglycemia. Performing DSMB can also increase self-efficacy with regard to the 
individual’s ability to manage their T2DM and thus may lead to a positive effect on 
general QoL and overall well-being (Cochran & Conn, 2008). 
 Depression is important to consider because it directly affects completion of 
DSMB and QoL (de Groot et al., 2016). Lin and colleagues (2004) studied the 
relationship between MDD and DSMB completion in 4463 individuals with diabetes 
(95.6% had T2DM). These authors found that MDD was associated with poorer 
completion of self-initiated behaviours that are difficult to maintain (e.g., physical 
activity, diet, and medication intake) but not with more preventive time-limited 
behaviours (e.g., blood glucose monitoring, foot inspections, and follow-up 
appointments, Lin et al.). Gonzalez and colleagues (2007) investigated the relationship of 
MDD and subclinical depression to DSMB completion in 879 adults with T2DM 
attending a primary care clinic. These authors found that those meeting criteria for MDD 
reported almost a full additional day of nonadherence to diet, physical activity, and blood 
glucose monitoring over the past week compared to individuals who did not meet criteria 
for MDD. Importantly, they found that depression symptom severity (a continuous 
measure) was a better predictor of the completion of all DSMB, with the exception of 
blood glucose monitoring, than meeting criteria for MDD (a dichotomous measure). Only 
MDD, and not depression symptoms, was significantly associated with decreased blood 
glucose monitoring (Gonzalez et al., 2007). The results of this study and subsequent 
replications (Gonzalez et al., 2016) indicate the importance of assessing current 
depression symptom severity and not just current or past diagnoses of MDD.   
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There is a paucity of evidence on the impact of cognitive functioning and DSMB 
completion on QoL. Cognitive abilities, completion of DSMB, and level of QoL are all 
reciprocally interrelated (Cochran & Conn, 2008; Feil et al., 2012; Primozic et al., 2012; 
Umegaki et al., 2013) and causation can only be fully established through longitudinal 
models. Given these relationships any one of these three constructs could have been 
chosen as an outcome under evaluation in the present study. The most interesting of these 
outcomes that encompasses all of these relationships is the effect of cognitive abilities 
and DSMB on QoL, as achieving better QoL and elucidating the barriers to achieving 
better QoL in T2DM are important clinical and humanistic goals. Rodriguez-Pascual and 
colleagues (2011) found a significant relationship between health-related QoL and 
cognitive impairment, depression symptoms, and functional deficits in individuals with 
T2DM. More severe cognitive impairment, depression symptoms, and functional deficits 
predicted worse perceived QoL. However, DSMBs were not assessed specifically, and 
there was no significant relationship between QoL and A1C (Rodriguez-Pascual et al., 
2011).  
Present Study 
 The present study was an exploratory investigation of two main questions. The 
first was the relationship between cognitive abilities/cognitive functioning and DSMB 
completion. That is, is cognitive functioning related to successful DSMB completion and 
which cognitive abilities are most related to successful DSMB completion? The second 
research question investigated the best predictors of diabetes specific QoL and the impact 
of diabetes on the lives of individuals with T2DM. These research questions were 
answered with two datasets. One was collected specifically for this dissertation, 
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hereinafter referred to as “the prospective study,” and the second was an archival dataset 
from the U.S. Health and Retirement Study (HRS, 2006), hereinafter referred to as “the 
archival study.”  
 The prospective study. The first research question was exploratory as previous 
research had found some significant relationships, but no patterns have emerged that 
allowed for strong specific directional a priori hypotheses. Anticipated results were that 
individuals with T2DM with weaker cognitive abilities (compared to norms and others in 
the sample) would have lower reported DSMB completion. The relationship of DSMB 
completion with demographic (social determinants of health) and disease variables in the 
prospective study sample was also analysed.  
Multiple measures of the cognitive abilities most likely to show deficits in those 
with T2DM (i.e., processing speed and cognitive flexibility/switching) along with at least 
one other measure of major cognitive abilities shown to be impaired in those with T2DM 
(i.e., overall cognitive functioning, memory, attention, working memory, and verbal 
fluency) were included. A questionnaire querying executive functioning through 
behaviours was included as it is important to assess executive functions using multiple 
modalities as objective neuropsychological tests of executive functioning do not always 
correlate well with observed behaviour (Strauss et al., 2006). Multiple measures of 
DSMB were used in order to gain more reliable measurement of all domains. Younger 
adults were included in the sample given the findings of Compeán-Ortiz and colleagues 
(2010) indicating that younger adults showed deficits in memory abilities that impacted 
their DSMB completion. Measures of depression, anxiety, and stress symptoms, 
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premorbid cognitive functioning, as well as information on demographic variables, 
disease variables, and comorbidities, were recorded.   
The second research question sought to determine the best predictors of diabetes-
related QoL in individuals with T2DM. Choice of measured predictors was informed by 
previous theory regarding individual barriers to good management of diabetes, including 
disease, demographic, and depression symptom variables. The size of the collected 
sample did not permit the investigation of these predictive relationships; however; the 
relationship of cognitive abilities, DSMB completion, and chosen predictor variables with 
diabetes-related QoL were investigated using correlational and group difference methods.  
The archival study. The measures used to answer the first and second research 
questions were different for the archival study and were restricted by the measures 
chosen for inclusion in the Health and Retirement Study (HRS, 2006). For the first 
exploratory research question, a total score on a screening measure of cognitive 
functioning was used to predict DSMB completion. Feil and colleagues (2012) used the 
HRS data to answer this first research question by constructing tertiles for cognitive 
functioning and dichotomizing DSMB completion as is common in epidemiological 
research (Bennette & Vickers, 2012). The current archival study analysed these data 
using statistical analyses more common in psychological research. The current archival 
study also included younger individuals with T2DM in the analysis given the findings of 
Compeán-Ortiz and colleagues (2010). Feil and colleagues excluded younger individuals 
with T2DM from their analyses. 
The archival study sought to answer the second research question in the same 
manner as the prospective study, by determining the best predictors of diabetes-related 
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QoL. The outcome measure was a questionnaire about the impact of diabetes in the 
participant’s life from the HRS diabetes dataset. Disease, demographic, and depression 
symptom variables comparable to those from the prospective study were entered in the 
first step of the model. DSMB and cognitive functioning were entered in the second step 
of the model.  
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CHAPTER II 
PROSPECTIVE STUDY METHOD 
Participants and Procedures 
This was a prospective cross-sectional exploratory study. Participants were adults 
with T2DM recruited from multiple outpatient and community centres specializing in the 
treatment of individuals with T2DM in the Windsor community. Windsor-Essex 
Community Health Centre sites in Windsor and Leamington, Hôtel-Dieu Grace 
Healthcare bariatric clinic, Windsor Regional Hospital diabetes clinic, Endocrinologist 
offices in Windsor, the Windsor Family Health Team, the Windsor-Essex branch of 
Diabetes Canada, the Erie St. Clair Local Health Integration Network, Life After Fifty, 
the Windsor-Essex Medical Society, City Centre Health Care, and the University of 
Windsor Participant Pool were contacted by the researcher for the purposes of 
recruitment. All of these organizations agreed to post or circulate the study flyer except 
for the Windsor Regional Hospital and City Centre Health Care. The study flyer was also 
posted at the University of Windsor and circulated on social media. Participants were 
given $20 and had their parking costs reimbursed as part of their participation in the 
study.   
Inclusion criteria for the prospective study consisted of: (a) 40 years of age or 
older, (b) at least a grade 8 education, (c) English proficiency sufficient to understand 
instructions and complete the tests and questionnaires, (d) diagnosis of T2DM for at least 
1 year, and (e) access to current medication(s) list and most recent A1C level to bring in 
for the testing appointment. Exclusion criteria for the prospective study were as follows: 
(a) diagnoses of diabetes other than T2DM (i.e. T1DM or gestational diabetes), (b) 
previous diagnosis of dementia, (c) history of neurological disease, including moderate to 
 33 
 
severe traumatic brain injury, (d) history of severe mental illness requiring 
hospitalization, (e) current substance abuse or history of severe substance abuse, (f) other 
serious diagnosed chronic diseases that are not typically comorbid with T2DM, including 
genetic/congenital disorders, severe respiratory diseases, cancers not in complete 
remission, etc., and (g) hearing or vision problems that cannot be corrected with aids and 
that would have an effect on the standardized administration of the neuropsychological 
measures.   
Thirty-one individuals responded to the advertisement and 26 were recruited and 
completed the study. The five volunteers who did not complete the study were excluded 
due to a diagnosis of dementia (n = 2), history of severe mental illness requiring 
hospitalization (n = 1), diagnosis of T1DM (n = 1), and diabetes duration of less than one 
year (n = 1). Participants were recruited from Windsor-Essex Community Health Centre 
sites (n = 20), from an endocrinologist office (n = 2), from the flyers posted at the 
University of Windsor (n = 2), from the Windsor Family Health Team (n = 1), and from 
the Hôtel-Dieu Grace Healthcare bariatric clinic (n = 1). 
Consent to the blood glucose test and the assessment was obtained upon first 
meeting with each participant. Once consent to participate in the study was obtained, the 
participant tested their blood glucose using a glucometer and testing strips provided by 
the researcher to minimize measurement error. The participant was able to use a 
personally-owned lancet if available; otherwise one was provided by the researcher. The 
researcher recorded the blood glucose level immediately preceding the assessment. If the 
blood glucose level was at or below 4.0 mmol/l, the assessment stopped, and the 
participant was directed to follow their regular procedure for treating hypoglycemia. No 
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participants had blood glucose below 4.0 mmol/l at the outset of the study and all 
participants left the testing appointment without medical incidents of any kind.  
The demographic questionnaire was then completed in interview format with the 
participant. Following this, the neuropsychological tests were administered followed by 
the diabetes self-management behaviour questionnaires, the diabetes-related QoL 
questionnaire, and the mood questionnaires. While the participant was completing the 
assessment an informant completed an informant version of the diabetes self-
management questionnaires. This only occurred for participants who were accompanied 
by a spouse or caregiver who was knowledgeable about the diabetes management 
regimen of the participant and who gave consent to allow the informant to complete the 
questionnaire. All procedures in the present study were approved by the University of 
Windsor Research Ethics Board (REB# 15-134). 
Measures 
All measures are discussed in the order of administration by the examiner during 
the assessment, unless otherwise specified. All measures were chosen for appropriateness 
of use with the participants to be included in the study.  
Demographic questionnaire and Charlson Comorbidity Index. The 
demographic questionnaire, which included questions to permit completion of the 
Charlson comorbidity index, took approximately 20 minutes and was completed as an 
intake interview with the participant in order for the researcher to clarify any responses 
and increase accuracy of the collected information (see Appendix 1).  The demographic 
questionnaire included questions about age, gender, ethnicity, birth place, years in 
Canada if not originally from Canada, primary language, English fluency,  highest 
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education level attained, number of years of English education completed, current 
occupation, current marital status and living arrangements, smoking status, amount of 
alcohol consumed on average, most recent measures of height and weight in order to 
calculate body mass index, current treatment modality (diet and exercise, oral 
hyperglycemic medications, insulin, or some combination) and complete medication list, 
duration of diabetes in years, presence of diabetes complications, presence of psychiatric 
diagnoses or treatment, whether there was hospitalization within the last year, and 
whether or not they had received the “Master Your Health” program or any other diabetes 
education program.  
The Charlson Comorbidity Index (CCI) was developed to estimate prognostic 
comorbidity in longitudinal studies (Charlson et al. 1987). It has been found to reliably 
predict mortality, length of hospital stay, and post-operative complications (Deyo et al. 
1992). The present study used the CCI to enable calculation of a summary score of 
comorbid conditions present along with T2DM to be used as a potential covariate in the 
statistical analyses. The CCI includes a list of 16 comorbid medical conditions that are 
assigned a weight of 1, 2, 3, or 6 corresponding to increased adjusted relative risk. The 
weighted values are added to obtain a total comorbidity score. Some medical conditions 
queried on the CCI were exclusion criteria for study participation and thus were not 
present in study participants: dementia, connective tissue disease, leukemia, malignant 
lymphoma, solid benign tumours and metastatic tumours, and AIDS. Medical conditions 
that were queried along with the demographic questionnaire during the intake interview 
included myocardial infarction, congestive heart failure, peripheral vascular disease, 
cerebrovascular disease, peptic ulcer disease, moderate to severe chronic kidney disease, 
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hemiplegia, liver disease, and chronic obstructive pulmonary disease. Diabetes, although 
queried by the CCI, was not included in the total comorbidity score unless the participant 
reported diabetes complications other than neuropathy. If a participant reported presence 
of neuropathy this was classified as peripheral vascular disease. The maximum score 
possible on this modified version of the CCI was 15.   
Neuropsychological measures and questionnaires. The neuropsychological 
measures included in the present study were selected as measures of the cognitive 
abilities most often affected in those with T2DM according to the meta-analyses and the 
systematic review discussed above (Kinga & Szamosközi, 2014; Monette et al., 2014; 
Palta et al., 2014; van den Berg et al., 2009; Vincent & Hall, 2015). These measures are 
also the measures that would be most likely to detect cognitive deficits in those with 
T2DM (Hachinski et al., 2006; Palta et al., 2014). The cognitive ability(ies) measured by 
each included neuropsychological test score are stated as each measure is discussed 
below in accordance with classifications provided in Strauss et al. (2006) and 
summarized in Table 1. 
The Montreal Cognitive Assessment (MoCA) was developed to be a cognitive 
screening test for Mild Cognitive Impairment (MCI, Nasreddine et al., 2005). The items 
on the test measure immediate and delayed memory, executive, visuospatial, language, 
attention, and orientation abilities with a total score out of 30 indicating current level of 
cognitive functioning (Nasreddine et al., 2005). The MoCA was found to be more 
sensitive than the Mini-Mental State Examination (MMSE) for detecting MCI (90% 
versus 18%) and Alzheimer’s Disease (AD) (100% versus 78%). Specificity of the 
MoCA was high at 87% (Nasreddine et al., 2005). The MoCA places higher demands on 
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executive functioning abilities than the MMSE, and this is important as executive 
functions are the priority for assessment in individuals with T2DM (Hachinski et al., 
2006). Administration of the MoCA takes approximately 10 minutes. A score of ≤ 25 
indicates possible MCI or AD. Internal consistency of the MoCA is good (Cronbach 
Alpha = 0.83) and test-retest reliability over an average of 35 days had a correlation of 
0.92 (Nasreddine et al., 2005).  
Index scores for the MoCA have been developed recently as an added aid in 
determining conversion from intact cognition to MCI or AD (Julayanont et al., 2014). 
Possible index scores are the Memory Index Score, calculated by adding the number of 
words recalled in free (given a weight of 3), cued (given a weight of 2), and multiple 
choice (given a weight of 1) recall, with a score ranging from 0 to 15; the Executive 
Index Score, calculated by adding the raw scores from the Trail Making Test part B, 
clock drawing, digit span forward and backward, A tapping, serial-7 subtraction, letter 
fluency, and abstraction items, and producing a score ranging from 0 to 13; the 
Visuospatial Index Score, calculated by adding the raw scores of the cube copy, clock 
drawing, and naming items, producing a score ranging from 0 to 7; the Language Index 
Score, calculated by adding the raw scores for naming, sentence repetition, and letter 
fluency, producing a score ranging from 0 to 6; the Attention Index Score, calculated by 
adding the raw scores for digit span forward and backward, vigilance (tapping when the 
letter A appeared in a string of letters read aloud), serial-7 subtraction, sentence 
repetition, and both immediate recall trial words, producing a score ranging from 0 to 18; 
and, lastly, the Orientation Index Score, ranging from 0 to 6, is calculated by summing 
the orientation items from the MoCA (Julayanont et al., 2014). All indices along with the 
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total MoCA score were good statistically significant predictors of conversion from intact 
cognition to MCI and AD with the exception of the Language Index Score (Julayanont et 
al., 2014).   
The Rey Auditory Verbal Learning test (RAVLT) is a list learning task that 
measures immediate memory, total learning, recall after a distracter task, recall after a 20 
minute delay, and recognition. Administration took approximately 10-15 minutes 
excluding the 20 minute delay. A list of 15 words was read aloud at the rate of one per 
second. The participant was asked to repeat as many words as they could remember in 
any order. This was done four more times with a fixed order of presentation for the 15 
words for a total of five learning trials. A second list of 15 new words was then presented 
and the participant was asked to recall as many words as they could in any order from the 
second list. Immediately following this the participant was asked to recall as many words 
as they could from the list that was presented five times. After a 20 minute delay the 
participant was asked to recall the words a final time.  They were then presented with a 
recognition task consisting of a list of 50 words containing the 30 words they had seen 
from the two lists as well as 20 new words that were phonemically or semantically 
similar to the words they had been presented with previously (Strauss et al., 2006).  
The Geffen norms from Strauss et al. (2006, pp. 795-6) were used as these 
encompassed the entire age range of participants in the present study. These norms are 
age and gender corrected as no age corrected only norms could be found for this task. 
The mean number of words recalled and pooled standard deviations were calculated for 
each age group collapsing across gender and the resulting means and standard deviations 
were used to norm the raw scores on this task. Cronbach alpha was high for the total 
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score (r = .90), test-retest reliability at one year was 0.60 for the fifth learning trial and 
0.70 for delayed recall, and delayed recall scores have high correlations with total 
learning scores (r > .75; Strauss et al., 2006). The Palta and colleagues (2014) meta-
analysis found larger effect sizes for the RAVLT as compared to the California Verbal 
Learning Test and a memory test should be included in assessment of individuals with 
T2DM (Hachinski et al., 2006). 
The Trail Making Test measures processing speed (Part A) and cognitive 
flexibility/shifting (Part B), the cognitive abilities most severely affected by T2DM 
(Monette et al., 2014). Administration took approximately 5 minutes unless there were 
severe impairments on the task. The participant was asked to connect numbers from 1 to 
25 that were randomly placed on the page in ascending order (Part A) and then connect 
numbers and letters in the same fashion, alternating between the two (Part B, Strauss et 
al., 2006). The time to completion raw score for parts A and B were converted to a T-
score adjusted for age according to norms from the CNNS (Schretlen et al., 2010). Test-
retest reliability was adequate in most healthy and clinical populations evaluated (Strauss 
et al., 2006). Part A and Part B were moderately correlated (r = .31), which suggests the 
two parts measure similar although somewhat different abilities (Strauss et al., 2006).  
The Salthouse Perceptual Comparison Test is a comparison task that can be used 
as a measure of processing speed (Schretlen et al., 2010). The task is timed and sensitive 
to mild difficulties with processing speed. The task also has a low motor demand, only 
requiring the participant to make same or different judgments and indicating their 
response by writing “S” or “D.” This was valuable to the present study as individuals 
with T2DM are more impaired on tasks of processing speed with motor task demands 
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(more representative of psychomotor efficiency) versus orally presented processing speed 
tasks (more representative of central processing speed, Monette et al., 2014). There were 
four conditions, two letter conditions, one with 3 letters and one with 6 letters, each 
completed for 30 seconds, and two pattern conditions, one with 3 line patterns and one 
with 6 line patterns, each completed for 30 seconds. The score was the number of correct 
responses achieved in each of the 30 second trials. The raw scores were converted to a T-
score adjusted for age according to norms from the Calibrated Neuropsychological 
Normative System (CNNS, Schretlen et al., 2010).  
The Digit Span test was used to measure attention (digit span forward) and 
working memory (digit span backwards, Schretlen et al., 2010). Participants heard a 
string of digits of increasing length over several trials and they were required to repeat 
them exactly as heard (forward) or in reverse order (backward). The scores were the 
longest digit string recalled for each condition. The raw scores were converted to a T-
score adjusted for age according to norms from the CNNS (Schretlen et al., 2010). 
The Color-Word Interference Test from the Delis-Kaplan Executive Function 
System (D-KEFS, Delis et al., 2001) was used to measure processing speed (trial 1 & 2), 
inhibition (trial 3), and inhibition and switching (trial 4), all abilities moderately affected 
by T2DM (Monette et al., 2014). Trial 1 required participants to name the colour of ink 
patches as quickly as possible. Trial 2 required participants to read colour words printed 
in black ink as quickly as possible. Trial 3 required participants to name the colour of ink 
a colour name was printed in as quickly as possible; the colour name did not match the 
colour of ink. Trial 4 required participants to complete the same task as trial 3 in addition 
to reading the colour word of items contained inside a box, but continuing to name the 
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colour ink for items not contained inside a box. Time to completion was the raw score for 
all 4 trials. The raw scores were converted to a scaled score adjusted for age according to 
norms from the D-KEFS (Delis et al., 2001). 
The verbal fluency task used the letters F, A, and S to measure phonemic fluency 
and the category animals to measure semantic fluency; both abilities are components of 
executive functioning. The participant was asked to name as many words as they could in 
one minute that begin with the letter F, then A, then S. They could not name proper 
names of people, places, or things and they could not name the same word with a 
different ending. They were then asked to name as many animals as they could in one 
minute (Strauss et al., 2006). Tombaugh and colleagues (1999) reported high internal 
consistency (α = .83) and acceptable test-retest reliability over a 5.6 year re-test period (r 
= .74). They also reported that animals named had a correlation of .52 with FAS scores. 
The norms from Tombaugh et al. were used in the present study. These norms were age 
and education corrected as no age corrected only norms could be found for this task. The 
mean number of words named and pooled standard deviations were calculated for each 
age group collapsing across education levels and the resulting means and standard 
deviations were used to norm the raw scores on this task.     
The Hopkins Adult Reading Test–A (HART–A) is a list of 34 irregularly 
pronounced words and a single letter that can be used as an estimate of premorbid 
intellectual abilities (Schretlen et al., 2009). The participant was asked to read the 35 
items aloud and was given credit for each item correctly read and pronounced. Cronbach 
alpha for the HART-A was high at .93 and the correlation of the short-form HART-A to 
the 70 word long-form HART was .98 (Schretlen et al., 2009). Test-retest reliability over 
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a 4-6 year period was high at .94. The raw score was converted to an age corrected Full-
Scale IQ score as per norms from the CNNS (Schretlen et al., 2010).  
The Rapid Estimate of Adult Literacy in Medicine – Short Form (REALM-SF) 
was used to estimate health literacy, a possible covariate in analysis of the relation 
between cognitive abilities and DSMB (Emery et al., 2010). The REALM-SF is a seven 
item list of medically related words that provides an estimated grade level of reading for 
health literacy based on how many of the seven words are read and pronounced correctly 
(0 words < 3rd grade, 1-3 words = 4th - 6th grade, 4-6 words = 7th - 8th grade, and 7 
words > 9th grade, Arozullah et al., 2007). The REALM-SF and the long-form 66 item 
REALM correlated highly with each other at 0.94 and had excellent agreement between 
assigned grade-levels (Arozullah et al., 2007). The REALM-SF correlated highly with the 
Wide Range Achievement Test – Revised total index score at 0.83 (Arozullah et al., 
2007). The validation sample included ethnic minorities and older adults. The HART-A 
and the REALM-SF took approximately 10 minutes to administer.  
The Behavioral Rating Inventory of Executive Functions – Adult Version 
(BRIEF-A) was included as it is a standardized self-report inventory of behaviours 
related to executive functioning, the cognitive domain that should be assessed most 
thoroughly in individuals with T2DM (Hachinski et al., 2006). Executive functioning is a 
broad category of cognitive abilities that organize and direct the domains of cognitive 
functioning, emotional responses, and behaviour (Roth et al., 2005). The BRIEF-A 
contains a number of scales that query different aspects of executive functioning, 
including Inhibition, Shifting, Emotional Control, Initiation, Working Memory, 
Planning/Organizing, Organization of Materials, Self-Monitoring, and Task Monitoring 
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(Roth et al., 2005). These scales were combined to form three summary indices, the 
Behavioural Regulation Index, the Metacognition Index, and the Global Executive 
Composite. The BRIEF-A has 75 items and higher scores indicate more difficulties with 
executive functioning. It took 10-15 minutes to complete. The BRIEF-A has excellent 
internal consistency (Cronbach α ranging from .93 to .96 for the three major indices and 
from .73 to .90 for the individual clinical scales) and test-retest reliability for an average 
one month interval (ranging from r = .93 to .94 for the three major indices and from .82 
to .93 for the individual clinical scales, Roth et al.). Expert consensus was used to assess 
content validity, and convergent and divergent validity was good (Roth et al., 2005).  
Table 1  
Summary of neuropsychological test scores and measured cognitive abilities and 
domains in the present study  
Measure  Score Cognitive Ability  Domain  
MoCA  Total score  N/A Overall cognitive 
functioning (this is 
a screener for MCI) 
RAVLT Trial 1 total words 
recalled  
Working memory  Executive 
functioning 
  
Total number of 
words recalled after 
five learning trials  
 
Learning and 
immediate recall   
 
Memory  
  
Total number of 
words recalled after 
a distractor task 
(trial 6) 
 
Immediate recall 
after distractor  
 
Memory  
  
Total number of 
words recalled after 
a 20 minute delay 
(trial 7) 
 
Delayed recall  
 
Memory  
  
List A recognition 
total number of 
words  
 
Recognition  
 
Memory  
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Trail Making Test Part A total time to 
completion  
Processing Speed  Processing Speed  
  
Part B total time to 
completion  
 
Cognitive 
flexibility/shifting  
 
Executive 
functioning  
Salthouse 
Perceptual 
Comparison Test 
Number of correct 
responses in 60 
seconds (letters) 
Processing Speed  Processing Speed 
  
Number of correct 
responses in 60 
seconds (patterns) 
 
Processing Speed  
 
Processing Speed 
Digit Span Test  Longest digit 
sequence recalled 
forward  
Attention  Attention  
  
Longest digit 
sequence recalled 
backward 
 
Working Memory  
 
Executive 
functioning 
Color-Word 
Interference Test 
Trial 1 time to 
completion  
Processing Speed  Processing Speed 
  
Trial 2 time to 
completion  
 
Processing Speed  
 
Processing Speed  
  
Trial 3 time to 
completion 
 
Inhibition  
 
Executive 
functioning  
  
Trial 4 time to 
completion 
 
Inhibition/Shifting  
 
Executive 
functioning  
FAS and Animals 
verbal fluency  
Total number of 
words named for F, 
A, and S trials  
Phonemic verbal 
fluency  
Executive 
functioning 
  
Total number of 
animals named  
 
Semantic verbal 
fluency  
 
Executive 
functioning 
 
DSMB measures. Three measures of DSMB were used in the present study: the 
Self-Management Profile for Type 2 Diabetes (SMP-T2D), the Summary of Diabetes 
Self-Care Activities (SDSCA), and the Diabetes Self-Management Questionnaire 
(DSMQ), see Appendix 2). These three measures of DSMB were used as each measure 
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includes unique domains of DSMB including the domains shown to be negatively 
impacted by cognitive deficits discussed earlier. The three measures also use different 
approaches to asking about DSMB. In addition, combining scores that measure the same 
DSMB domains across measures allowed for a more reliable estimate of each of the 
behaviours each domain measures. Each of the three measures will now be discussed. 
Scores from each measure and how they were averaged for the data analysis are 
summarized in Table 2.  
The Self-Management Profile for Type 2 Diabetes (SMP-T2D) is a 12-item scale 
and required 3-5 minutes to complete. It measures four dimensions of diabetes self-
management: blood glucose monitoring, medication taking, healthy eating, and engaging 
in physical activity (Peyrot et al., 2012). Four scores are produced; there is no summary 
score for the scale (Peyrot et al., 2012) Participants were asked to indicate completion of 
behaviours over the past week. The questions on the SMP-T2D are asked in a way that 
queries the number of days participants missed completing DSMB, instead of asking 
them to report a lack of compliance in completing required behaviours with the 
assumption that participants would be more likely to report the former over the latter 
(Peyrot et al., 2012).  
Content validity  of the SMP-T2D was assessed by literature review, interviews 
with 49 individuals with T2DM, an expert panel composed of experts in epidemiology 
and diabetes care, and a pilot study with a sample of 83 individuals with T2DM (Peyrot 
et al., 2012). Criterion validity was poor with correlations between the four content areas 
and A1C falling between -.03 and .07 (Peyrot et al., 2012). This is not unusual. A1C is 
the “Gold Standard” measure for diabetes management. However A1C, because blood 
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glucose levels are variable in T2DM, is known to correlate poorly with other indicators of 
diabetes management, such as self-reported DSMB and random and fasting blood glucose 
levels (Walker & Usher, 2003). Construct validity was good with all convergent and 
divergent a priori hypotheses being supported at statistically significant levels. 
Cronbach’s alpha was high with a median of .80 and a range of .71 to .87 across content 
areas. Test-retest reliability was good for a 1 week interval (r = .83, Peyrot et al., 2012). 
The SMP-T2D was found to be the psychometrically strongest DSMB measure in a 
recent review of DSMB measures (Caro-Bautista et al., 2014). 
The Summary of Diabetes Self-Care Activities (SDSCA) is an 11-item scale with 
6 supplemental scale items. It took 6-8 minutes to complete. It is the most widely used 
measure of DSMB in the literature (Schmitt et al., 2013). The five core self-management 
domains are diet (which has a general diet subscale and a specific diet subscale), exercise, 
blood glucose testing, foot care, and smoking. Smoking was queried during the intake 
interview; therefore this item was omitted from the questionnaire. The supplemental 
domain used in the present study is medication taking (Toobert et al., 2000). Participants 
were asked to report on how many of the past 7 days they completed the queried 
behaviours. Toobert and colleagues reported numerical psychometric properties for an 
earlier version of the scale, but not for the revised version that will be employed in the 
current study. They reported that the items of the revised scale were chosen because they 
showed consistent mean values across studies, lack of ceiling or floor effects, temporal 
stability, internal consistency, predictive validity, sensitivity to change, ease of scoring, 
and ease of interpretation (Toobert et al., 2000).  
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Caro-Bautista and colleagues (2014) reviewed the first version of the SDSCA and 
found the measure to have good content validity, intermediate internal consistency, and 
poor criterion and test-retest reliability. As with the SMP-T2D, the poor criterion validity 
was due to limitations in A1C as “Gold Standard” comparison criterion measure (Schmitt 
et al., 2013). The revised version of the SDSCA was the only DSMB measure to meet all 
the criteria for recommended use in another review of DSMB measures (Eigenmann et 
al., 2009). Schmitt and colleagues reported a Cronbach alpha of .63 for the revised 
version of the SDSCA. The Cronbach alphas for two of the four diet items representing 
the general diet subscale, and for the exercise, blood glucose testing, and foot care 
domains ranged from .69 to .88. The two other diet items representing the specific diet 
subscale had a Cronbach alpha of .15 (Schmitt et al., 2013). As such, the current study 
only used the two general diet subscale items leading to a final scale of 10 items (8 core 
[smoking item also omitted] and 2 supplemental). Schmitt and colleagues also reported 
adequate test-retest reliability. In the present study the SDSCA produced five scores; 
there is no summary score for the SDSCA.   
The Diabetes Self-Management Questionnaire (DSMQ) is a 16 item scale that 
took 4-6 minutes to complete (Schmitt et al., 2013). Participants were asked to rate on a 
4-point scale how much each of the 16 statements related to self-care activities applied to 
them when thinking back over the past 8 weeks. The DSMQ measures four domains: 
glucose management (includes medication and blood glucose monitoring), dietary 
control, physical activity, and health care use (attending diabetes-related medical 
appointments). The DSMQ was developed specifically to be correlated with A1C level, 
the “Gold Standard” criterion measure (Schmitt et al., 2013). All 16 items on the DSMQ 
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negatively correlated with A1C indicating lower A1C when better diabetes self-care was 
reported, as would be expected. Fourteen of the 16 items had statistically significant 
correlations with A1C level (mean r = -.23, SD = 0.09, range = -.09 to -.38). Cronbach 
alpha for the overall scale was .84, and ranged from .6 to .77 for individual subscales 
(Schmitt et al., 2013).  
The DSMQ provided five scores, one for each of the four domains and a total 
score for the measure. Exploratory and confirmatory factor analyses confirmed the four 
factor structure of the DSMQ (Schmitt et al., 2013). The authors suggested that the 
significant correlation of the DSMQ total score with A1C (r = −0.38, p < 0.001), in 
contrast to the lack of significant associations of  the SDSCA and the DSMQ with A1C,  
was due to differences in conceptualization of DSMB among the three measures and to 
differences in the time frame participants were asked to address. The DSMQ included 
questions about self-care behaviours and about attending medical appointments as 
opposed to only questions about self-management behaviours as the other two measures 
did. The queried timeframe of the DSMQ was eight weeks versus one week for the 
SDSCA and SMP-T2D. These differences allowed for a more reliable estimate of self-
care behaviours and for a better predictor of A1C levels (Schmitt et al., 2013). 
Participants were asked to bring to the assessment a spouse or caregiver who was 
knowledgeable about the participant’s diabetes treatment regimen. The spouse or 
caregiver completed a modified and combined version of the DSMB measures (see 
Appendix 2) while the participant was completing the assessment. There were only seven 
informants in the present study. All informants were spouses of the participants. Given 
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the small number of informants and high incidence of missing data due to “don’t know” 
responses, informant data were not analysed in the present study.   
Table 2  
Summary of DSMB scores provided by each measure and used in the analyses 
Measure  Domain Score 
SMP-T2D Medication  
Blood glucose monitoring 
 Diet  
 Physical Activity  
SDSCA Medication  
Blood glucose testing  
General diet  
 Exercise  
 Foot care  
DSMQ Medication  
Blood glucose monitoring  
 Diet 
 Physical activity  
 Healthcare use 
 Total Score  
Average score used in analysis DSMB measures included in average score 
DSMB Medication SMP-T2D and SDSCA medication scores; 
DSMQ medication excluded (Cronbach’s 
α=.876) 
DSMB Blood Glucose SMP-T2D, SDSCA, and DSMQ blood 
glucose monitoring scores (Cronbach’s 
α=.881) 
DSMB Diet SMP-T2D and DSMQ diet scores; SDSCA 
diet excluded (Cronbach’s α=.756) 
DSMB Exercise  SMP-T2D, SDSCA, and DSMQ exercise 
scores (Cronbach’s α=.913) 
SDSCA Foot Care  Not an average score  
DSMQ Healthcare Use  Not an average score 
DSMQ Total Score Not an average score 
Note. Average scores were calculated in the following way: First, individual scores from 
each DSMB measure were converted to z-scores; Second, the mean of z-scores for each 
average DSMB score was calculated; Finally, this score was converted to a t-score for 
ease of interpretation; DSMQ medication was excluded from the Medication average 
score due to poor internal consistency (Cronbach’s α=.664 when included). SDSCA diet 
was excluded from Diet average score due to poor internal consistency (Cronbach’s 
α=.553 when included)      
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Diabetes-related Quality of Life measure. The Audit of Diabetes Dependent 
Quality of Life (ADDQoL) was developed to measure overall QoL and the impact of 
diabetes on QoL. The ADDQoL allowed participants to indicate the impact of their 
diabetes on 19 aspects of life, to indicate whether the impact is positive or negative, as 
well as to indicate the perceived importance of each of the QoL aspects. It took 
approximately 10 minutes to complete. There was one general item that queried current 
QoL and 19 subsequent items that queried various life domains and the impact of 
diabetes on these domains, including leisure, work, relationships, self-image, finances, 
and independence (Bradley & Speight, 2002). The newest version of the ADDQoL19, 
which was used in the present study, included simplified instructions, questions, and 
wording (Bradley, 2012). The ADDQoL19 was chosen as it is a well validated measure 
of the impact of diabetes on QoL across multiple relevant life domains (Ostini et al., 
2012). In addition, diabetes specific QoL measures have been found to be more valid and 
reliable measures of QoL in individuals with diabetes when compared to general and 
health-related QoL measures (El Achhab et al., 2008).  
Ostini and colleagues (2014) reported that three reviews have found that the 
ADDQoL is a reliable instrument with good face and content validity. In their study, 
using the Multitrait-Multimethod approach, they reported that the ADDQoL19 has good 
construct validity; a priori hypotheses were supported and analyses demonstrated 
convergent and divergent validity (Ostini et al., 2014). Internal consistency of items was 
very high (α = .95, Ostini et al., 2014).    
Mood measures. Measures of depression symptoms were given to participants as 
depression symptoms have been shown to impact DSMB completion (Lin et al., 2004) 
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and continuous measures of depression symptoms capturing subclinical symptom levels 
have been shown to better predict the impact of depression on DSMB completion than a 
diagnosis of MDD (Gonzalez et al., 2016). 
 The Geriatric Depression Scale - Short-Form (GDS-SF) is a 15 item screening 
measure for depression symptoms in older adults that employs a yes/no answer format 
that is easier for those with cognitive deficits, lower education, or less proficiency with 
English to understand and complete (Edelstein et al., 2010). The participant was asked to 
indicate if they had experienced symptoms of depression in the past week. The GDS-SF 
took 5-7 minutes to complete.  The GDS-SF has high internal consistency (α= .88). The 
correlation between the GDS-SF and the 30 item long-form is .89 and the two measures 
have similar sensitivity and specificity (Edelstein et al., 2010). The raw scores were 
converted to a T-score adjusted for age according to norms from the CNNS (Schretlen et 
al. 2010).  
The Depression Anxiety Stress Scale – Short-form (DASS-21) is a 21 item 
screening measure for depression, anxiety, and stress symptoms (Lovibond & Lovibond, 
1995). It was beneficial to measure anxiety and stress symptoms in the current study as 
individuals with T2DM experience higher levels of anxiety and stress than those without 
T2DM (de Groot et al., 2016; Emery-Tiburcio et al., 2015) and these symptoms could 
impact DSMB completion and diabetes-related QoL. The participant was asked to rate 
how much each statement has applied to them in the past week on a 4-point scale (0-3). 
The DASS-21 took approximately 8 minutes to complete. The 42 item long-form of the 
DASS has strong psychometric properties (Carmin & Ownby, 2010). The DASS-21 has 
been found to have good internal consistency, excellent convergent validity, and good 
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discriminant validity (Carmin & Ownby, 2010). The raw scores were converted to a z-
score according to norms from the DASS manual (Lovibond & Lovibond, 1995). 
Both the GDS-SF and the DASS-21 were used in the present study as neither 
measure was originally developed and validated to assess mood symptoms for the entire 
age range of participants in the present study, although, subsequent studies have shown 
that the GDS-SF can be used with younger adults (Rule et al., 1989; Sivrioglu et al., 
2009) and that the DASS-21 can be used with older adults (Gloster et al., 2008).  
Differences in depression symptom levels reported using both measures were 
investigated.  
Analyses  
Descriptive statistics were reported based on raw scores for all data and age-
corrected standardized scores for the neuropsychological and mood measures based on 
the norms described above for each measure. Normed age-corrected scores from the 
neuropsychological measures were used in all analyses to minimize error as the sample 
was not large enough to use covariates. The REALM-SF was not included in the analyses 
as all but two participants had a medical literacy level of equal to or greater than a Grade 
9 level. The other two participants had a medical literacy level equivalent to a Grade 8 
reading level. None of the measures used in the study required a reading level greater 
than Grade 8. All variables for which paired t-tests and repeated measures ANOVAs 
were done were recoded if the variables were not measured on the same scale. 
Associations between the demographic and disease variables and the DSMB and QoL 
scores were analysed and reported along with the descriptive statistics for these variables.  
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The first research question was answered by analysing the Pearson r correlations 
between all measures of cognitive functioning and the average DSMB scores. The second 
research question was answered by analysing the Pearson r correlations between 
diabetes-related and general QoL and all measures of cognitive functioning and the 
average DSMB scores. The potential difference between the two measures of depression 
symptoms was analysed. Lastly, additional exploratory analyses were completed to 
investigate potential differences on the three measures of processing speed administered 
in the study and also potential differences between the objective neuropsychological tests 
and the self-report behavioural data provided by the BRIEF. Measures of effect size (r
2
, 
Cohen’s d, ω2) were calculated and reported where appropriate.  
Assumptions and missing data. The statistical assumptions for t-tests, 
ANOVAs, and correlations were evaluated. There were no outliers (defined as a z-score 
greater or lesser than 3.29, Tabachnick & Fidell, 2007) on most variables used in the 
analysis. The MoCA Orientation scale had two extreme scores (both z = -3.397) and the 
DSMQ Healthcare Use score had one extreme score (z = -3.965). However in both 
instances, these outliers did not represent actual extreme values in the population. For the 
MoCA Orientation scale, the outliers are individuals who scored 5/6 whereas every other 
participant scored 6/6. For the DSMQ Healthcare Use score, the outlier reported 
relatively lower health-care use than the rest of the participants in the sample. Most 
participants scored 10/10 for health care use, the outlier scored 5.56/10. Ceiling effects 
for both of these variables are concordant with the sample in the present study having 
been drawn from healthy community dwelling adults attending their maintenance medical 
appointments. Given this, the outliers were not removed from the analyses.  
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Normality was investigated using multiple methods which included inspection of 
histograms, use of the Shapiro-Wilks test, and inspection of skewness and kurtosis 
values. All variables in the analyses satisfied the assumption of normality except for the 
MoCA Orientation scale and the DSMQ Healthcare Use score. Both variables had 
elevated negative skew (greater than |2|) and positive kurtosis (greater than |3|). These 
violations are due to the ceiling effects discussed above and thus the variables were not 
transformed. Interpretation of significant findings involving these two variables took into 
account the fact that these variables contain outliers and were not normally distributed.     
Bivariate scatter plots were inspected for every pair of variables for which 
Pearson r correlations coefficients were calculated. The linearity and homoscedasticity 
assumptions were satisfied for all correlations in the analysis based on acceptably linear 
and homoscedastic patterns in the scatter plots. Levene’s test was used to evaluate the 
homogeneity of variances assumption for the independent t-tests and the one-way 
ANOVAs. For the independent t-tests, if Levene’s test was significant, the equal variance 
not assumed t statistic was reported and interpreted where necessary. For the one-way 
ANOVAs, Levene’s test was not significant for all ANOVAs except for the Employment 
Status ANOVA with DSMB Exercise and Diabetes-related QoL as the dependent 
variables. However, in both instances, the largest variance was less than four times larger 
than the smallest variance. Mauchly’s test of sphericity was not significant for all 
repeated measures ANOVAs except for the one with medication as the outcome variable. 
For this test, the Greenhouse-Geisser corrected statistic was interpreted.   
Three participants had scores missing from one or two of the three DSMB 
measures that comprised the average DSMB scores. Two participants were missing 
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scores for the SDSCA and DSMQ medication score and one participant was missing a 
score for the DSMQ blood glucose score. For these three participants, the average DSMB 
score was calculated from the one or two available scores. One participant who did not 
take medication had missing data for all three DSMB measures for the medication score. 
Thus, all analyses involving the DSMB Medication score have a sample size of 25 
participants. These were the only missing data in the prospective study.  All statistical 
analyses were completed using the Statistical Package for the Social Sciences (SPSS) 
version 22.  
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CHAPTER III 
PROSPECTIVE STUDY RESULTS 
Descriptive statistics were calculated for all demographic, health, and diabetes-
related variables, as well as, all neuropsychological, DSMB, Mood, and QoL measures. 
These are reported first. Next, relationships between the demographic, health, diabetes-
related variables, and mood measures with the measures of DSMB and QoL were 
evaluated. Following this, correlations between the neuropsychological measures and the 
DSMB measures were calculated to answer the first research question. Correlations 
between the DSMB and neuropsychological measures and the QoL measures were then 
calculated to answer the second research question. Next, comparisons of scores on the 
depression and processing speed measures were done to answer questions about the 
possible differences due to the age of the participants for the depression measures and to 
the differing motor demands of the processing speed measures. Finally, additional 
exploratory analyses were conducted comparing scores on self-report and performance 
based neuropsychological measures of processing speed.  
Descriptive Statistics  
 The descriptive statistics for the demographic, health, and diabetes-related 
variables for the 26 participants are found in Table 3. All data were self-reported except 
for BMI, most recent A1C, medications taken, and pre-testing blood glucose. BMI was 
calculated from self-reported most recent height and weight measurements. All but two 
participants completed high school. The study sample overall was highly educated and 
overwhelmingly of white race and Canadian ethnicity. On average the sample had a BMI 
classified in the obese range, low levels of reported current and chronic pain, low levels 
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of comorbid conditions as measured by the CCI, A1C levels slightly above the 7% target 
range, and pre-testing blood glucose in the hyperglycemic range.   
Table 3 
Descriptive statistics for demographic, health, and diabetes-related variables (N=26) 
Variable N(%)
a
 Mean (SD) Min-Max 
Demographic  
Age   62.12 (12.599) 41-83 
Years of Education  14.46 (2.642) 9-22 
Female Gender 11(42.3)   
Ethnicity 
b
  
  White or Canadian 25(96.2) 
Eastern European  1(3.8) 
Birthplace
b
  
  Canada 25(96.2) 
 Eastern Europe 1(3.8) 
Language spoken day-to-day
b
  
  English 25(96.2) 
French, but fluent in English 1(3.8) 
Employed  
  
Yes 9(34.6) 
No 3(11.5) 
Retired 14(53.8) 
Partnered   
  Single, Divorced, or Widowed 9(34.6) 
Married or Cohabitating 17(65.4) 
Informant Present 7(26.9)   
Health and diabetes-related  
Smokes Cigarettes
b
 2(7.7)   
Drinks Alcohol 11(42.3)   
BMI (kg/m
2
)  33.700 (6.648) 19.0-44.9 
Current Pain 0-9 scale
c
  1.63 (2.287) 0-7 
Chronic Pain 0-9 scale
c
  2.00 (2.884) 0-9 
Total score on CCI
c
  1.08 (1.294) 0-4 
Previous Psychiatric Dx
b
 4(15.4)   
Hospitalized Past Year
b
 3(11.5)    
Past Diabetes Education
b
  26(100)    
Diabetes Duration in years   13.04 (10.204) 1-36 
Most Recent A1C (%)
c
  7.185 (1.225) 5.0-10.6 
Hospitalized for Hypo
b
 1(3.8)    
Reported T2DM Complication 7(26.9)   
Treatment Modality    
Diet & Exercise 3(11.5)  
Medication only 9(34.6) 
Medication & Insulin 14(53.8) 
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Other Medication  
High Cholesterol 21(80.8)   
Hypertension 24(92.3)   
Hypothyroid 7(26.9)   
Cardiovascular  5(19.2)   
Elevated Uric Acid 2(7.7)   
Acid Reflux 7(26.9)   
Arthritis 3(11.5)   
HRT 1(3.8)   
Fibromyalgia 2(7.7)   
Anxiety 1(3.8)   
Depression 5(19.2)   
Aspirin 81mg 12(46.2)    
Blood Glucose Pre-Testing (mmol/l)
c
  10.131 (3.491) 5.2-18.6 
Note. BMI: Body Mass Index; CCI: Charlson Comorbidity Index; DASS: Depression 
Anxiety Stress Scale; Dx: Diagnosis; GDS: Geriatric Depression Scale; Hypo: 
Hypoglycemia; HRT: Hormone Replacement Therapy   
a
All percentages indicate a yes response or the response is included in the variable label 
unless otherwise indicated or there are multiple groups  
b
Not enough variability in answers to perform analyses for associations with DSMB and 
QoL 
c
Higher scores indicate worse symptoms, worse diabetes control, or greater comorbidity   
 
Table 4 contains the average raw and normed scores for all neuropsychological 
tests administered. The estimated Full-Scale IQ of the sample based on the Hopkins 
Adult Reading Test (HART) was in the high average range. Twelve participants scored 
below the cut-off on the Montreal Cognitive Assessment (MoCA), indicating possible 
cognitive impairment. However, all mean scores on all neuropsychological tests were in 
the average range as per the age-corrected norms except for the majority of the memory 
measures from the Rey Auditory Verbal Learning Test (RAVLT), which were in the low 
average range. The norms used for the RAVLT in the present study could have 
underestimated the performance of participants on this measure as compared to other 
available norms (Strauss et al, 2006); however, the norms used in the present study were 
the only norms that encompassed the entire age range of participants recruited in the 
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study.  Thus, the sample on average is cognitively intact based on their performance on 
the objective neuropsychological measures.  
The participants reported difficulties with executive functioning that fell within 
the low average range for most indices of the Behavioral Rating Inventory of Executive 
Functions (BRIEF) in contrast to their average range performance on the objective 
measures of executive functioning. The proportion of participants that scored below 1.5 
standard deviations from the mean varied by measure, was generally low overall (less 
than 15% of the sample for the majority of scores), and was highest for the RAVLT and 
BRIEF scores.  
Table 4 
Descriptive statistics for neuropsychological measures and questionnaires (N=26)    
Test  Mean(SD)
a 
 
Sample 
Min-
Max 
Test 
Min-
Max 
Mean (SD)
b
  
N(%) of 
people 1.5 
SD below 
the mean 
MoCA  
     
Total Score 24.769 (2.717) 18-30 0-30 
 
12 (46.2) 
Memory Index 11.192 (2.638) 6-15 0-15 
  
Executive Index 11.038 (1.661) 7-13 0-13 
  
Visuospatial 
Index 
6.038 (0.916) 4-7 0-7 
  
Language Index 4.885 (1.107) 3-6 0-6 
  
Attention Index 16.115 (1.840) 12-18 0-18 
  
Orientation 
Index 
5.923 (0.272) 5-6 0-6 
  
RAVLT  
     
Trial 1 4.192 (1.415) 0-7 0-15 -0.973 (1.024) 6 (23.1) 
Trial 5 9.038 (2.705) 3-14 0-15 -0.817 (1.245) 9 (34.6) 
Total Learning 36.077 (9.952) 18-57 0-75 -0.966 (1.093) 9 (34.6) 
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List B 4.115 (1.840) 1-8 0-15 -0.535 (1.219) 7 (26.9) 
Trial 6 7.077 (3.224) 1-12 0-15 -0.700 (1.363) 7 (26.9) 
Trial 7 6.385 (2.872) 1-12 0-15 -0.811 (0.912) 7 (26.9) 
Recognition 
Hits 
11.731 (2.376) 6-15 0-15 -0.142 (1.053) 3 (11.5) 
Salthouse  
     
Letter 25.731 (6.792) 14-40 0-64 48.692 (10.810) 2 (7.7) 
Pattern 35.769 (9.066) 21-53 0-64 52.192 (11.795) 3 (11.5) 
Total 
61.500 
(15.321) 
36-93 0-128 49.808 (11.541) 3 (11.5) 
TMT A
c
  
39.485 
(15.512) 
17.370-
92.160 
0-300 46.962 (9.374) 3 (11.5) 
TMT B
c
  
90.434 
(35.272) 
32.750-
207.580 
0-300 49.346 (9.604) 3 (11.5) 
Longest Digit 
Span      
Forward 5.962 (1.113) 5-9 0-9 45.808 (8.971) 0 (0) 
Backward 4.346 (1.263) 2-7 0-8 44.308 (10.921) 5 (19.2) 
Total 10.308 (1.934) 8-15 0-17 44.077 (9.125) 4 (15.4) 
D-KEFS 
Colour-Word       
Condition 1
c
 31.692 (5.485) 
23.110-
42.440 
0-90 10.269 (2.393) 0 (0) 
Condition 2
c
 23.532 (3.797) 
18.000-
33.330 
0-90 10.423 (2.452) 1 (3.8) 
Condition 3
c
 
64.897 
(15.375) 
42.620-
107.870 
0-180 10.308 (2.936) 3 (11.5) 
Condition 4
c
 
76.509 
(24.055) 
41.600-
148.280 
0-180 9.577 (3.580) 3 (11.5) 
F A S Total 
34.231 
(11.931) 
15-58 
0- No 
Max. 
-0.463 (1.107) 4 (15.4) 
Animals Total  19.077 (5.699) 9-31 
0- No 
Max. 
0.203 (1.299) 4 (15.4) 
HART-A 24.654 (5.314) 11-34 0-35 116.000 (10.092) 0 (0.000) 
BRIEF 
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Inhibit
d
 11.846 (2.588) 8-17 8-24 53.692 (8.615) 4 (15.4) 
Shift
d
 10.423 (2.469) 6-15 6-18 60.192 (11.154) 11 (42.3) 
Emotional 
Control
d
 
16.654 (4.390) 10-27 10-30 58.538 (12.166) 9 (34.6) 
Self-Monitor
d
 9.769 (2.388) 6-15 6-18 55.231 (11.119) 4 (15.4) 
Initiate
d
 14.154 (3.484) 8-21 8-24 61.500 (12.744) 11 (42.3) 
Working 
Memory
d
 
13.808 (3.175) 9-20 8-24 62.000 (12.060) 10 (38.5) 
Plan/Organize
d
 15.615 (4.158) 10-27 10-30 57.038 (12.472) 8 (30.8) 
Task Monitor
d
 10.192 (2.433) 6-15 6-18 58.462 (11.951) 7 (26.9) 
Organization of 
Materials
d
 
12.692 (4.231) 8-22 8-24 53.500 (13.453) 5 (19.2) 
Behaviour 
Regulation
d
 
48.692 (9.303) 30-70 30-90 58.423 (10.871) 6 (23.1) 
Metacognition
d
 
66.462 
(15.039) 
42-104 40-120 61.500 (15.895) 7 (26.9) 
Global 
Executive 
Composite
d
 
115.154 
(22.632) 
72-158 70-210 59.808 (11.696) 8 (30.8) 
Note. BRIEF: Behavioral Rating Inventory of Executive Functions; D-KEFS: Delis-
Kaplan Executive Function System; HART-A: Hopkins Adult Reading Test–A; MoCA: 
Montreal Cognitive Assessment; RAVLT: Rey Auditory Verbal Learning Test; TMT: 
Trail Making Test 
a
Raw scores 
b
Normed scores  
c
Higher raw scores indicate worse performance  
d
Higher raw and normed scores indicate worse self-rated performance  
 
Table 5 contains the average scores on all measures of Diabetes Self-Management 
Behaviours (DSMB). Reported completion of DSMB was highest for medication taking 
and healthcare use, followed by blood glucose testing and dietary control. Reported 
completion was lowest on average for exercise and foot care. There were significant 
differences between reported blood glucose testing (p = .037) and exercise (p < .001) 
DSMB completion across the three measures of DSMB (see Table 5). There were 
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significant differences between medication (t(22) = 2.545, p = .018, d = .531) and blood 
glucose (t(25) = -2.296, p = .024, d = .470) on the SDSCA and SMP-T2D. Participants 
reported significantly higher medication taking on the SDSCA compared to the SMP-
T2D and the reverse for blood glucose testing with significantly higher reported DSMB 
completion on the SMP-T2D compared to the SDSCA.  
Table 5 
Descriptive statistics for DSMB (N=26)  
 
SDSCA SMP-T2D DSMQ   
 
Mean(SD) 
Min-
Max Mean(SD) 
Min-
Max Mean(SD) 
Min-
Max 
F(df) p 
Medication 
 
9.658 (.641)
 a
 
 
7.86-10 
 
9.257 
(1.245)
 b
 
 
5.71-
10 
 
8.913 
(2.336)
 a 
 
0-10 
 
1.628
c
 
(1.196, 
26.308) 
 
.208 
 
Blood 
Glucose 
 
6.566 (3.458) 
 
0-10 
 
7.857 
(3.435) 
 
0-10 
 
7.111 
(2.740)
 b
 
 
1.11-
10 
 
3.536  
(2, 48) 
 
.037 
 
Diet 
 
7.006 (2.250) 
 
0-10 
 
6.154 
(2.807) 
 
0-10 
 
6.026 
(1.875) 
 
2.50-
10 
 
1.869  
(2, 50) 
 
.165 
 
Exercise 
 
4.506(3.527) 
 
0-10 
 
3.828 
(2.709) 
 
0-10 
 
6.368 
(3.072) 
 
0-10 
 
19.312 
(2, 50) 
 
<.001 
 
Foot Care 
 
4.121 (3.448) 
 
0-10 
      
 
HealthCare 
Use 
     
9.530 
(1.002) 
 
5.56-
10 
  
 
Total 
Score 
     
7.360 
(1.319) 
 
4.62-
10 
  
Notes. Diabetes Self-Management Behaviour (DSMB) scores are out of 10; SDSCA: 
Summary of Diabetes Self-Care Activities; SMP-T2D: Self-Management Profile for 
Type 2 Diabetes; DSMQ: Diabetes Self-Management Questionnaire  
a
N=23 
b
N=25 
c 
Greenhouse-Geisser correction applied  
 
Table 6 contains the descriptive statistics for the Audit of Diabetes Dependent 
Quality of Life (ADDQoL), the Depression Anxiety Stress Scale (DASS-21), and the 
Geriatric Depression Scale (GDS-SF). Average diabetes-related quality of life (DRQoL) 
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showed a slightly negative impact of diabetes on QoL with a mean level of DRQoL of 
8.539. No impact of diabetes on QOL is equivalent to a score of 9 on the ADDQoL. The 
mean general quality of life (GQoL) for the sample was good at 5.269. The midpoint of 4 
represents neither good nor bad GQoL on the ADDQoL.  
The mean score on the GDS-SF was below the cut-off of 5 indicating that on 
average the participants did not report elevated symptoms of depression on this measure. 
The mean scores of the DASS-21 Depression and Anxiety scales were in the mild 
symptom range. The mean score of the DASS-21 Stress scale was in the normal range.  
Table 6 
Descriptive statistics for ADDQoL and Mood (N=26) 
 
Raw Mean 
(SD) 
Sample Min-
Max 
Test Min-
Max 
Normed 
Mean(SD) 
ADDQoL 
DRQoL 
8.539 (1.096) 6.33-9.89 0-12  
 
ADDQoL GQoL 
5.269 (.827) 4-7 0-7  
 
GDS
a
 
 
4.461 (3.972) 
 
0-14 
 
0-15 
 
62.846 (11.915) 
 
DASS 
Depression
a
 
 
11.153 
(11.651) 
 
0-42 
 
0-42 
 
.738 (1.651) 
 
DASS Anxiety
a
 
 
8.308 (6.757) 
 
0-22 
 
0-42 
 
.695 (1.308) 
 
DASS Stress
a
 
 
10.769 (8.140) 
 
0-28 
 
0-42 
 
.064 (1.041) 
Notes. ADDQoL: Audit of Diabetes Dependent Quality of Life; DASS: Depression 
Anxiety Stress Scale; DRQoL: Diabetes-related Quality of Life; GDS: Geriatric 
Depression Scale; GQoL: General Quality of Life  
a
Higher scores indicate worse symptoms  
 
Relationships Between DSMB and QoL with Demographics and Health Variables 
 Relationships between the demographic, health, diabetes-related variables, and 
mood with the DSMB and QoL measures can be found in Table 7. There were no 
significant relationships or differences between any DSMB or QoL measures and years of 
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education, employment status, between participants who had informants come with them 
and those who did not, reported current and chronic pain, CCI score, and pre-testing 
blood glucose level.  
 The age of participants was significantly correlated with blood glucose testing (r 
= .446, p = .023, r
2 
= .199) with blood glucose DSBM completion increasing with 
increasing age. Participants differed significantly on blood glucose testing (t(15.767) = 
2.164, p = .046, d = .958), healthcare use (t(10.658) = 2.252, p = .046, d = 1.080), and 
total (t(24) = 2.629, p = .015, d = 1.085) DSMB completion by gender. For all three 
behaviours the men performed their DSMBs significantly more often than the women. 
Participants who were in a domestic partnership completed their foot care DSMB 
significantly more often than participants who did not report having romantic partners 
(t(24) = 2.304, p = .030, d = .989). Participants who drank alcohol at least once a month 
had significantly worse foot care DSMB completion than participants who did not drink 
alcohol (t(22.154) = -2.357, p = .028, d = .989). Total DSMB completion scores were 
significantly correlated with BMI (r = -.488, p = .011, r
2 
= .238). As BMI increased, total 
DSMB completion decreased.  
 Geriatric Depression Scale scores correlated significantly with exercise (r = -.399, 
p = .043, r
2 
= .159) and total (r = -.419, p = .033, r
2 
= .176) DSMB completion, as well as 
with general QoL (r = -.758, p < .001, r
2 
= .575). Higher reported depression symptoms 
on the GDS-SF were significantly related to lower exercise and total DSMB behaviour 
completion and lower general QoL. DASS-21 Depression scores were significantly 
correlated with general QoL (r = -.682, p < .001, r
2 
= .465). As reported depression 
symptoms increased general QoL decreased. DASS-21 anxiety scores were significantly 
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correlated with blood glucose DSMB completion (r = .409, p = .038, r
2 
= .167), as well as 
with diabetes-related (r = -.430, p = .029, r
2 
= .185) and general QoL (r = -.466, p = .016, 
r
2 
= .217). Participants with higher reported anxiety symptoms were more likely to have 
higher blood glucose DSMB completion and significantly lower diabetes-related and 
general QoL. DASS-21 Stress scores were significantly correlated with general QoL (r = 
-.589, p = .002, r
2 
= .347). Participants with higher reported stress symptoms were more 
likely to have significantly lower general QoL. 
 Diabetes duration was significantly correlated with exercise (r = -.412, p = .036, 
r
2 
= .170) and foot care DSMB completion (r = .419 , p = .033, r
2 
= .176), as well as with 
diabetes-related QoL (r = -.391, p = .048, r
2 
= .153). Exercise DSMB completion and 
diabetes-related QoL decreased as diabetes duration increased, whereas foot care DSMB 
completion increased as diabetes duration increased. Most recent A1C level was 
significantly correlated with diet DSMB completion (r = -.450, p = .021, r
2 
= .203) and 
general QoL (r = -.410, p = .037, r
2 
= .168). As A1C level increased, diet DSMB 
completion and general QoL significantly decreased. Participants with reported diabetes 
complications significantly differed on healthcare use DSMB completion (t(18) = 2.480, 
p = .023, d = .684) and on general QoL (t(24) = -2.236, p = .035, d = -1.029). Participants 
with complications reported significantly higher healthcare use and significantly lower 
general QoL. Treatment modality was significantly related to blood glucose (F(2,23) = 
4.603, p = .021, ω2 =.247), diet (F(2,23) = 8.609, p = .002, ω2 =.393), and exercise 
(F(2,23) = 5.152, p = .014, ω2 =.271) DSMB completion, as well as general QoL 
(F(2,23) = 5.156, p = .014, ω2 =.271). Blood glucose DSMB completion was highest for 
participants taking both medication and insulin, followed by those using diet and exercise 
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to treat their T2DM, and was lowest for individuals who only take medication. Diet 
DSMB completion was highest for participants using diet and exercise to treat their 
T2DM, followed by those who only take medication, and was lowest for individuals 
taking both medication and insulin. Exercise DSMB completion was highest for 
participants using diet and exercise to treat their T2DM, followed by those who only take 
medication, and was lowest for individuals taking both medication and insulin. Finally, 
general QoL was highest for participants using diet and exercise to treat their T2DM, 
followed by those who only take medication, and was lowest for individuals taking both 
medication and insulin.   
Table 7 
Significant relationships and differences between demographic, health, diabetes-related, 
and mood variables and DSMB and QoL (N=26) 
Variable 1
a
 2 3 4 5 6 7 8 9 
Demographic  
Age   *        
Years of Education          
Female Gender  *
b
    *
b
 *   
Employed 
 
        
Yes 
No 
Retired 
Partnered  
 
   
* 
    
Single, Divorced, or Widowed 
Married or Cohabitating 
Informant Present          
Health and diabetes-related   
Drinks Alcohol     *
b
     
BMI        *   
Current Pain
c
          
Chronic Pain
c
          
Score on CCI
c
          
GDS
c
    *   *  ** 
DASS Depression
c
         ** 
DASS Anxiety
c
  *      * * 
DASS Stress
c
         ** 
Diabetes Duration    * *   *  
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Most Recent A1C
c
   *      * 
Reported T2DM Complication      *
b 
  * 
Treatment Modality  * ** *     * 
Diet & Exercise 
Medication only 
Medication & Insulin 
Blood Glucose Pre-Testing 
(mmol/l)
c
 
         
Note. Continuous variables are correlations with DSMB and QoL; Dichotomous variables 
are independent t-tests with DSMB and QoL; Categorical variables with more than 2 
groups are One-way ANOVA with DSMB and QoL; The Ethnicity, Birthplace, Language 
spoken day-to-day, Smokes Cigarettes, Previous Psychiatric Diagnosis, Hospitalized Past 
Year, Past Diabetes Education, and Hospitalized for Hypoglycemia variables were not 
included in the analyses as there is not sufficient variability to permit reliable 
comparisons; 1: DSMB Medication; 2: DSMB Blood Glucose; 3: DSMB Diet; 4: DSMB 
Exercise; 5: SDSCA Foot Care; 6: DSMQ Healthcare Use; 7: DSMQ Total Score; 8: 
ADDQoL Diabetes-related QoL; 9: ADDQoL General QoL; BMI: Body Mass Index; 
CCI: Charlson Comorbidity Index; DASS: Depression Anxiety Stress Scale; GDS: 
Geriatric Depression Scale 
a
N=25 
b
Equal variances not assumed t-value interpreted  
c
Higher scores indicate worse symptoms, worse diabetes control, or greater comorbidity   
*p <.05 
**p <.01 
 
Correlations Between Neuropsychological Measures and DSMB  
The correlations between DSMB and the neuropsychological measures calculated 
to answer the first research question can be found in Table 8. Medication DSMB 
completion was significantly correlated with the BRIEF Initiate (r = -.639, p = .001, r
2 
= 
.408) and Metacognition (r = -.400, p = .047, r
2 
= .160) scales. Increasing difficulties with 
initiation and metacognition were significantly related to decreasing medication DSMB 
completion. Blood glucose DSMB completion was significantly correlated with FAS 
total score (r = .577, p = .002, r
2 
= .333) and the BRIEF Inhibit (r = .449, p = .021, r
2 
= 
.202), Emotional Control (r = .459, p = .018, r
2 
= .211), and Behaviour Regulation (r = 
.413, p = .036, r
2 
= .171) scales. Better performance on the FAS was significantly related 
to increased blood glucose DSMB completion. Increasing difficulties with inhibition, 
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emotional control, and behaviour regulation were significantly related to greater blood 
glucose DSMB completion. Diet DSMB completion was significantly correlated with 
BRIEF Emotional Control (r = -.436, p = .026, r
2 
= .190), Self-Monitor (r = -.439, p = 
.025, r
2 
= .193), Initiate (r = -.440, p = .025, r
2 
= .194), and Behaviour Regulation (r = -
.425, p = .031, r
2 
= .181) scales. Increasing difficulties with emotional control, self-
monitoring, initiation, and behaviour regulation were significantly related to decreasing 
diet DSMB completion. There were no significant correlations between Exercise and 
Foot Care DSMB completion and the neuropsychological measures. Healthcare Use 
DSMB completion was significantly correlated with the MoCA Orientation score (r = 
.515, p = .007, r
2 
= .265). Increasing Healthcare Use was significantly related to better 
orientation MoCA scores. Total DSMB completion was significantly correlated to BRIEF 
Plan/Organize (r = -.422, p = .032, r
2 
= .178) and Metacognition (r = -.421, p = .032, r
2 
= 
.177) scales. Increasing difficulties with planning, organizing, and metacognition were 
significantly related to decreasing total DSMB completion.  
Correlations of Neuropsychological Measures and DSMB with QoL  
 The correlations between DSMB and neuropsychological measures with 
Diabetes-Related and General QoL that were calculated to answer the second research 
question can be found in Table 8. Regarding the correlations between DSMB and QoL, 
Blood Glucose DSMB completion was significantly correlated to Diabetes-Related QoL 
(r = -.514, p = .007, r
2 
= .264). Increasing blood glucose DSMB completion was 
significantly related to decreasing diabetes-related QoL. Total DSMB completion was 
significantly correlated with General QoL (r = .418, p = .034, r
2 
= .175). Increasing total 
DSMB completion was significantly related to increasing general QoL.     
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 As for the correlations between the neuropsychological measures and the QoL, 
Diabetes-Related QoL correlated significantly with recognition memory on the RAVLT 
(r = .493, p = .011, r
2 
= .243). Higher scores on recognition memory were significantly 
related to higher levels of diabetes-related QoL. General QoL correlated significantly 
with TMT A (r = .460, p = .018, r
2 
= .212), TMT B (r = .562, p = .003, r
2 
= .316), and D-
KEFS Colour-Word Trial 1 (r = .528, p = .006, r
2 
= .279) scores. Better performance on 
all three neuropsychological measures was significantly related to better general QoL. 
Finally, General QoL correlated significantly with all but one of the scales of the BRIEF 
(Shift: r = -.470, p = .015, r
2 
= .221; Emotional Control: r = -.555, p = .003, r
2 
= .308; 
Self-Monitor: r = -.594, p = .001, r
2 
= .353; Initiate: r = -.450, p = .021, r
2 
= .202; 
Working Memory: r = -.565, p = .003, r
2 
= .319; Plan/Organize: r = -.451, p = .021, r
2 
= 
.203; Task Monitor: r = -.563, p = .003, r
2 
= .317; Organization of Materials: r = -.487, p 
= .012, r
2 
= .237; Behavioural Regulation: r = -.618, p = .001, r
2 
= .382; Metacognition: r 
= -.643, p < .001, r
2 
= .413; and Global Executive Composite: r = -.635, p < .001, r
2 
= 
.403). Increasing reported difficulties with abilities measured by each scale were 
significantly related to poorer general QoL. Overall, reported general QoL decreased in 
the presence of poorer processing speed and executive functioning abilities.  
Table 8 
Pearson r correlations between neuropsychological measures, DSMB, and QoL (N=26)  
  
DSMB 
Medicationa 
DSMB 
Blood 
Glucose 
DSMB 
Diet 
DSMB 
Exercise 
SDSCA 
Foot 
Care 
DSMQ 
Healthcare 
Use 
DSMQ 
Total 
Score 
ADDQoL 
DRQoL 
ADDQoL 
GQoL 
ADDQoL 
         
DRQoL -.174 -.514** .112 .152 .081 .240 .024 1 .317 
GQoL .212 -.079 .352 .300 .277 .159 .418* .317 1 
MoCA 
         
Total Score -.060 .324 -.249 -.019 -.166 .203 .169 -.082 .082 
Memory Index .149 .204 -.188 .083 -.131 .120 .103 -.169 -.153 
Executive 
Index 
-.269 .229 -.279 -.229 -.328 .038 -.072 -.036 .021 
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Visuospatial 
Index 
-.219 .343 -.063 -.071 -.251 .214 .198 -.142 .197 
Language 
Index 
.189 .319 -.132 .060 -.035 .109 .189 .077 .166 
Attention Index .043 .291 -.107 .057 -.055 .223 .242 .126 .163 
Orientation 
Index 
-.175 -.208 -.083 .014 -.288 .515** .198 .349 -.082 
RAVLT 
         
Trial 1 .261 .146 .078 .180 .018 -.353 .100 -.257 -.159 
Trial 5 .082 .098 -.255 .115 -.160 .082 .148 .112 .094 
Total Learning -.006 .183 -.305 .134 -.150 -.074 .152 .113 .171 
List B -.113 .194 -.200 .034 -.102 -.159 -.033 -.082 .086 
Trial 6 -.086 -.050 -.210 .172 -.257 .118 .131 .245 .127 
Trial 7 .015 -.049 -.126 .236 -.121 .099 .216 .261 .217 
Recognition 
Hits 
.040 -.131 -.107 .039 .268 .195 .153 .493* .226 
Salthouse 
         
Letter -.033 .378 -.143 -.140 -.099 -.018 .033 .132 .184 
Pattern -.024 .103 -.209 .059 -.158 .158 .122 .250 .220 
Total .002 .257 -.163 -.038 -.139 .053 .095 .187 .215 
TMT A .175 .174 .201 .029 -.118 -.106 .101 -.008 .460* 
TMT B -.047 .120 -.009 .176 .094 -.006 .189 .213 .562** 
Longest Digit 
Span          
Forward .000 .181 .085 -.083 -.219 .088 .201 -.041 .293 
Backward -.086 .065 -.096 .159 .058 .156 .176 .149 .088 
Total -.125 .152 -.011 .009 -.064 .174 .211 .085 .209 
D-KEFS 
Colour-Word          
Condition 1 .263 .303 -.082 .112 .127 .055 .256 .193 .528** 
Condition 2 .147 .205 .012 .041 .113 -.115 .067 .072 .158 
Condition 3 -.178 .215 -.023 .130 -.226 -.160 -.107 .080 .080 
Condition 4 -.252 .091 -.221 .025 -.226 .079 -.022 .042 .108 
F A S Total .059 .577** -.189 -.016 -.018 -.101 .071 -.143 .114 
Animals Total  .116 .379 -.205 -.193 -.153 -.215 -.028 .023 .040 
HART-A -.033 .190 -.284 -.196 .077 -.176 -.234 .007 .000 
BRIEF 
         
Inhibit .237 .449* -.259 .153 -.034 .086 .158 -.195 -.257 
Shift -.216 -.075 -.157 -.294 -.154 -.341 -.386 -.070 -.470* 
Emotional 
Control 
-.072 .459* -.436* -.376 -.082 -.244 -.335 -.208 -.555** 
Self-Monitor -.264 .245 -.439* -.275 -.075 -.090 -.386 -.229 -.594** 
Initiate -.639** .150 -.440* -.383 -.196 .061 -.313 -.020 -.450* 
Working 
Memory 
.011 -.011 .014 .046 .122 -.254 -.252 -.099 -.565** 
Plan/Organize -.380 .026 -.223 -.197 -.289 -.308 -.422* -.076 -.451* 
Task Monitor -.225 .244 -.130 -.049 -.174 -.267 -.226 -.238 -.563** 
Organization of 
Materials 
-.225 .073 -.321 -.160 -.115 -.081 -.285 -.198 -.487* 
Behaviour -.100 .413* -.425* -.294 -.110 -.214 -.316 -.245 -.618** 
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Regulation 
Metacognition -.400* .093 -.381 -.196 -.214 -.180 -.421* -.074 -.643** 
Global 
Executive 
Composite 
-.260 .245 -.351 -.244 -.143 -.213 -.361 -.202 -.635** 
Note: DRQoL: Diabetes-related Quality of Life; GQoL: General Quality of Life  
a
N=25 
*p <.05 
**p <.01 
 
Comparisons of Depression Measures  
 The comparison of the two depression symptom measures used in the present 
study can be found in Table 9. The difference between the GDS-SF and the DASS-21 
depression scores was not significant when comparing non-age-corrected GDS-SF scores 
to the DASS-21 depression scores, which do not have age-corrected norms (see Table 9). 
However, when the age-corrected GDS-SF scores were compared to the non-age-
corrected DASS-21 depression scores the difference became statistically significant (see 
Table 9) with participants reporting significantly higher levels of depression symptoms 
on the GDS-SF when compared to the DASS-21. The magnitude of the difference was 
moderate (d = .484).  
Table 9 
Comparison of depression measure scores 
 t(25) p Cohen’s d 
GDS –DASS Depression 
Age corrected GDS 2.467 .021 0.484 
Non-age-corrected GDS 1.946 .063 0.381 
Note. DASS: Depression Anxiety Stress Scale; GDS: Geriatric Depression Scale  
Comparisons of Processing Speed Measures  
Participants’ scores on the measures of processing speed were compared due to 
the differing motor and visual scanning task demands of the processing speed tasks. TMT 
A has the greatest motor and visual scanning task demands, followed by the Salthouse 
Letter test. C-W Trial 2 has no motor component and requires the least amount of visual 
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scanning compared to the TMT A and the Salthouse Letter test. The TMT A, the 
Salthouse Letter, and the C-W Trial 2 tests all use letters or words as the test stimuli. 
Participants performed progressively worse on the measures of processing speed as motor 
and visual scanning demands increased (see means in Table 10). However, the difference 
was only statistically significant when comparing the most demanding task (TMT A) to 
the least demanding task (CW Trial 2). The magnitude of the difference was moderate (d 
= -.487). 
Table 10 
Comparisons of processing speed measures with differing motor and visual scanning 
demands 
 t(25) p Cohen’s d 
TMT A - Salthouse Letter -0.929 0.362 -0.182 
TMT A - CW Trial 2 -2.467 0.021 -0.487 
Salthouse Letter  - CW Trial 2 -1.586 0.125 -0.311 
Test  Mean (SD)  
TMT A  46.962 (9.374) 
Salthouse Letter  48.692 (10.810) 
CW Trial 2 51.519 (8.213) 
Note. CW: Colour Word; TMT: Trail Making Test 
 
Comparisons of Self-report and Performance Based Neuropsychological Measures 
 Self-report BRIEF scores were compared to the performance based 
neuropsychological tests that measure equivalent cognitive abilities. For all comparisons, 
participants scored lower on the self-report BRIEF measures compared to their scores on 
the performance based neuropsychological measures (see means in Table 11). However, 
the differences were only statistically significant for both shifting ability comparisons 
(see Table 11). The magnitude of the shifting ability differences was moderate to large 
(see Cohen’s d values in Table 11).  
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Table 11 
Exploratory comparisons of BRIEF scores to corresponding cognitive abilities  
 t(25) p Cohen’s d 
CW Trial 3 - BRIEF Inhibit  1.584 0.126 0.311 
CW Trial 4 - BRIEF Shift 2.719 0.012 0.533 
TMT B - BRIEF Shift  3.578 0.001 0.702 
RAVLT Trial 1 - BRIEF Working Memory  0.696 0.493 0.137 
LDSB - BRIEF Working Memory  
 
1.959 0.061 0.384 
Test  Mean (SD)  
BRIEF Inhibit 46.308 (8.615) 
CW Trial 3 51.192 (9.744) 
BRIEF Shift 39.808 (11.154) 
CW Trial 4 48.721 (11.993) 
TMT B 49.346 (9.604) 
BRIEF Working Memory 38.000 (12.060) 
RAVLT Trial 1 40.268 (10.245) 
LDSB 44.308 (10.921) 
Note. BRIEF scores were reverse scored so that higher scores indicated better 
performance; Means and SD were reported as T-scores; BRIEF: Behavioral Rating 
Inventory of Executive Functions; CW: Colour Word; LDSB: Longest Digit Span 
Backwards; RAVLT: Rey Auditory Verbal Learning Test; TMT: Trail Making Test 
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CHAPTER IV 
PROSPECTIVE STUDY DISCUSSION  
 The prospective study sought first to determine the relationship between cognitive 
abilities and DSMB completion and second to determine the relationship between 
cognitive functioning and DSMB completion with diabetes-related and general QoL. Due 
to the small sample size, these relationships were investigated using univariate statistics 
within the context of the prospective study being an exploratory study. Scores on the 
DSMB measures will be discussed first. Next, the correlations between DSMB and the 
neuropsychological measures answering the first research question and the correlations 
between DSMB and the neuropsychological measures with diabetes-related and general 
QoL answering the second research question will be discussed. Finally, the results 
encompassing the depression measures, the processing speed tests, and the objective and 
self-report measures of executive functioning will be discussed. Study strengths and 
limitations will conclude the prospective study discussion.  Future directions are 
discussed throughout where relevant.  
DSMB Measures 
Reported completion of DSMB in this study was highest for medication taking 
and healthcare use, followed by blood glucose testing and dietary control. Reported 
completion was lowest on average for exercise and foot care. These results are in line 
with reported rates of completion of each domain of DSMB in the literature where 
medication adherence is highest, followed by blood glucose testing, dietary control, 
physical activity, and foot-care (Ahola & Groop, 2013; Gillani, 2012; Gonzalez et al., 
2016). However, the percentage of the sample reporting successfully completing their 
DSMB is higher than what has been reported in the literature (Ahola & Groop, 2013; 
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Gillani, 2012; Gonzalez et al., 2016).  The reported healthcare use was high in this study 
compared to reported rates in the literature (Gillani, 2012). This is likely an artifact of the 
sample having been recruited from the offices where they attend their healthcare 
appointments.  
The questions on the SDSCA ask on how many of the past 7 days DSMB were 
completed whereas the SMP-T2D asks on how many of the past 7 days the participant 
missed completing their DSMB with the assumption that individuals are more likely to 
report missing the completion of their DSMB due to difficulties rather than report a lack 
of compliance in completing their required behaviours (Peyrot et al., 2012). In the present 
study, this assumption held true for medication, diet, and exercise DSMB where reported 
rates of DSMB completion were higher on the SDSCA as compared to the SMP-T2D, 
although the differences were only statistically significant for medication DSMB 
completion. The assumption was not supported for blood glucose DSMB completion. 
Reported rates of blood glucose DSMB completion were statistically significantly higher 
on the SMP-T2D as compared to the SDSCA.    
To the best of the researcher’s knowledge this was the first study to use multiple 
validated self-report measures of DSMB completion to investigate the relationships 
between DSMB completion and cognitive functioning. The finding of significant 
differences in self-reported DSMB completion across measures purporting to measure the 
same behaviours across the same time span (for SDSCA and SMP-T2D) in the same 
individual is noteworthy. In the present study, order effects and fatigue cannot be ruled 
out as the explanations for these significant differences; however, future research should 
investigate these differences. If the differences in self-reported DSMB completion across 
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measures are replicated, self-report measures of DSMB will need to be revised to gain a 
more reliable measurement of self-reported DSMB completion.  
Correlations Between Neuropsychological Measures and DSMB  
 There were only two statistically significant relationships between DSMB 
completion and the objective neuropsychological measures. First, there was a significant 
relationship between phonemic verbal fluency and blood glucose DSMB completion with 
higher scores on FAS correlating with increased blood glucose DSMB completion. 
Phonemic verbal fluency is a measure of executive functioning (Strauss et al., 2006) that 
is sensitive to the cognitive dysfunction present in T2DM (Wong et al., 2014). This is the 
first study reporting a specific relationship between phonemic verbal fluency and blood 
glucose DSMB completion; however,  other studies have linked better executive 
functioning to increased DSMB completion in those with T2DM (Asimakopoulou & 
Hampson, 2002; Gatlin & Insel, 2015; Primozic et al., 2012; Rosen et al., 2003; Thabit et 
al., 2009).  
 Second, there was a significant relationship between the MoCA Orientation Index 
and healthcare use DSMB completion. Better orientation was correlated with greater use 
of healthcare. Although being properly oriented to date and location is certainly 
necessary to attend healthcare appointments, this finding is likely an artifact of the ceiling 
effects in the data of both of these non-normally distributed variables. The individuals in 
the sample of the prospective study were relatively healthy community dwelling 
volunteers who were recruited while they were attending their healthcare appointments. 
Thus, the ceiling effects on the MoCA Orientation Index and the healthcare use DSMB 
completion measures are to be expected.  
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 There were many statistically significant relationships between the BRIEF (a self-
report measure of executive functioning) and DSMB behaviour completion. Increased 
medication DSMB completion was significantly related to lower reported difficulties 
with metacognition and specifically with initiation. The component abilities of 
metacognition-- initiation, working memory, planning, organization, and task monitoring-
- are all required in order to successfully manage taking medication, especially when 
there are multiple medications that need to be taken at different times during the day 
(Emery et al., 2015; Koekkoek et al., 2015; Tomlin & Asimakopoulou, 2014; Wasserman 
et al., 2015). Increased diet DSMB completion was significantly related to lower reported 
difficulties with behaviour regulation and specifically with emotional control and self-
monitoring. Disruptions in behaviour regulation, especially in emotional control, have 
been found to heavily influence diet DSMB completion, especially in those with 
depression and eating disorders (de Groot et al., 2016; Gonzalez et al., 2016).  
Increased blood glucose DSMB completion was significantly related to increasing 
difficulties with behavioural regulation and specifically with inhibition and emotional 
control. This finding seems contradictory; however, given that those with T2DM do not 
test their blood glucose as frequently when they have good A1C levels and do not take 
insulin (SMBG International Working Group, 2008), it is possible that individuals with 
poorer disease management (higher A1C values and requiring insulin), possibly due to 
poorer behavioural regulation, are testing their blood glucose more often than those with 
better disease management.  There was a positive correlation between A1C level and 
blood glucose DSMB completion in the present study indicating that participants with 
higher A1C levels (worse glycemic control) reported increased blood glucose DSMB 
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completion, although the correlation was not statistically significant (r = .179, p > .05). 
However, there was a statistically significant difference between individuals managing 
their T2DM with insulin and those using only medication or diet and exercise (t(24) = 
2.861, p = .009, d = 1.171) with those taking insulin reporting significantly greater blood 
glucose DSMB completion. Finally, increased total DSMB completion was significantly 
related to lower reported difficulties with metacognition and specifically with planning 
and organization. As with medication DSMB completion, the component abilities of 
metacognition are all required in order to successfully complete all DSMB (Emery et al., 
2015; Koekkoek et al., 2015; Tomlin & Asimakopoulou, 2014; Wasserman et al., 2015). 
To the best of the researcher’s knowledge, the present investigation was the first 
study to use a self-report measure of executive functioning to investigate the relationship 
between executive functioning abilities and DSMB completion. Given that executive 
functioning abilities are essential to successful DSMB completion (Vincent & Hall, 2015; 
Wasserman et al., 2015), and the limits of standardized performance-based 
neuropsychological tests of executive functioning in predicting behaviour and functional 
outcomes such as DSMB completion (Chaytor et al., 2006), the inclusion of self-report 
measures of executive functioning in investigations of DSMB completion should occur 
much more frequently. Further, standardized performance based measures of executive 
functioning almost exclusively measure the metacognitive aspects of executive 
functioning, whereas the BRIEF measures the behaviour regulatory and emotional 
control aspects of executive functioning in addition to the metacognitive aspects (Roth et 
al., 2005). Given the relationships between behaviour regulation and emotional control 
and DSMB completion in the present study and the higher prevalence of depression and 
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anxiety in those with T2DM (de Groot et al, 2016), it will be necessary in future studies 
to assess both the metacognitive and behavioral regulatory aspects of executive 
functioning to gain a complete understanding of the effects of executive dysfunction on 
DSMB completion.  
The validated BRIEF scales are based on self-reported difficulties completing 
concrete behaviours as opposed to the abstract deficits measured by objective 
neuropsychological tests (Roth et al., 2005). Clinicians working with individuals with 
diabetes who have difficulties completing their DSMB could use their patient’s self-
reported difficulties from the BRIEF scales as a starting point to develop individually 
tailored interventions to increase DSMB completion. These kinds of individually tailored 
patient-centered interventions have been found to be the most effective in increasing 
DSMB completion (Johnson & Marrero, 2016). Psychologists are well trained to develop 
and deliver these interventions provided they receive training in the disease process and 
psychosocial and cognitive effects of diabetes. This training is becoming increasingly 
available (Hunter, 2016).  
The majority of the correlations between the neuropsychological measures and 
DSMB completion were not significant in the present study. First and foremost, this is 
due to the small sample size and low power to detect significant relationships. However 
beyond this limitation, every study investigating the relationships between cognitive 
functioning and DSMB completion in individuals without dementia has reported null 
findings (Asimakopoulou & Hampson, 2002; Compeán-Ortiz et al., 2010; Gatlin & Insel, 
2015; Primozic et al., 2012; Rosen et al., 2003; Thabit et al., 2009). The review and meta-
analyses of cognitive functioning in individuals with T2DM (Monette et al., 2014; Palta 
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et al., 2014; van den Berg et al., 2009; Vincent & Hall, 2015) have reliably found 
cognitive deficits in individuals with T2DM in all cognitive abilities and domains ranging 
from .20 - .45 standard deviations units. Impairments in the completion of complex daily 
activities such as DSMB completion are not usually expected until an individual’s 
cognitive impairments are approximately 1.5 standard deviations below the mean (Albert 
et al., 2011). Further, individuals with T2DM with small decrements in cognitive 
functioning within the range found in the meta-analyses of cognitive functioning in 
T2DM are not likely to have new difficulties with DSMB completion due to these 
cognitive deficits (Koekkoek et al., 2015). Cognitive impairment is not likely to produce 
changes or increasing difficulties in DSMB completion until it reaches the level of mild 
cognitive impairment or dementia (Koekkoek et al., 2015). This does not preclude the 
existence of difficulties with DSMB completion from relative weaknesses in cognitive 
functioning that have existed over the lifetime of the individual; however, these 
difficulties would be a target for individually tailored interventions and these 
idiosyncratic difficulties would likely be masked in group-based quantitative analyses. 
This assumption requires further research using qualitative methods.  
The majority of participants in the present study scored above the threshold for 
cognitive impairment (1.5 standard deviations below the mean) on the 
neuropsychological measures (Table 4) and overall all scores on the neuropsychological 
tests were in the low average to average range. The sample size in the present study 
precludes the investigation of comparisons of DSMB completion of the individuals who 
scored above 1.5 standard deviations below the mean to those who scored 1.5 standard 
deviations below the mean. Future investigations should endeavour to do this given the 
 81 
 
many null findings in studies where participants do not have cognitive deficits at the level 
of dementia. The threshold of the level of cognitive deficits needed to impact DSMB 
completion must be identified in addition to the cognitive abilities and domains that most 
impact DSMB completion.  Finally, the majority of significant relationships between the 
neuropsychological measures and DSMB completion came from the BRIEF scores. The 
largest proportion of individuals who scored in the range suggestive of possible cognitive 
impairment occurred on the BRIEF scales (Table 4). This finding provides preliminary 
evidence that the relationships between executive functioning and DSMB completion 
may only be present when deficits are greater on average than the .20 -.45 standard 
deviations below the mean that are observed in the T2DM population as a whole.  
Correlations of Neuropsychological, DSMB, and Mood Measures with QoL  
Neuropsychological measures and QoL. Better scores on TMT A, TMT B, and 
D-KEFS Colour-Word Trial 1 were significantly related to increasing general QoL. 
Increasing reported difficulties with all but one of the executive functioning abilities 
measured by the BRIEF scales was significantly related to poorer general QoL. Thus, 
general QoL was negatively impacted by poorer processing speed and executive 
functioning abilities. This finding is concerning as processing speed and executive 
functioning, especially shifting abilities measured by the TMT B, are the cognitive 
abilities with the greatest magnitude of impairment in the T2DM population (Monette et 
al., 2014; Vincent & Hall, 2015). However; to the best of the researcher’s knowledge, 
this is the first study to investigate the relationships between cognitive functioning and 
general and diabetes-related QoL in individuals with T2DM using a large number of 
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neuropsychological tests. Further research on these relationships and their impact on 
DSMB completion is needed.  
DSMB, Mood, and QoL. More total DSMB completion was significantly related 
to better general QoL. This relationship is well established in the literature (Cochran & 
Conn, 2008; Gonzalez et al., 2016; Hunter, 2016). Increasing blood glucose DSMB 
completion was significantly correlated to decreasing diabetes-related QoL. Increased 
blood glucose testing has been shown to negatively impact QoL (Gonder-Frederick et al., 
2016; Simon et al., 2008).  Elevated depression symptom scores were significantly 
related to decreased exercise DSMB completion and general QoL. These relationships are 
also well established in the literature (Cochran & Conn, 2008; de Groot et al, 2016; 
Gonzalez et al., 2016). 
Increased anxiety symptoms were significantly correlated to increased blood 
glucose DSMB completion and decreased diabetes-related and general QoL. As above, 
increased blood glucose testing has also been shown to increase anxiety symptoms 
(Gonder-Frederick et al., 2016; Simon et al., 2008). There is a 20% increase in the 
incidence of anxiety disorders in people with diabetes compared to those without 
diabetes; however, there have been no studies of routine screening for anxiety disorders 
in healthcare settings for patients with diabetes (de Groot et al., 2016). In the present 
study, 14 (53.8%) participants had anxiety symptoms in the normal range, 2 (7.7%) 
participants had anxiety symptoms in the mild range, 5 (19.2%) participants had anxiety 
symptoms in the moderate range, 3 (11.5%) participants had anxiety symptoms in the 
severe range, and 2 (7.7%) participants had anxiety symptoms in the extremely severe 
range as measured by the DASS-21. Anxiety symptoms are not equivalent to anxiety 
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disorders; a diagnostic assessment would be required to diagnose an anxiety disorder. 
However, 38.4% of participants in the current study who were community dwelling 
volunteers reported moderate to extremely severe levels of anxiety symptoms. Four of the 
seven anxiety items of the DASS-21 query somatic symptoms that commonly occur in 
individuals with T2DM. This could be leading to an overestimation of anxiety symptoms 
in these individuals as measured by the DASS-21.  Nevertheless, routine screenings of 
anxiety symptoms should be done in individuals with T2DM. Especially because 
individuals with anxiety and depression tend to believe that completing their DSMB will 
negatively impact their QoL (de Groot et al., 2016). This belief has been shown to be 
false as DSMB education and completion increase QoL (Cochran & Conn, 2008).  
General QoL was measured using a single item measured on a 7-point Likert 
scale as this is how this construct is measured on the ADDQoL. Any findings in the 
present study relating to general QoL must be replicated using a validated measure of 
general QoL. It would also likely prove fruitful to investigate these relationships using a 
measure of health-related QoL that is not specific to diabetes given that many individuals 
with T2DM have medical comorbidities that could impact their health-related QoL.  
Comparisons of Depression Measures  
Scores on the two depression measures used in the current study were not 
significantly different when non-age-corrected scores were compared. However, when 
the age-corrected scores on the GDS-SF were compared to the non-age-corrected scores 
of the DASS-21, there was a significant difference in reported depression symptoms, with 
participants reporting significantly more depression symptoms on the GDS-SF as 
compared to the DASS-21. The GDS-SF was developed to assess depression symptoms 
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in older adults (Edelstein et al., 2010) and given the significant differences may be more 
appropriate to use as a screening measure for depression symptoms in older adults with 
T2DM. The GDS-SF and DASS-21 contain equivalent numbers of items querying the 
somatic symptoms of depression. In individuals with T2DM it is essential to query 
whether self-reported symptoms on a depression screening measure are due to depression 
or are due to T2DM. This must be done as part of a diagnostic evaluation and cannot be 
determined solely from responses to a self-report depression screening measure (de Groot 
et al., 2016).   
Comparisons of Processing Speed Measures  
Participant’s scores on three measures of processing speed were compared. 
Participant’s performance worsened as motor and visual scanning task demands of the 
processing speed measures increased. The differences in performance were only 
significant for the task with the greatest motor and visual scanning task demands (TMT 
A) as compared to the task with the least motor and visual scanning task demands (C-W 
Trial 2). There were no significant differences between these two measures and the 
Salthouse Letter test, the measure with intermediate motor and visual scanning task 
demands.  
This finding is salient for a couple of reasons. First, processing speed deficits are 
common in individuals with T2DM and processing speed tasks with motor demands 
show a larger magnitude of impairment than processing speed tasks with oral task 
demands (Monette et al, 2014). This is likely due to deficits in psychomotor efficiency 
caused by the peripheral neurological changes common in those with T2DM impacting 
performance on processing speed tasks with higher motor demands (Awad et al., 2004). 
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Greater visual scanning demands could also impact performance on processing tasks in 
individuals with T2DM who have impaired vision due to retinopathy (Awad et al., 2004). 
These conflations of processing speed with psychomotor efficiency and visual scanning 
may lead to overestimated processing speed deficits in individuals with T2DM. This is 
problematic as peripheral and central neurological changes due to T2DM may not co-
occur in the same individual (Manschot et al., 2008). Second, the TMT A is a commonly 
used measure of processing speed in clinical neuropsychological assessments (Strauss et 
al., 2006). If the TMT A is used as the only measure of processing speed in a 
neuropsychological assessment of an individual with T2DM, processing speed deficits 
may be overestimated especially if the person has peripheral nerve damage due to 
diabetes complications. For these reasons, performance on measures of processing speed 
with differing motor and visual scanning task demands warrants further study in 
individuals with T2DM to determine the magnitude of these differences. This research 
could inform test selection for neuropsychological assessment with individuals with 
T2DM. For now, clinicians should strive whenever possible to administer more than one 
measure of processing speed with differing task demands when assessing individuals 
with T2DM.  
Comparisons of Self-report and Performance Based Neuropsychological Measures 
Comparisons were made between the self-report BRIEF scores and the 
performance based neuropsychological tests that measure the same cognitive abilities. 
For all comparisons, participants scores were lower on the self-report BRIEF measures 
compared to their scores on the performance based neuropsychological measures. 
However, the only statistically significant differences were for both shifting ability 
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comparisons. This is important because shifting abilities have some of the largest 
magnitudes of impairments relative to other cognitive abilities in individuals with T2DM 
(Monette et al., 2014; Vincent & Hall, 2015) and participants’ self-reported difficulties 
with shifting abilities exceeded those measured by the objective measures in the present 
study. The meaning and mechanisms of these differences in self-report and objective 
measures of shifting abilities and executive functioning more broadly in individuals with 
T2DM requires further study.  
Individuals with T2DM are self-reporting difficulties with executive functioning 
that may not be detected with objective neuropsychological tests, and the effects of these 
impairments on DSMB completion may be missed when working clinically with 
individuals with T2DM. This has the potential to impact diabetes management outcomes 
given the many significant correlations of BRIEF scale scores with DSMB completion 
and QoL in the present study. In addition, setting aside the assumption that the self-report 
measure is detecting deficits that the objective test may be missing, the situation remains 
that individuals with T2DM are reporting difficulties with executive functioning on self-
report measures that correlate with DSMB completion. These difficulties could be 
improved through interventions that psychologists are well suited to develop and provide 
(Hunter, 2016). These interventions could increase DSMB completion in these 
individuals either directly by improving their executive functioning abilities or 
accommodating their executive functioning deficits, or indirectly by improving 
individual’s self-efficacy and mood, both factors that can impact DSMB completion (de 
Groot et al., 2016; Gonzalez et al., 2016).  
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Strengths and limitations  
 
 This study has many strengths. To the best of the knowledge of the researcher, 
this was the first study to use multiple self-report measures of DSMB completion to 
investigate relationships with cognitive functioning and QoL and the relationships 
between self-reported completion on each of the DSMB measures. This was also the first 
study to assess the relationship between self-reported executive functioning abilities and 
DSMB completion, between self-reported depression symptoms on the GDS-SF and the 
DASS-21, and between cognitive functioning using a large number of 
neuropsychological tests and diabetes-related and general QoL in a T2DM sample.  
The greatest limitation of the present study was the small sample size. The sample 
was also predominantly of white race and Canadian ethnicity, well-educated, and 
consisted mostly of volunteers recruited while attending their healthcare appointments. 
Thus, the sample as a whole had low average to average cognitive functioning, and 
reported higher levels of DSMB completion and QoL than would be expected from the 
T2DM population as whole (Ahola & Groop, 2013; Gillani, 2012; Gonzalez et al., 2016). 
This combined with the low power due to the small sample size likely resulted in under-
detection of relationships between cognitive functioning, DSMB completion, and QoL.  
This was an exploratory study and any significant relationships found must be 
replicated in future studies using larger samples and multivariate statistics to gain a more 
complete understanding of the relationships investigated in the present study. Given the 
small sample size, the relationships between cognitive functioning, DSMB completion, 
and QoL could not be investigated further by taking into account the effects of 
demographic, health, and diabetes-related variables other than age. However, in their 
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review, van den Berg et al., (2009) reported that adjusting for risk factors other than age 
did not significantly change the results for the cognitive deficits found in individuals with 
T2DM. Further investigations are required to determine if this would be the case for the 
relationships between cognitive functioning, DSMB completion, and QoL. Age-corrected 
normed scores on the neuropsychological measures were used in the analyses to adjust 
for the effects of age on cognitive functioning. Not all tests were normed using the same 
normative sample and thus this could have led to differences in the corrections for age 
across neuropsychological measures. However, this is what is done in clinical settings 
and tests that were co-normed from the CNNS were used where possible in the present 
study.  
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CHAPTER V 
ARCHIVAL STUDY METHOD  
Participants and Procedures 
The participants in the archival study came from the Health and Retirement Study 
(HRS) Core 2002 survey and the follow-up 2003 diabetes study (HRS, 2006). The HRS 
is an American national survey completed longitudinally. Prevalence rates of T2DM in 
Americans are comparable to those of Canadians (Canadian Institute for Health 
Information, 2015). Beginning in 1992, participants in the HRS have been surveyed 
every two years. A new cohort is added every six years; four cohorts have been added 
along with the original 1992 cohort. The survey is sponsored by the National Institute on 
Aging and managed by the University of Michigan. As of 2007, the survey was 
representative of the entire US population born before 1948 with a sample of more than 
30 000 participants, although Americans of African and Latin descent/ethnicity were 
oversampled. Interviews were done with participants every two years in-person or over 
the phone. Participants over the age of 80 were given priority for in-person interviews. 
Interviews could be done with informants for participants who were unwilling or unable 
to complete the interview but consented to having an informant, usually a spouse or 
daughter, complete the interview on their behalf. Approximately 10% of the sample had 
informants who completed the interviews on behalf of the participant. The study 
collected detailed information on physical and mental health and demographic 
information, including entire surveys on economic, employment, marital, and family 
status and history, retirement planning, and use and access to public and private support 
systems available to older adults in the United States (further information is available at 
http://hrsonline.isr.umich.edu/).  
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In October 2003, a survey was sent in the mail to 2 350 participants who reported 
having diabetes in the HRS 2002 core survey. This survey queried self-reported 
information on diabetes treatment, self-management behaviours, and coping with living 
with diabetes. Participants were also asked to return a blood spot that would measure 
A1C. In total, 1 901 (80.894% response rate) and 1 233 (64.861% response rate) 
completed the survey and returned the A1C measure, respectively. The sample size for 
the present study was determined by the number of participants who met the inclusion 
and exclusion criteria for the study. 
Inclusion criteria for the archival study consisted of: (a) 40 years of age or older, 
(b) diagnosis of T2DM for at least 1 year, (c) completion of the cognitive functioning, 
DSMB, and Impact of Diabetes in Life measures. Exclusion criteria for the archival study 
were as follows: (a) diagnoses of diabetes other than T2DM (i.e., T1DM or gestational 
diabetes) or if type of diabetes was unknown; (b) previous diagnosis of dementia or a 
score on the cognitive functioning measure that would be indicative of possible dementia; 
(c) not residing in the community; (d) an informant completed the interview from the 
2002 core study, as there is no cognitive functioning data for participants; (e) an 
informant completed the 2003 diabetes survey. The inclusion and exclusion criteria for 
the archival study were less stringent than for the prospective study due to the larger 
sample size of the archival study, the greater availability of covariate variables, and the 
nature of the comorbidity measure included in the Diabetes study.   
Of the 1901 individuals with T2DM that completed the 2003 diabetes survey 
individuals without T2DM (unknown: n = 248, T1DM: n = 50), with diabetes duration 
for less than one year (n = 17), that did not live in the community (n = 29), that had an 
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informant complete the interview (n = 144), who had a previous diagnosis of dementia (n 
= 21), for whom there was no TICS total score (n = 494), with a score on the TICS 
indicating a possible dementia (≤ 8, n = 9), who had an informant complete the diabetes 
survey (n = 56), who did not complete the Impact of Diabetes in Life measure (n = 22) or 
who answered 5 or fewer questions on the Impact of Diabetes in Life measure (n = 24), 
and who did not complete any of the 4 DSMB outcome measures (n = 11) were excluded. 
After the inclusion and exclusion criteria were applied the number of individuals eligible 
for participation in the current study was 776 for the analyses without A1C and 565 for 
the analyses with A1C.  
Measures 
The most appropriate available measures present in the HRS datasets were chosen 
to parallel as closely as possible the measures in the prospective study.    
Demographic and disease variables and the Total Illness Burden Index. The 
demographic and disease variables included in the analyses as covariates were age in 
years at the time of data collection, gender, race (white, black, other), annual household 
income, years of education, length of diabetes duration in years, previous completion of a 
diabetes education program, A1C level, type of diabetes treatment regimen (diet/exercise, 
oral medication, insulin, or oral medication and insulin), depression symptom level, body 
mass index, a diagnosis of elevated cholesterol, and score on the Total Illness Burden 
Index (TIBI).  
The TIBI is an imputed variable representing a score of diseases comorbid with 
diabetes in 15 domains including organ systems affected by diabetes complications 
(Greenfield, et al. 1995). The TIBI is scaled from 0 to 100. Higher scores indicated 
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greater severity of comorbidities. The measure was developed to be used in studies with 
functional status and quality of life outcomes as most measures of comorbidity are used 
to estimate mortality (Greenfield, et al., 1995). The 15 domains covered by the TIBI 
include: hearing loss, hypertension, nonspecific bowel disease, genitourinary problems, 
gastrointestinal autonomic neuropathy, foot disease, lower gastrointestinal disease, upper 
gastrointestinal disease, musculoskeletal problems, vision problems, congestive heart 
failure, chronic obstructive pulmonary disease, ischemic heart disease, renal disease, and 
neurological problems.  
Cognitive functioning measure. Cognitive functioning was measured in the 
2002 core survey using an abbreviated version of the Telephone Interview for Cognitive 
Status (TICS, Brandt et al., 1988, Breitner et al., 1995). The TICS was developed from 
the Mini-Mental State Examination (MMSE) to be used in telephone surveys to screen 
for cognitive impairment. The modified version used in the HRS has been shown to have 
good psychometric properties, including strong internal and construct validity (Ofstedal 
et al., 2006). The maximum achievable score was 35 with higher scores indicating better 
cognitive functioning. The total score was composed of immediate recall (max. 10 
points), delayed recalled (max. 10 points), serial 7s (max. 5 points), counting backwards 
(max. 2 points), orientation (max. 4 points), and naming (max. 4 points).  
DSMB measure. There were two DSMB measures present in the HRS 2003 
diabetes study dataset. The first was based on the Summary of Diabetes Self-Care 
Activities (SDSCA, Schmitt et al., 2013; Toobert et al., 2000) described above in the 
DSMB measures section of the prospective study. Only the domains of 
medication/insulin intake, diet, and blood glucose testing were included in the HRS 
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diabetes dataset and in the analyses in the current archival study. The average score for 
medication/insulin intake was used in the analyses. If there was only one score for either 
medication or insulin intake, this single score was used in the analyses in place of an 
average score. The second measure was adapted from the Diabetes Care Profile 
(Fitzgerald et al., 1996). Five items asked about DSMB completed over the past six 
months in the domains of medication taking, engaging in exercise, following a prescribed 
diet, measuring blood glucose levels, and checking feet. Participants were asked to rate: 
“Over the past six months, how difficult has it been to do each of the following exactly as 
the doctor who takes care of your diabetes suggested?” Each domain was measured on a 
Likert scale ranging from 1 to 5, with 1 = so difficult that I could not do it at all, and 5 = 
not difficult, I got it exactly right. A mean total score on this scale was used in the present 
study with higher scores indicating less difficulty with DSMB completion. Internal 
consistency for the total score was found to be adequate (α = .71, Heisler et al., 2007).  
Impact of Diabetes in Life measure. This measure was developed specifically 
for use in the HRS 2003 diabetes study based on theoretical models for factors 
influencing diabetes treatment behaviours and attitudes (Heisler et al., 2007). It is a 
measure of the impact of diabetes on the life of the participant, in both functional and 
emotional domains. The questionnaire asked: “Which of the following diabetes issues are 
currently a problem for you?” Each question was measured on a Likert scale ranging 
from 1 to 5, with 1 = not a problem, and 5 = serious problem. A mean total score on this 
scale was used in the present study with higher scores indicating greater impact of 
diabetes on the participant’s life. There were 10 items that asked about finding money to 
pay for medications, keeping up with commitments at work or at home, having goals for 
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diabetes care, feeling discouraged by the diabetes treatment plan, coping with diabetes 
complications, restrictions on eating, uncomfortable interactions with family and friends, 
feeling overwhelmed by the diabetes treatment regimen, and worrying about low blood 
sugar and future diabetes complications.    
Depression measure. The measure of depression symptoms present in the dataset 
was administered at the same time as the TICS. The measure is an 8-item questionnaire 
based on the 20-item Center for Epidemiologic Studies Depression Scale. Higher scores 
indicated greater severity of depression symptoms. The 8-item measure was found to be a 
valid single-factor measure of depression symptoms in older adults (Karim et al., 2014). 
The questionnaire queried yes/no responses to feeling depressed, happy (reverse scored), 
lonely, and sad, feeling like they could not get going, feeling that everything done is 
effortful, that sleep was restless, and that life was enjoyed (reversed scored) over the past 
week.  
Analyses  
Descriptive statistics were reported for all variables in the analysis along with 
Pearson r correlations between the DSMB subscales and total score and the TICS score, 
between the TICS score and the Impact of Diabetes in Life score, and between the DSMB 
subscales and total score and the Impact of Diabetes in Life score. 
 The first research question was answered using hierarchical MRAs to determine 
the relationship between each of the DSMB measures and cognitive functioning while 
accounting for variables known to be related to DSMB completion. The first step 
included demographic and disease variables that correlated significantly with each of the 
outcomes. The second step included the TICS score. The outcomes were medication, diet, 
blood glucose, or total DSMB completion. There were a total of six hierarchical MRAs 
 95 
 
done to answer the first research question, one with medication DSMB as the outcome, 
one with blood glucose DSMB as the outcome, two with diet DSMB as the outcome with 
and without A1C, and two with total DSMB as the outcome with and without A1C. The 
second research question also used hierarchical MRA to determine what predicts the 
impact of diabetes on life in individuals with T2DM. The first step included demographic 
and disease variables that correlated significantly with the outcome. The second step 
included the TICS score and the DSMB total score. The outcome was the Impact of 
Diabetes in Life measure. Two hierarchical MRAs were run to answer the second 
research question with and without A1C as a step one variable.  
Missing data and dummy coding. There were missing data on many of the step 
1 variables in the analyses. The data were not missing completely at random and thus 
imputing missing values would have biased the parameter estimates. A1C was the only 
continuous covariate with a large proportion of missing data. Separate hierarchical MRAs 
were done with and without A1C in step 1 for outcome variables that included A1C as a 
step 1 variable. Household income values were missing for 29.8% of the sample and 
diabetes duration values were missing for 14.9% of the sample. These variables were thus 
categorized in order to preserve as much data as possible. Household income was 
categorized as <20
th
 percentile (below the poverty line for most households), >20
th
 but < 
50
th
, >50
th
 percentile, and missing according to 2002 U.S. Census Bureau data for 
household income Table A-2 (https://www.census.gov/data/tables/2016/demo/income-
poverty/p60-256.html). This was done given that individuals under the poverty line 
would be most likely to struggle financially and thus have household income possibly 
impact DSMB completion, followed by those between the 20
th
 and 50
th
 percentiles, as 
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compared to individuals with household incomes above the 50
th
 percentile. Diabetes 
duration was categorized as ≤ 5 years, ≥6 to ≤ 15 years, ≥ 16 years, and missing based on 
two studies showing that diabetes knowledge significantly differed for those with 
duration of ≤ 5 years compared to those with a duration of ≥6 years (Kassahun et al., 
2016) and that individuals with diabetes durations of greater than >15 years have 
significantly higher risks of cardiovascular complications (Shah et al., 2010), both factors 
that could impact DSMB completion.  
The remaining variables with missing data were missing values in small 
proportions (0.5 to 5.4%). Missing values were estimated based on the category those 
with missing values were most likely to belong to given base rates in the population and 
in the sample. For diabetes education, 42 individuals (5.4%) with missing values were 
assumed to have completed diabetes education. For diabetes treatment modality, 11 
individuals (1.4%) with missing values were assumed to be taking only medication for 
their diabetes treatment management. For smoking status, 4 individuals (0.5%) with 
missing values were assumed to be non-smokers. For BMI, 7 individuals (0.9%) were 
missing values. The missing values all came from women in the sample, thus the median 
BMI for women in the sample (28.350) was substituted for the missing values for these 
participants. Finally for cholesterol level, 35 individuals (4.5%) with missing values were 
assumed to have elevated levels of cholesterol.  
Each of the 8 hierarchical MRAs was run with and without the replaced missing 
values. There were no significant differences when replaced missing values were used as 
compared to running the analyses with list-wise case deletion except for when the 
cholesterol level variable was included in the analyses. As such, the 35 individuals with 
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missing data on the cholesterol variable were excluded from the analyses as there was no 
other way to estimate missing values that would not bias the data. For all other variables 
with missing data, the missing values were replaced as described above for all analyses in 
an effort to preserve as much data as possible.  
For the total DSMB and Diabetes Impact outcomes, some individuals did not 
complete every item that made up the total score for each measure. If individuals 
completed less than 60% of the items they were excluded from the study as described 
above. In order to preserve data and include individuals in the analyses who completed at 
least 60% of the items but had missing values on some items (n = 206 for total DSMB 
and n = 51 for diabetes impact); a mean score of completed items was calculated and then 
multiplied by 5 for the total DSMB scores and by 10 for the diabetes impact score. This 
resulted in a total score equivalent across all participants included in the analyses even if 
they had not answered every item on the total DSMB or diabetes impact measures.  
Categorical step 1 variables were dummy coded to allow for inclusion as 
predictors in the hierarchical MRAs. Race was coded with white race as the baseline. 
There was one dummy coded variable comparing white individuals to black individuals 
and another variable comparing white individuals to individuals with an “other” race. 
Male gender was the baseline for the gender dummy coded variable. Household income 
was coded with income >50
th
 as the baseline. There were three dummy coded variables: 
one comparing <20
th
 percentile income to the >50
th
 percentile income, one comparing 
>20
th
 but <50
th
 percentile income to the >50
th
 percentile income, and one comparing 
individuals with missing values on household income to those with >50
th
 percentile 
income. Not having received diabetes education was the baseline for the diabetes 
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education dummy coded variable. Diabetes treatment modality was coded with those 
being treated with diet and exercise only as the baseline. There were three dummy coded 
variables: one comparing those taking medication only to those being treated with diet 
and exercise only, one comparing those taking insulin only to those being treated with 
diet and exercise only, and one comparing those taking both medication and insulin to 
those being treated with diet and exercise only. Diabetes duration was coded with those 
with a duration of ≥6 to ≤ 15 years as the baseline. There were three dummy coded 
variables: one comparing those with a duration of ≤ 5 years to those with a duration of ≥6 
to ≤ 15 years, one comparing those with a duration of ≥ 16 years to those with a duration 
of ≥6 to ≤ 15 years, and one comparing those with missing values to those with a duration 
of ≥6 to ≤ 15 years. Being a non-smoker was the baseline for the smoking status dummy 
coded variable.  
Assumptions and outliers. The assumptions of hierarchical MRA were evaluated 
for each of the 8 hierarchical MRAs completed in the present study. The assumptions of 
adequate sample size, linearity, absence of multicollinearity, and independence of errors 
were met for all 8 of the hierarchical MRAs. Univariate normality (skewness values 
greater than ± 2 and kurtosis values ± 3) and thus the assumption of normally distributed 
residuals was violated for the medication DSMB and Diabetes Impact hierarchical 
MRAs. Univariate normality was attained for the diet, blood glucose, and total DSMB 
completion outcomes. The multivariate residuals histograms approached, but did not 
completely fit the normal distribution. There were no influential observations in any of 
the 8 hierarchical MRAs as all Cook’s distance’s values were <.1. The number of outliers 
on Y (standardized residuals > |2.5|) ranged from 3 to 28 across the 8 hierarchical MRAs 
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and the number of outliers on X (Mahalanobis distance with p = .001 cut-off) ranged 
from 1 to 29 across the 8 hierarchical MRAs. The assumption of homoscedasticity was 
violated for all 8 hierarchical MRAs. As such, outliers were left in the analyses and 
bootstrapping (simple sampling, 1000 samples, bias-corrected and accelerated 95% CI) 
was done for all 8 of the hierarchical MRAs. Results were reported for all 8 hierarchical 
MRAs with and without bootstrapping. Only the bootstrapped results were interpreted. 
All statistical analyses were completed using SPSS version 22.  
 
 
    
 
  
 100 
 
CHAPTER VI 
ARCHIVAL STUDY RESULTS 
 Descriptive statistics were calculated for all demographic and disease related 
variables included in the analyses, as well as, for the TICS, DSMB, and Diabetes Impact 
measures. These are reported first. Next, Pearson r correlations between the TICS and the 
DSMB measures, between the DSMB measures and the Diabetes Impact measure, and 
between the Diabetes Impact measure and the TICS are reported. Finally, the six 
hierarchical MRAs with DSMB measures as the outcome are reported to answer the first 
research question and the two hierarchical MRAs with Diabetes Impact as the outcome 
measure are reported to answer the second research question.  
Descriptive Statistics 
Descriptive statistics for the sample are reported in Table 12. On average, 
participants in the sample were older and had completed at least a grade 12 education. 
The participants in the sample reported few depression symptoms. The average BMI was 
in the overweight range and the average A1C value was just over the 7% target value. 
Significant relationships of the demographic and disease-related variables with the 
DSMB measures and the diabetes impact measure are also reported in Table 12. Only 
variables with significant relationships with study outcome variables were included in 
step one of the hierarchical MRAs for a particular outcome. For medication DSMB, the 
variables included in step one were: age, years of education, race, household income and 
smoking status. For blood glucose DSMB, the variables included in step one were: 
gender, smoking status, diabetes education, and treatment modality. For diet DSMB, the 
variables included in step one were: age, depression symptoms, BMI, TIBI, and elevated 
cholesterol with and without A1C. For total DSMB, the variables included in step one 
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were: depression symptoms, BMI, and TIBI with and without A1C. Finally for diabetes 
impact, the variables included in step one were: age, years of education, gender, race, 
depression symptoms, BMI, TIBI, diabetes education, diabetes duration, elevated 
cholesterol, and treatment modality with and without A1C. Although these variables had 
significant zero order correlations with the outcome variable in each of the respective 
MRAs where they were included as predictors in step 1, these variables were not always 
significant predictors of the outcome variable when all variables were included in the 
model (see Tables 16, 18, 20, 22, 24, 26, 28, 30).    
Table 12 
Descriptive statistics for demographic and disease-related variables (N=776)
a
 
Variable N(%)
b
 Mean (SD) Min-Max 1 2 3 4 5 
Demographic       
Age   72.707 (6.147) 45-95 *  *  * 
Years of Education   12.077 (3.030) 0-17 *    * 
Female Gender 389(50.01)    *   * 
Race    
  *    * 
White  653(84.1) 
Black 99(12.8) 
Other 24(3.1) 
Household Income    
*     
<20
th
 percentile 213(27.4)  
>20
th
 to < 50
th
 197(25.4) 
>50
th
 percentile 135(17.4) 
Missing 231(29.8) 
Disease-related        
Smokes Cigarettes 45(5.8)   * *    
Depression Symptoms
c
  1.530 (1.892) 0-8   * * * 
BMI  
 29.085 (5.334) 
17.90-
53.30 
  * * * 
Score on TIBI
c
 
 
33.931 
(18.174) 
0-89.90   * * * 
Past Diabetes Education  414(53.4)     *   * 
Diabetes Duration    
    * 
≤ 5 years 197(25.4)  
≥6 to ≤ 15 years 243(31.3) 
≥ 16 years 220 (28.4) 
Missing 116(14.9) 
A1C (N=565)
c
  7.084 (1.157) 4.80-15.20   * * * 
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Elevated Cholesterol 
(N=741)  
455(61.4)   
  *  * 
Treatment Modality    
 *   * 
Diet & Exercise 76(9.8)  
Medication only 521(67.1) 
Insulin only 97(12.5)  
Medication & Insulin 82(10.6) 
Note. Continuous variables are correlations with DSMB and Diabetes Impact; 
Dichotomous variables are independent t-tests with DSMB and Diabetes Impact; 
Categorical variables with more than 2 groups are One-way ANOVA with DSMB and 
Diabetes Impact; 1: DSMB Medication; 2: DSMB Blood Glucose; 3: DSMB Diet; 4: 
DSMB Total; 5: Diabetes Impact; BMI: Body Mass Index; TIBI: Total Illness Burden 
Index 
a 
N=776 unless otherwise indicated 
b
All percentages indicate a yes response or the response is included in the variable label 
unless otherwise indicated or there are multiple groups  
c
Higher scores indicate worse symptoms, worse diabetes control, or greater comorbidity   
*p <.05 
 
 Descriptive statistics for the TICS, DSMB, and Diabetes Impact measures can be 
found in Table 13. On average, participants reported completing their medication DSMB 
most often, followed by blood glucose and diet DSMB, which were reportedly completed 
at roughly the same frequency. Reported difficulty with total DSMB completion was low 
with the average score indicating that participants managed to complete their DSMB as 
recommended by their healthcare practioners without difficulty most of the time. Average 
reported diabetes impact on life was quite low, with 156 (20.1%) reporting no diabetes 
impact. In total, 96.4% of participants scored 20 or less out of 40 on the measure.  
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Table 13 
Descriptive statistics for TICS, DSMB, and Diabetes Impact 
 N Mean (SD) Sample Min-Max Test Min-Max 
TICS 776 22.254 (4.565) 10-35 0-35 
 
Medication DSMB 
 
689 
 
6.719 (1.066) 
 
1-7 
 
1-7 
 
Blood Glucose DSMB 
 
683 
 
5.697 (2.110) 
 
1-7 
 
1-7 
 
Diet DSMB 
 
729 
 
5.646 (1.588) 
 
1-7 
 
1-7 
 
Total DSMB 
 
750 
 
20.934 (2.846) 
 
10-25 
 
5-25 
 
Diabetes Impact
a
 
 
776 
 
5.992 (6.609) 
 
0-40 
 
0-40 
Notes. DSMB: Diabetes Self-Management Behaviour; TICS: Telephone Interview for 
Cognitive Status   
a
Higher scores indicate worse impact. 
 
Correlations between the TICS, DSMB, and Diabetes Impact 
 The correlations between the TICS, DSMB, and diabetes impact can be found in 
Table 14. The TICS total score was significantly correlated with medication DSMB. 
Higher scores on the TICS were significantly related to increased reported medication 
DSMB completion. There were no other significant correlations between the TICS and 
DSMB or diabetes impact. Diabetes impact was significantly correlated with medication, 
diet, and difficulty with total DSMB completion. Increasing impact of diabetes on life 
was significantly related to lower medication and diet DSMB completion and with more 
reported difficulty with total DSMB completion. Although these correlations were 
statistically significant, the proportion of variance accounted for by these correlations was 
low ranging from 0.6 to 7.2%.   
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Table 14 
Pearson r correlations between DSMB, TICS, and Diabetes Impact 
 
DSMB 
Medication 
DSMB Blood 
Glucose 
DSMB 
Diet 
DSMB 
Total 
Diabetes 
Impact 
TICS 
     
R .100
**
 -.041 -.057 .021 -.070 
P .008 .289 .125 .571 .051 
N 689 683 729 750 776 
r
2
 .010 .002 .003 .000 .005 
Diabetes 
Impact      
R -.079
*
 -.026 -.254
**
 -.269
**
 
 
P .038 .491 <.001 <.001 
 
N 689 683 729 750 
 
r
2
 .006 .001 .065 .072 
 
Note: TICS: Telephone Interview for Cognitive Status   
*p <.05 
**p <.01 
 
DSMB Analyses Answering the First Research Question 
Medication DSMB. The model including age, education, race, household 
income, and smoking status in step one and cognitive functioning in step two accounted 
for 5% of the variance in medication DSMB completion (see Table 15). Cognitive 
functioning did not account for significantly more variance than the step one variables 
(F(1, 679) = .l36, p = .713). Age, education, and black race (as compared to the baseline 
of white race) were significant predictors of medication DSMB completion in step one 
(see Table 16). Age and black race remained significant predictors of medication DSMB 
completion in step two; however, education was no longer a significant predictor in step 
two. Cognitive functioning was not a significant predictor of medication DSMB 
completion.   
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Table 15  
Model Summary 
Model R R
2
 
Adj. 
R
2
 
Std. Error 
of the Est. 
Change Statistics 
R
2 
Change 
F 
Change df1 df2 
Sig. F 
Change 
Step 1 0.222 .049 .038 1.046 .049 4.409 8 680 <.001 
Step 2 0.222 .050 .037 1.046 .001 .136 1 679 .713 
Note. Adj: Adjusted; Est: Estimate; Sig: Significance; Std: Standard 
Table 16 
Model Coefficients with Bootstrapping (n=689) 
Coefficients 
  
Bootstrapped Coefficients 
Model B 
Std. 
Error β t Sig. 
 
r 
 
Sig. Bias 
Std. 
Error Sig. 
BCa 95% CI 
Lower Upper 
1 
     
  
     
(Constant) 7.716 .522 
 
14.793 <.001   -.008 .585 .001 6.636 8.823 
Age -.017 .007 -.100 -2.578 .010   .000 .008 .035 -.034 -.001 
Education .029 .013 .084 2.201 .028   .001 .013 .032 .006 .057 
Black Race -.455 .122 -.144 -3.741 <.001   -.003 .175 .013 -.838 -.115 
Other Race .129 .229 .021 .563 .573   .002 .081 .106 -.048 .292 
Household Income 
<20th Percentile 
-.138 .123 -.057 -1.121 .263 
  
.005 .113 .218 -.357 .103 
Household Income 
>20th to < 50th 
Percentile 
.051 .124 .021 .415 .679 
  
.002 .089 .556 -.119 .222 
Household Income 
Missing 
-.070 .121 -.030 -.580 .562 
  
.003 .109 .511 -.286 .157 
Smoking  .142 .176 .030 .806 .420   .005 .080 .082 -.024 .318 
2 
     
  
     
(Constant) 7.621 .582 
 
13.083 <.001   -.004 .677 .001 6.304 9.008 
Age -.017 .007 -.097 -2.442 .015 -.100 .009 .000 .008 .048 -.035 .000 
Education .027 .015 .077 1.831 .067 .133 .003 .001 .014 .064 .000 .058 
Black Race -.446 .124 -.141 -3.599 <.001 -.148 <.001 -.003 .175 .014 -.840 -.084 
Other Race .135 .230 .022 .589 .556 .040 .293 .002 .086 .105 -.037 .315 
Household Income 
<20th Percentile 
-.136 .123 -.057 -1.110 .268 -.604 .095 .005 .114 .230 -.363 .108 
Household Income 
>20th to < 50th 
Percentile 
.051 .124 .021 .415 .679 .074 .052 .002 .090 .551 -.122 .223 
Household Income 
Missing 
-.069 .121 -.030 -.570 .569 -.045 .241 .002 .108 .514 -.279 .157 
Smoking .148 .177 .032 .837 .403 .037 .334 .006 .084 .075 -.016 .336 
TICS .004 .010 .016 .369 .713 .100 .008 .000 .011 .747 -.017 .026 
Note. BCa 95% CI: Bias-Corrected and Accelerated 95% Confidence Interval; Sig. 
Significance; Std: Standard; TICS: Telephone Interview for Cognitive Status 
 
 
Blood Glucose DSMB. The model including gender, diabetes education, 
treatment modality, and smoking status in step one and cognitive functioning in step two 
accounted for 4.3% of the variance in blood glucose DSMB completion (see Table 17). 
Cognitive functioning did not account for significantly more variance than the step one 
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variables (F(1, 675) = 1.296, p = .255). Diabetes education, taking insulin only or both 
medication and insulin (as compared to a baseline of diet and exercise only) for diabetes 
treatment, and smoking status were significant predictors of blood glucose DSMB 
completion in step one (see Table 18). All significant predictors in step one remained 
significant in step two. Cognitive functioning was not a significant predictor of blood 
glucose DSMB completion.   
Table 17  
Model Summary 
Model R R
2
 
Adj. 
R
2
 
Std. Error 
of the Est. 
Change Statistics 
R
2 
Change 
F 
Change df1 df2 
Sig. F 
Change 
Step 1 0.202 .041 .032 2.075 .041 4.816 6 676 <.001 
Step 2 0.207 .043 .033 2.075 .002 1.296 1 675 .255 
Note. Adj: Adjusted; Est: Estimate; Sig: Significance; Std: Standard 
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Table 18 
Model Coefficients with Bootstrapping (n=683) 
Coefficients 
  
Bootstrapped Coefficients 
Model B 
Std. 
Error β t Sig. 
 
r 
 
Sig. Bias 
Std. 
Error Sig. 
BCa 95% CI 
Lower Upper 
1 
     
  
     
(Constant) 4.917 .286 
 
17.176 <.001   .008 .320 .001 4.221 5.565 
Gender .310 .159 .074 1.949 .052   .000 .162 .066 -.006 .654 
Diabetes 
Education 
.422 .161 .100 2.616 .009 
  
-.002 .167 .020 .092 .723 
Treatment 
Modality: Meds 
Only 
.352 .276 .079 1.278 .202 
  
-.009 .311 .242 -.219 .984 
Treatment 
Modality: 
Insulin Only 
.867 .335 .142 2.585 .010 
  
-.002 .334 .014 .216 1.557 
Treatment 
Modality: Meds 
and Insulin 
.824 .356 .119 2.311 .021 
  
-.024 .352 .012 .136 1.464 
Smoking -.820 .347 -.089 -2.359 .019   .015 .407 .036 -1.595 -.024 
2 
     
  
     
(Constant) 5.379 .497 
 
10.825 <.001   .005 .494 .001 4.390 6.354 
Gender .304 .159 .072 1.908 .057 .081 .035 -.001 .162 .071 -.012 .644 
Diabetes 
Education 
.433 .162 .102 2.679 .008 .166 .002 -.002 .167 .011 .098 .735 
Treatment 
Modality: Meds 
Only 
.329 .276 .074 1.189 .235 -.066 .086 -.009 .309 .275 -.242 .936 
Treatment 
Modality: 
Insulin Only 
.830 .337 .136 2.465 .014 .092 .017 -.002 .336 .020 .193 1.519 
Treatment 
Modality: Meds 
and Insulin 
.791 .358 .114 2.211 .027 .060 .115 -.024 .352 .019 .123 1.418 
Smoking -.858 .349 -.093 -2.458 .014 -.095 .013 .016 .410 .028 -1.643 -.045 
TICS -.020 .017 -.043 -1.138 .255 -.041 .289 .000 .017 .243 -.057 .016 
Note. BCa 95% CI: Bias-Corrected and Accelerated 95% Confidence Interval; Sig. 
Significance; Std: Standard; TICS: Telephone Interview for Cognitive Status 
 
Diet DSMB. The model including age, BMI, TIBI, depression symptoms, and 
cholesterol in step one and cognitive functioning in step two accounted for 11.2% of the 
variance in diet DSMB completion (see Table 19). Cognitive functioning did not account 
for significantly more variance than the step one variables (F(1, 691) = 2.563, p = .110). 
Age and TIBI were significant predictors of diet DSMB completion in step one (see 
Table 20). All significant predictors in step one remained significant in step two. 
Cognitive functioning was not a significant predictor of diet DSMB completion.   
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Table 19  
Model Summary 
Model R R
2
 
Adj. 
R
2
 
Std. Error 
of the Est. 
Change Statistics 
R
2 
Change 
F 
Change df1 df2 
Sig. F 
Change 
Step 1 0.329 .108 .102 1.487 .108 16.822 5 692 <.001 
Step 2 0.334 .112 .104 1.486 .003 2.563 1 691 .110 
Note. Adj: Adjusted; Est: Estimate; Sig: Significance; Std: Standard 
Table 20 
Model Coefficients with Bootstrapping (n=698) 
Coefficients 
  
Bootstrapped Coefficients 
Model B 
Std. 
Error β t Sig. 
 
r 
 
Sig. Bias 
Std. 
Error Sig. 
BCa 95% CI 
Lower Upper 
1 
     
  
     
(Constant) 4.621 .883 
 
5.234 <.001   .069 .885 .001 2.869 6.504 
Age .032 .010 .119 3.161 .002   -.001 .010 .002 .012 .049 
BMI -.018 .012 -.061 -1.469 .142   -.001 .012 .147 -.041 .004 
TIBI -.018 .004 -.214 -5.001 <.001   .000 .004 .001 -.025 -.011 
Depression -.060 .032 -.071 -1.901 .058   .000 .037 .105 -.129 .008 
Cholesterol -.100 .120 -.031 -.838 .402   -.003 .120 .402 -.327 .135 
2 
     
  
     
(Constant) 5.324 .985 
 
5.404 <.001   .075 1.016 .001 3.140 7.508 
Age .029 .010 .107 2.798 .005 .173 <.001 -.001 .011 .006 .009 .047 
BMI -.018 .012 -.062 -1.495 .135 -.205 <.001 -.001 .012 .144 -.041 .004 
TIBI -.019 .004 -.220 -5.131 <.001 -.288 <.001 .000 .004 .001 -.026 -.011 
Depression -.066 .032 -.078 -2.070 .039 -.147 <.001 .000 .037 .076 -.137 .005 
Cholesterol -.077 .120 -.024 -.639 .523 -.103 .006 -.003 .121 .510 -.313 .171 
TICS -.020 .013 -.060 -1.601 .110 -.052 .172 .000 .014 .134 -.047 .008 
Note. BCa 95% CI: Bias-Corrected and Accelerated 95% Confidence Interval; BMI: 
Body Mass Index; Sig. Significance; Std: Standard; TIBI: Total Illness Burden Index; 
TICS: Telephone Interview for Cognitive Status 
 
Diet DSMB with A1C. The model including age, BMI, TIBI, depression 
symptoms, cholesterol, A1C in step one and cognitive functioning in step two accounted 
for 12.6% of the variance in diet DSMB completion (see Table 21). Cognitive 
functioning did not account for significantly more variance than the step one variables 
(F(1, 511) = .277, p = .599). Age, TIBI, and A1C were significant predictors of diet 
DSMB completion in step one (see Table 22). All significant predictors in step one 
remained significant in step two. Depression symptoms became a significant predictor in 
step 2. Cognitive functioning was not a significant predictor of diet DSMB completion. 
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Adding A1C to the model accounted for an additional 1.4% of the variance in diet DSMB 
completion.   
Table 21 
Model Summary 
Model R R
2
 
Adj. 
R
2
 
Std. Error 
of the Est. 
Change Statistics 
R
2 
Change 
F 
Change df1 df2 
Sig. F 
Change 
Step 1 0.354 .125 .115 1.440 .125 12.197 6 512 <.001 
Step 2 0.354 .126 .114 1.441 .001 .277 1 511 .599 
Note. Adj: Adjusted; Est: Estimate; Sig: Significance; Std: Standard 
Table 22 
Model Coefficients with Bootstrapping (n=519) 
Coefficients 
  
Bootstrapped Coefficients 
Model B 
Std. 
Error β t Sig. 
 
r 
 
Sig. Bias 
Std. 
Error Sig. 
BCa 95% CI 
Lower Upper 
1 
     
  
     
(Constant) 5.588 1.110 
 
5.035 <.001   -.006 1.061 .001 3.447 7.720 
Age .031 .012 .114 2.632 .009   .000 .011 .009 .005 .055 
BMI -.007 .014 -.025 -.520 .603   .000 .014 .616 -.034 .020 
TIBI -.018 .004 -.221 -4.449 <.001   .000 .004 .001 -.027 -.010 
Depression -.066 .037 -.078 -1.793 .074   .000 .043 .132 -.144 .016 
Cholesterol -.127 .135 -.040 -.941 .347   .005 .138 .345 -.403 .174 
A1C -.175 .055 -.131 -3.149 .002   -.002 .065 .007 -.308 -.052 
2 
     
  
     
(Constant) 5.921 1.279 
 
4.631 <.001   .019 1.269 .001 3.345 8.540 
Age .030 .012 .108 2.386 .017 .165 <.001 .000 .012 .016 .004 .054 
BMI -.008 .014 -.027 -.553 .580 -.188 <.001 .000 .014 .590 -.035 .019 
TIBI -.018 .004 -.223 -4.475 <.001 -.293 <.001 .000 .004 .001 -.027 -.010 
Depression -.068 .037 -.080 -1.828 .068 -.155 <.001 .000 .043 .128 -.145 .015 
Cholesterol -.119 .136 -.038 -.870 .385 -.102 .021 .005 .142 .381 -.407 .195 
A1C -.175 .055 -.132 -3.162 .002 -.159 <.001 -.002 .065 .007 -.309 -.053 
TICS -.008 .015 -.023 -.526 .599 -.019 .666 -.001 .016 .643 -.037 .020 
Note. BCa 95% CI: Bias-Corrected and Accelerated 95% Confidence Interval; BMI: 
Body Mass Index; Sig. Significance; Std: Standard; TIBI: Total Illness Burden Index; 
TICS: Telephone Interview for Cognitive Status 
 
Total DSMB. The model including BMI, TIBI, and depression symptoms in step 
one and cognitive functioning in step two accounted for 8.9% of the variance in difficulty 
with total DSMB completion (see Table 23). Cognitive functioning did not account for 
significantly more variance than the step one variables (F(1, 745) = .024, p = .877). TIBI 
was the only significant predictor of difficulty with total DSMB completion in step one 
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(see Table 24). TIBI remained a significant predictor in step two. Cognitive functioning 
was not a significant predictor of difficulty with total DSMB completion.  
Table 23  
Model Summary 
Model R R
2
 
Adj. 
R
2
 
Std. Error 
of the Est. 
Change Statistics 
R
2 
Change 
F 
Change df1 df2 
Sig. F 
Change 
Step 1 0.298 .089 .085 2.723 .089 24.214 3 746 <.001 
Step 2 0.298 .089 .084 2.724 .001 .024 1 745 .877 
Note. Adj: Adjusted; Est: Estimate; Sig: Significance; Std: Standard 
Table 24 
Model Coefficients with Bootstrapping (n=750) 
Coefficients 
  
Bootstrapped Coefficients 
Model B 
Std. 
Error β t Sig. 
 
r 
 
Sig. Bias 
Std. 
Error Sig. 
BCa 95% CI 
Lower Upper 
1 
     
  
     
(Constant) 22.701 .552 
 
41.100 <.001   -.006 .532 .001 21.517 23.714 
BMI -.006 .021 -.012 -.314 .753   .000 .020 .746 -.040 .032 
TIBI -.044 .006 -.280 -6.990 <.001   .000 .006 .001 -.056 -.032 
Depression -.056 .054 -.038 -1.035 .301   -.001 .060 .352 -.170 .062 
2 
     
  
     
(Constant) 22.776 .735 
 
30.976 <.001   -.003 .762 .001 21.140 24.264 
BMI -.006 .021 -.012 -.307 .759 -.138 <.001 .000 .020 .753 -.042 .033 
TIBI -.044 .006 -.280 -6.984 <.001 -.295 <.001 .000 .006 .001 -.057 -.032 
Depression -.057 .055 -.038 -1.046 .296 -.166 .001 -.001 .061 .350 -.170 .062 
TICS -.003 .022 -.005 -.155 .877 .021 .571 .000 .023 .881 -.046 .043 
Note. BCa 95% CI: Bias-Corrected and Accelerated 95% Confidence Interval; BMI: 
Body Mass Index; Sig. Significance; Std: Standard; TIBI: Total Illness Burden Index; 
TICS: Telephone Interview for Cognitive Status 
 
 
Total DSMB with A1C. The model including BMI, TIBI, depression symptoms, 
and A1C in step one and cognitive functioning in step two accounted for 11.7 % of the 
variance in difficulty with total DSMB completion (see Table 25). Cognitive functioning 
did not account for significantly more variance than the step one variables (F(1, 537) = 
.033, p = .856). TIBI was the only significant predictor of difficulty with total DSMB 
completion in step one (see Table 26). TIBI remained a significant predictor in step two. 
Cognitive functioning was not a significant predictor of difficulty with total DSMB 
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completion. Adding A1C to the model accounted for an additional 2.8% of the variance 
in difficulty with total DSMB completion.   
Table 25  
Model Summary 
Model R R
2
 
Adj. 
R
2
 
Std. Error 
of the Est. 
Change Statistics 
R
2 
Change 
F 
Change df1 df2 
Sig. F 
Change 
Step 1 0.342 .117 .110 2.634 .117 17.765 4 538 <.001 
Step 2 0.342 .117 .109 2.637 .001 .033 1 537 .856 
Note. Adj: Adjusted; Est: Estimate; Sig: Significance; Std: Standard 
Table 26 
Model Coefficients with Bootstrapping (n=543) 
Coefficients 
  
Bootstrapped Coefficients 
Model B 
Std. 
Error β t Sig. 
 
r 
 
Sig. Bias 
Std. 
Error Sig. 
BCa 95% CI 
Lower Upper 
1 
     
  
     
(Constant) 23.741 .921 
 
25.772 <.001   .001 .940 .001 21.835 25.637 
BMI .006 .023 .011 .251 .802   .000 .022 .780 -.037 .049 
TIBI -.048 .007 -.315 -6.730 <.001   .000 .007 .001 -.061 -.033 
Depression -.076 .064 -.050 -1.188 .235   -.001 .074 .302 -.220 .071 
A1C -.178 .097 -.074 -1.829 .068   .000 .110 .102 -.385 .035 
2 
     
  
     
(Constant) 23.855 1.114 
 
21.410 <.001   .001 1.190 .001 21.421 26.291 
BMI .006 .023 .012 .254 .800 -.142 .001 -.001 .022 .783 -.038 .049 
TIBI -.048 .007 -.315 -6.726 <.001 -.329 <.001 .000 .007 .001 -.061 -.033 
Depression -.078 .065 -.051 -1.200 .231 -.141 .001 -.001 .075 .310 -.219 .066 
A1C  -.179 .097 -.075 -1.834 .067 -.101 .018 .000 .110 .103 -.387 .031 
TICS -.005 .026 -.007 -.182 .856 .027 .537 .000 .027 .870 -.057 .050 
Note. BCa 95% CI: Bias-Corrected and Accelerated 95% Confidence Interval; BMI: 
Body Mass Index; Sig. Significance; Std: Standard; TIBI: Total Illness Burden Index; 
TICS: Telephone Interview for Cognitive Status 
 
Diabetes Impact Analyses Answering the Second Research Question 
Diabetes Impact. The model including age, education, race, gender, diabetes 
education, treatment modality, diabetes duration, BMI, TIBI, depression, and cholesterol 
in step one and cognitive functioning and difficulty with total DSMB completion in step 
two accounted for 25.1% of the variance in diabetes impact (see Table 27). Cognitive 
functioning and difficulty with total DSMB completion accounted for significantly more 
variance over and above step one variables (F(2, 700) = 13.282, p < .001). Age, taking 
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medication only (as compared to a baseline of diet and exercise only) for diabetes 
treatment, TIBI, and depression symptoms were significant predictors of diabetes impact 
in step one (see Table 28). All significant predictors in step one remained significant in 
step two. In addition, taking insulin only (as compared to a baseline of diet and exercise 
only) for diabetes treatment became significant in step two. Cognitive functioning was 
not a significant predictor of diabetes impact; however, difficulty with total DSMB 
completion was a significant predictor of diabetes impact. For every one standard 
deviation decrease on the measure of total DSMB completion there was a 0.179 standard 
deviation increase in diabetes impact. Recalling that higher DSMB scores mean less 
difficulty with DSMB completion, this means that less difficulty with DSMB completion 
was associated with less impact of the diabetes of the individual’s life.   
Table 27  
Model Summary 
Model R R
2
 
Adj. 
R
2
 
Std. Error 
of the Est. 
Change Statistics 
R
2 
Change 
F 
Change df1 df2 
Sig. F 
Change 
Step 1 0.472 .223 .205 5.919 .223 12.592 16 702 <.001 
Step 2 0.501 .251 .232 5.818 .028 13.282 2 700 <.001 
Note. Adj: Adjusted; Est: Estimate; Sig: Significance; Std: Standard 
Table 28 
Model Coefficients with Bootstrapping (n=719) 
Coefficients 
  
Bootstrapped Coefficients 
Model B 
Std. 
Error Β t Sig. 
 
r 
 
Sig. Bias 
Std. 
Error Sig. 
BCa 95% CI 
Lower Upper 
1 
     
  
     
(Constant) 12.206 3.737 
 
3.266 .001   .121 3.910 .001 3.726 19.978 
Age -.143 .040 -.128 -3.553 <.001   -.001 .040 .001 -.219 -.064 
Education -.102 .077 -.047 -1.331 .184   -.003 .089 .255 -.268 .052 
Black Race .076 .687 .004 .111 .912   -.011 .877 .926 -1.586 1.799 
Other Race 2.901 1.268 .077 2.287 .022   -.093 2.012 .150 -.777 6.611 
Gender .336 .459 .025 .733 .464   .006 .456 .471 -.537 1.196 
Diabetes 
Education 
.708 .453 .053 1.564 .118 
  
-.005 .472 .135 -.294 1.640 
Treatment 
Modality: 
1.403 .802 .099 1.749 .081 
  
-.042 .593 .021 .259 2.427 
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Meds Only 
Treatment 
Modality: 
Insulin Only 
1.670 1.039 .084 1.608 .108 
  
-.047 .966 .093 -.291 3.404 
Treatment 
Modality: 
Meds and 
Insulin 
1.563 1.079 .072 1.449 .148 
  
-.013 .943 .105 -.272 3.420 
Diabetes 
Duration: 
≤5years 
-.253 .604 -.017 -.419 .675 
  
-.001 .538 .635 -1.340 .772 
Diabetes 
Duration: 
≥16 years 
.734 .587 .050 1.251 .211 
  
.017 .615 .239 -.443 1.906 
Diabetes 
Duration: 
Missing 
-.031 .720 -.002 -.043 .966 
  
-.016 .715 .974 -1.463 1.260 
BMI -.054 .048 -.044 -1.116 .265   .000 .050 .267 -.149 .046 
TIBI .103 .015 .285 6.923 <.001   .000 .016 .001 .072 .133 
Depression .717 .126 .203 5.677 <.001   .003 .158 .001 .402 1.023 
Cholesterol .539 .477 .040 1.129 .259   .010 .460 .250 -.289 1.461 
2 
     
  
     
(Constant) 21.881 4.325 
 
5.059 <.001   .077 4.356 .001 12.899 30.349 
Age -.141 .040 -.126 -3.484 .001 -.161 <.001 -.001 .039 .001 -.214 -.062 
Education -.099 .082 -.045 -1.208 .228 -.100 .007 -.003 .095 .312 -.278 .064 
Black Race .083 .689 .004 .121 .904 .042 .260 -.009 .838 .917 -1.374 1.647 
Other Race 2.664 1.250 .071 2.132 .033 .082 .021 -.094 2.093 .206 -1.380 6.456 
Gender .507 .454 .038 1.116 .265 .097 .010 .008 .446 .267 -.344 1.392 
Diabetes 
Education 
.773 .445 .058 1.734 .083 .069 .065 -.003 .463 .099 -.220 1.713 
Treatment 
Modality: 
Meds Only 
1.442 .789 .101 1.828 .068 -.045 .233 -.043 .621 .021 .222 2.553 
Treatment 
Modality: 
Insulin Only 
2.015 1.025 .101 1.966 .050 .098 .009 -.058 .965 .034 .138 3.730 
Treatment 
Modality: 
Meds and 
Insulin 
1.676 1.062 .077 1.579 .115 .089 .018 -.025 .946 .088 -.195 3.531 
Diabetes 
Duration: 
≤5years 
-.234 .593 -.015 -.394 .694 -.111 .003 -.009 .533 .653 -1.263 .747 
Diabetes 
Duration: 
≥16 years 
.908 .578 .062 1.571 .117 .088 .018 .021 .603 .136 -.279 2.125 
Diabetes 
Duration: 
Missing 
-.302 .709 -.016 -.426 .670 .030 .416 -.016 .709 .681 -1.739 1.024 
BMI -.055 .047 -.045 -1.174 .241 .158 <.001 .000 .049 .247 -.151 .040 
TIBI .083 .015 .230 5.481 <.001 .379 <.001 .000 .016 .001 .052 .114 
Depression .680 .125 .192 5.447 <.001 .305 <.001 .002 .158 .001 .369 .991 
Cholesterol .583 .470 .043 1.242 .215 .136 <.001 .012 .458 .210 -.261 1.538 
TICS -.023 .055 -.016 -.423 .673 -.069 .066 .000 .058 .651 -.138 .097 
Total DSMB -.419 .082 -.179 -5.125 <.001 -.270 <.001 .002 .083 .001 -.581 -.257 
Note. BCa 95% CI: Bias-Corrected and Accelerated 95% Confidence Interval; BMI: 
Body Mass Index; DSMB: Diabetes Self-Management Behaviour; Sig. Significance; Std: 
Standard; TIBI: Total Illness Burden Index; TICS: Telephone Interview for Cognitive 
Status 
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Diabetes Impact with A1C. The model including age, education, race, gender, 
diabetes education, treatment modality, diabetes duration, BMI, TIBI, depression, 
cholesterol, and A1C in step one and cognitive functioning and difficulty with total 
DSMB completion in step two accounted for 29.5% of the variance in diabetes impact 
(see Table 29). Cognitive functioning and difficulty with total DSMB completion 
accounted for significantly more variance over and above step one variables (F(2, 503) = 
9.846, p < .001). Age, education, other race (as compared to the baseline of white race), 
diabetes education, taking medication only (as compared to a baseline of diet and 
exercise only) for diabetes treatment, TIBI, and depression symptoms were significant 
predictors of diabetes impact in step one (see Table 30). All significant predictors in step 
one remained significant in step two. Cognitive functioning was not a significant 
predictor of diabetes impact; however, difficulty with total DSMB completion was a 
significant predictor of diabetes impact.  For every one standard deviation decrease on the 
measure of total DSMB completion there was a 0.172 standard deviation increase in 
diabetes impact. Recalling that higher DSMB scores mean less difficulty with DSMB 
completion, this means that less difficulty with DSMB completion was associated with 
less impact of the diabetes of the individual’s life. Adding A1C to the model accounted 
for an additional 4.4% of the variance in diabetes impact.   
Table 29  
Model Summary 
Model R R
2
 
Adj. 
R
2
 
Std. Error 
of the Est. 
Change Statistics 
R
2 
Change 
F 
Change df1 df2 
Sig. F 
Change 
Step 1 .517 .268 .243 5.728 .268 10.858 17 505 <.001 
Step 2 .543 .295 .269 5.630 .028 9.846 2 503 <.001 
Note. Adj: Adjusted; Est: Estimate; Sig: Significance; Std: Standard 
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Table 30 
Model Coefficients with Bootstrapping (n=523) 
Coefficients 
  
Bootstrapped Coefficients 
Model B 
Std. 
Error β t Sig. 
 
r 
 
Sig. Bias 
Std. 
Error Sig. 
BCa 95% CI 
Lower Upper 
1 
     
  
     
(Constant) 17.670 4.788 
 
3.691 <.001   .137 5.231 .002 7.672 27.831 
Age -.195 .049 -.165 -4.018 <.001   .000 .050 .001 -.288 -.094 
Education -.232 .089 -.104 -2.592 .010   -.006 .103 .034 -.444 -.046 
Black Race -.512 .895 -.023 -.572 .567   .044 1.173 .647 -2.635 2.040 
Other Race 5.543 1.524 .141 3.637 <.001   .109 2.838 .049 -.044 11.559 
Gender -.178 .523 -.014 -.340 .734   -.016 .513 .733 -1.208 .712 
Diabetes 
Education 
1.109 .520 .084 2.134 .033 
  
-.019 .512 .036 .129 2.066 
Treatment 
Modality: 
Meds Only 
1.410 .904 .098 1.559 .120 
  
-.012 .680 .042 .058 2.638 
Treatment 
Modality: 
Insulin Only 
1.180 1.236 .055 .955 .340 
  
-.008 1.209 .325 -.996 3.497 
Treatment 
Modality: 
Meds and 
Insulin 
.600 1.249 .027 .481 .631 
  
.008 1.137 .587 -1.646 3.056 
Diabetes 
Duration: 
≤5years 
-.483 .682 -.032 -.708 .479 
  
.012 .598 .430 -1.707 .739 
Diabetes 
Duration: 
≥16 years 
.529 .672 .036 .787 .432 
  
.012 .718 .449 -.802 2.070 
Diabetes 
Duration: 
Missing 
-.901 .821 -.047 -1.097 .273 
  
-.001 .768 .250 -2.402 .604 
BMI -.088 .055 -.073 -1.600 .110   -.003 .058 .137 -.206 .016 
TIBI .107 .017 .303 6.336 <.001   .000 .018 .001 .074 .143 
Depression .812 .150 .224 5.431 <.001   .008 .210 .001 .390 1.246 
Cholesterol .372 .551 .027 .675 .500   .033 .543 .487 -.738 1.655 
A1C .158 .228 .028 .692 .489   -.005 .214 .449 -.276 .556 
2 
     
  
     
(Constant) 29.927 5.624 
 
5.322 <.001   .346 5.892 .001 18.427 41.564 
Age -.209 .050 -.177 -4.203 <.001 -.189 <.001 .000 .048 .001 -.295 -.111 
Education -.195 .094 -.088 -2.072 .039 -.140 .001 -.003 .106 .070 -.426 .006 
Black Race -.640 .893 -.028 -.716 .474 .019 .669 .030 1.100 .536 -2.673 1.655 
Other Race 5.583 1.499 .142 3.724 <.001 .150 .001 .106 2.869 .045 -.152 11.991 
Gender .055 .518 .004 .106 .915 .071 .103 -.005 .505 .905 -1.021 .992 
Diabetes 
Education 
1.105 .511 .084 2.163 .031 .104 .017 -.020 .498 .031 .129 2.000 
Treatment 
Modality: 
Meds Only 
1.474 .889 .103 1.658 .098 -.019 .662 -.008 .707 .034 .040 2.761 
Treatment 
Modality: 
Insulin Only 
1.686 1.221 .078 1.380 .168 .089 .041 .003 1.225 .174 -.574 4.020 
Treatment 
Modality: 
Meds and 
Insulin 
.670 1.228 .030 .545 .586 .080 .067 .017 1.101 .539 -1.585 3.021 
Diabetes 
Duration: 
-.466 .672 -.031 -.693 .489 -.115 .009 .018 .587 .430 -1.641 .739 
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≤5years 
Diabetes 
Duration: 
≥16 years 
.657 .662 .044 .993 .321 .091 .037 .013 .707 .344 -.658 2.214 
Diabetes 
Duration: 
Missing 
-1.232 .811 -.064 -1.520 .129 -.018 .682 -.019 .775 .120 -2.737 .199 
BMI -.086 .054 -.071 -1.586 .113 .165 <.001 -.003 .057 .140 -.199 .018 
TIBI .085 .017 .241 4.896 <.001 .375 <.001 -.001 .018 .001 .050 .119 
Depression .749 .148 .206 5.071 <.001 .328 <.001 .007 .209 .003 .343 1.184 
Cholesterol .497 .544 .037 .915 .361 .111 .011 .025 .555 .368 -.667 1.774 
A1C .050 .225 .009 .223 .824 .092 .035 -.006 .226 .819 -.388 .447 
TICS -.083 .066 -.056 -1.273 .203 -.085 .051 -.002 .070 .230 -.215 .049 
Total DSMB -.407 .096 -.172 -4.232 <.001 -.278 <.001 -.006 .103 .001 -.608 -.225 
Note. BCa 95% CI: Bias-Corrected and Accelerated 95% Confidence Interval; BMI: 
Body Mass Index; DSMB: Diabetes Self-Management Behaviour; Sig. Significance; Std: 
Standard; TIBI: Total Illness Burden Index; TICS: Telephone Interview for Cognitive 
Status 
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CHAPTER VII 
ARCHIVAL STUDY DISCUSSION  
 The archival study sought first to determine the relationship between cognitive 
functioning and DSMB completion and second to determine the relationship between 
cognitive functioning and DSMB completion and the impact of diabetes on the life of the 
individual. These relationships were investigated using hierarchical multiple regression 
analysis. Overall performance of the sample on the measures of DSMB completion and 
diabetes impact will be discussed first. Next, the analyses with DSMB completion as the 
outcome answering the first research question will be discussed followed by the analyses 
with diabetes impact as the outcome measure answering the second research question. 
Study strengths and limitations will conclude the archival study discussion.  Future 
directions are discussed throughout where relevant. 
DSMB Completion and Diabetes Impact 
DSMB completion was highest for medication DSMB followed by blood glucose 
and diet DSMB. This corresponds to completion patterns reported by other studies, where 
medication DSMB completion is highest followed by the other domains of DSMB (Ahola 
& Groop, 2013; Gonzalez et al., 2016). Average reported difficulty with total DSMB 
completion was low which corresponds to the high rates of DSMB completion of the 
participants in this sample. Average reported diabetes impact on life was very low, with 
20% of the sample reporting no impact of diabetes on life and 97% of participants 
reporting half of the maximum possible impact of diabetes on their lives. These reported 
rates of the impact of diabetes on life are lower than what is generally reported (Debono 
& Cachia, 2007); however, this is difficult to assess as the measure of diabetes impact on 
life used in the archival study was developed specifically for the HRS survey and 
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evaluations of the validity and reliability, as well as, average performance on the measure 
have not occurred.  
Relationships Between Cognitive Functioning and DSMB Completion  
Cognitive functioning as measured by the TICS was not a significant predictor of 
completion for medication, blood glucose, and diet DSMB or for the total difficulty with 
DSMB completion both when A1C was included as a variable in the model and when it 
was not. Rosen and colleagues (2003) also failed to find any relationship between a 
cognitive screening measure (MMSE) and DSMB completion. Similarly, there was no 
relationship between the MoCA total score and DSMB completion in the prospective 
study. Thabit and colleagues (2009) did report a significant relationship between 
increased MMSE scores and increased total DSMB completion. All other previous 
studies did not include a cognitive screening measure, only used the screening measure as 
an exclusion criterion, or included individuals with dementia. Overall, investigating the 
relationship between cognitive functioning and DSMB completion using only a cognitive 
screening measure appears to be of limited utility, and studies should strive to include 
validated neuropsychological measures of multiple cognitive domains and abilities.   
Feil and colleagues (2012) found that lower cognitive functioning as measured by 
the TICS was significantly related to more difficulty with exercise and diet DSMB 
completion. They did not find any significant associations between the TICS and 
difficulty with blood glucose or foot care DSMB completion and they did not investigate 
the relationships between the TICS and difficulty with medication DSMB completion due 
to high ceiling effects on this variable indicating very low levels of difficulty with 
medication DSMB completion (Feil et al., 2012). Feil and colleagues dichotomized the 
individual components of the difficulty with DSMB completion total score that was used 
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in the present study and they did not analyse the medication, blood glucose, and diet 
DSMB completion measures that are based on the SDSCA as was done in the present 
study. Further, these authors made no mention of missing data or how these were handled 
in their analyses (Feil et al., 2012). This makes unclear what their findings are based on 
given the high levels of missing data in the HRS datasets and their reported sample size 
of 1398 as compared to the maximum sample size of 776 in the present study. This 
sample size of 776 included replacement of missing data as described in the data analyses 
section. Therefore, the results of the present study and those of Feil and colleagues are 
not directly comparable even though the analyses in both studies were completed with the 
same dataset.  
Relationships of Cognitive Functioning and DSMB Completion with Diabetes 
Impact  
 
Cognitive functioning and difficulty with total DSMB completion together 
accounted for significantly more variance over and above demographic and health-related 
variables when A1C was included in the model and also when it was not. However, 
cognitive functioning was not a significant independent predictor of diabetes impact in 
either model. Difficulty with total DSMB completion was a significant predictor of 
diabetes impact in both models and accounted for the significant increase in R
2
. Increased 
reported impact of diabetes on life lead to a significant increase in reported difficulty with 
total DSMB completion. It is no surprise that more difficulty with DSMB completion 
could lead to a greater perceived impact of diabetes on the individual’s life (Gonzalez et 
al., 2016).  
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Strengths and Limitations  
 
 The archival study was completed with a large nationally representative sample of 
Americans with T2DM (HRS, 2006). There was no relationship between cognitive 
functioning and DSMB completion. One reason for this is the TICS is a screening 
measure that is not sensitive to the cognitive deficits most often found in those without 
T2DM (Tomlin & Sinclair, 2016). There is no measure of processing speed on the TICS 
and the only component of executive functioning that is assessed is working memory. 
Working memory is only marginally impaired in individuals with T2DM (Monette et al., 
2014, Vincent & Hall, 2015). Executive deficits in individuals with T2DM can be missed 
if they are not assessed directly (Thabit et al., 2009). Thus, had validated 
neuropsychological measures of multiple cognitive domains and abilities been used, there 
may have been significant relationships between cognitive functioning and DSMB 
completion. The use of these measures is not feasible in large studies where data is 
collected over the phone as was done in the HRS study.  
 The DSMB measures in the archival study were adapted from validated measures, 
but their use in survey format has not been validated. The total DSMB score was a 
measure of difficulty with DSMB completion and not a measure of actual DSMB 
completion. In addition, the impact of diabetes on life measure was developed for the 
HRS study and has not been validated. There was a lot of missing data in the present 
study and the data were not missing completely at random; however, efforts were made 
to preserve as much data as possible without introducing bias. Survey methodology is not 
the optimal way to collect data on DSMB completion, especially given that this area of 
study is still in its infancy.  
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 The TICS data was gathered months before the DSMB completion and impact of 
diabetes on life data. Cognitive functioning of participants could have changed during 
this time. The medication, blood glucose, and diet DSMB completion measures asked 
about completion within the last seven days. DSMB completion at the time the TICS data 
were collected could have been different than what was reported in the survey. This 
limitation also applies to the impact of diabetes on life measure which asked about 
current impact. For cross-sectional investigations, all data should be collected within a 
short time span as was done in the prospective study.   
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CHAPTER VIII 
GENERAL DISCUSSION  
 The general discussion will address future directions in the research of the 
relationships between cognitive functioning and DSMB completion as these pertain to 
interventions needed to address the impact of cognitive functioning on DSMB 
completion, a holistic model that considers the multiple barriers to successful DSMB 
completion, and methodological recommendations for future studies in this area.   
Interventions Needed Based on Relationships of Cognitive Functioning and DSMB  
 The importance of recognizing the impact of cognitive functioning on DSMB 
completion and T2DM treatment outcomes is steadily increasing (Kirkman et al., 2012; 
Primozic et al., 2012; Vincent & Hall, 2016, Wong et al., 2014) and many authors have 
pointed to the shortcomings of the current model of diabetes education and treatment 
(Ahola & Groop, 2013; Gillani, 2012; Gonzalez et la., 2016; Tomlin & Asimakopoulou, 
2014, West et al., 2016). The model of simply using didactic instruction to teach those 
with T2DM how to complete their medication, blood glucose, diet, and physical activity 
DSMB is insufficient for successful completion of these behaviours (Gillani, 2012; West 
et al., 2016). Individuals with T2DM need to be taught problem-solving skills, goal 
setting, and behavioural regulation strategies (Gonzalez et al., 2016; Gillani, 2012). In 
addition, behaviour change interventions need to be incorporated into diabetes education 
and treatment to increase the rates of DSMB completion (Tomlin & Asimakopoulou, 
2014). More attention must also be paid to the aspects of motivation, self-efficacy, and 
mental health that affect DSMB completion and QoL (Hunter 2016, Tomlin & Sinclair, 
2016). Finally, the effects of cognitive deficits on DSMB completion must be taken into 
account and alleviated or accommodated through cognitive interventions (Compeán-Ortiz 
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et al., 2010; Gatlin & Insel, 2015; Monette, 2012; Primozic et al., 2012; Wasserman et 
al., 2015)  
 Psychologists and neuropsychologists are well trained to provide these types of 
interventions and adjuncts to diabetes treatment education that have been recommended 
to improve DSMB completion and T2DM treatment outcomes (Fisher et al., 2005; 
Hunter, 2016; Johnson & Marrero, 2016). However, psychologists and 
neuropsychologists do not typically receive training in the disease process, psychosocial, 
and cognitive aspects of T2DM that they would need to develop and deliver these 
interventions (Hunter, 2016; Johnson & Marrero, 2016). This is changing now with the 
American Psychological Association offering certifications and continuing education 
programs specific to working with individuals with diabetes (Hunter, 2016).   
Many studies have shown the effectiveness of psychological interventions to 
increase DSMB completion including problem-solving therapy, cognitive behavioural 
therapy, motivational interviewing, patient empowerment, and family therapy (Fisher et 
al., 2005; Gonzalez et al., 2016; Hunter, 2016). However, the majority of individuals with 
T2DM do not have access to these interventions either because they are not part of their 
routine T2DM treatment regimens, there are not enough service providers offering these 
interventions, and these interventions often require out-of-pocket payment (Hunter, 
2016).  
There are currently no validated cognitive interventions designed to help 
individuals with T2DM increase their DSMB completion by accommodating weaknesses 
in cognitive functioning with strategies that are used in cognitive rehabilitation with other 
patient groups. This is largely due to the lack of research on the links between cognitive 
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functioning and DSMB completion (Bruce, 2015; Wasserman et al., 2015) and the fact 
that neuropsychologists do not typically receive specific training to work with individuals 
with T2DM. As a result, any recommendations made to improve or accommodate 
cognitive functioning deficits in individuals with T2DM with regards to their DSMB 
completion are made based on clinical experience but have not been researched or 
validated (Bruce, 2015; Koekkoek et al., 2015; Wasserman et al., 2015).  
There is a large need for the development and validation of interventions that seek 
to improve or accommodate cognitive deficits in individuals with T2DM in order to 
increase DSMB completion, improve A1C, and delay or prevent diabetes complications 
including cognitive impairment and dementia (Koekkoek et al., 2015; Wasserman et al., 
2015). Existing well validated cognitive interventions such as Goal Management 
Training (Levine et al., 2012) or the Memory and Aging Program (Wiegand et al., 2013) 
could be adapted to make use of the strategies and skills from these interventions 
specifically to increase DSMB completion through compensatory behaviours.  
A Holistic Model Addressing All Barriers to DSMB Completion 
 
 The prospective and archival studies focused on barriers at the individual level as 
cognitive deficits represent an individual level barrier to DSMB completion and diabetes 
treatment adherence (Ahola & Groop, 2013; Bailey & Kodack, 2011; Emery et al., 2010). 
However, there are barriers to DSMB completion at the treatment level and at the 
environment level (Ahola & Groop, 2013; Bailey & Kodack, 2011; Castellon et al., 
2009).  
 The Social Ecological model provides an excellent theoretical backdrop for 
DSMB completion and T2DM treatment regimens (Fisher et al., 2005; Johnson & 
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Marrero, 2016). The Social Ecological model acknowledges that behaviour (i.e. DSMB) 
has multiple causes and the individual with T2DM has individual characteristics that 
determine their likelihood of completing their DSMB; however, there are many other 
factors outside of the control of the individual that contribute to their successful DSMB 
completion (Fisher et al., 2005). Factors external to the individual include the people 
around them and their interpersonal relationships (family, friends, peers, co-workers); 
their community (healthcare setting, media, institutional regulations); and the larger 
society (culture, economic and educational policies, provincial and federal policies and 
regulations, Fisher et al., 2005; Gillani, 2012; Johnson & Marrero, 2016). All of these 
factors interact and contribute to facilitating or hindering DSMB completion (Fisher et 
al., 2005; Johnson & Marrero, 2016).   
 Psychologists usually intervene at the individual and interpersonal level and not 
as much at the community and societal level (Johnson & Marrero, 2016). The 
interventions discussed in the previous section take into consideration many individual 
level factors that are neglected by the traditional medical model (Johnson & Marrero, 
2016). Interpersonal, community, and societal level factors would also influence the 
effectiveness of these interventions. A particular individual with T2DM could not 
reasonably be expected to successfully complete their DSMB if there were many 
interpersonal, community, and societal factors external to them hindering their treatment 
management and self-care activities (Fisher et al., 2005). For example, at the 
interpersonal level, intrusive involvement by others such as spouses or other caregivers 
that is controlling in nature can hinder DSMB completion and T2DM treatment 
adherence (Weibe et al. 2016). At the community level, diet and exercise DSMB 
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completion is more difficult if the person lives in an area where access to healthy foods 
and safe settings to exercise are limited (Fisher et al., 2005).   
At the societal level, medication and blood glucose DSMB completion could be 
hindered in individuals of lower SES who may not be able to pay for their medications, 
needles, insulin, test strips, and lancets (Gonzalez et al., 2016). In Canada, despite having 
universal healthcare, 57% of individuals with diabetes report that they do not complete 
their medication and blood glucose DSMB as recommended by their healthcare 
practitioners because they cannot afford their medications and supplies (Diabetes 
Canada). In Ontario, individuals without private coverage for prescription medications 
must pay a deductible equivalent to 4% of their income before they can have their 
medication and insulin costs covered. In addition, needles and lancets are not covered by 
this plan and must be paid for out-of-pocket by individuals under the age of 65 
(Government of Ontario). In the United States, where many individuals, especially those 
with lower SES, do not have any healthcare insurance, the societal level barrier of the 
cost of medications and supplies to treat T2DM could be expected to have an even 
greater impact than described above. Given the poorer diabetes treatment outcomes for 
those of lower education (Emery et al., 2010; Gonder-Frederick et al., 2016; Gonzalez et 
al., 2016), SES (Bailey & Kodack, 2011; Bruce, 2015; Gillani, 2012; Gonder-Frederick et 
al., 2016; Gonzalez et al., 2016; Johnson & Marrero, 2016; Weibe et al. 2016), and with 
minority status be it ethnic (Bailey & Kodack, 2011; Gonder-Frederick et al., 2016; 
Gonzalez et al., 2016; Hunter, 2016; Kirkman et al., 2012; Weibe et al., 2016), disability 
(de Groot et al., 2016; Emery et al., 2010; Gillani, 2012), or gender (Emery et al., 2010; 
Gillani, 2012), societal level factors impact greatly on DSMB completion and successful 
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treatment outcomes cannot be achieved for all individuals with T2DM while systemic 
inequalities exist.  
Psychologists could become more involved in shaping policies at the community 
and societal level to decrease barriers to DSMB completion in addition to the work done 
at the individual and interpersonal levels (Johnson & Marrero, 2016). If they do not, 
successes made at the individual and interpersonal levels will continue to be undermined 
by barriers at the community and societal levels and the most vulnerable individuals with 
T2DM will continue to have poorer DSMB completion, T2DM treatment outcomes, and 
QoL (de Groot et al., 2016). Psychologists and other healthcare practitioners should work 
collaboratively with individuals with T2DM to establish shared treatment goals and 
empower individuals to identify and remove or alleviate barriers to DSMB completion at 
all levels whenever possible (Ahola & Groop, 2013; Fisher et al., 2005; Gillani, 2012; 
Gonzalez et al., 2016; Hunter, 2016; Johnson & Marrero, 2016; Kirkman et al., 2012; 
Weibe et al., 2016). There should also be more studies of the societal barriers and their 
impact on DSMB completion and T2DM treatment adherence in order to provide 
evidence for policy changes that could reduce or eliminate these barriers (Fisher et al., 
2015; Gillani, 2012; Johnson & Marrero, 2016; Weibe et al., 2016).  
Future Methodological Directions  
 
 Much more research is needed to determine the nature and shape of the 
relationships between cognitive functioning and DSMB completion (Tomlin & Sinclair, 
2016). The relationships between cognitive functioning, DSMB completion, and 
diabetes-related and general QoL require further investigation as this was the first study 
to explicitly investigate these relationships with several measured cognitive abilities and 
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domains. For the most part, studies investigating the relationships between cognitive 
functioning and DSMB completion have relied on self-report measures of DSMB 
completion. Given the general shortcomings of self-report data leading to possible 
inaccurate reporting due to social desirability, errors in recall, or lack of insight (Caro-
Bautista et al., 2014) and the differences in reporting found in the prospective study 
across DMSB completion measures completed by the same individual in the same time 
span, methods other than self-report should be employed in future studies. Other methods 
of assessing medication DSMB include pill counts, pharmacy refill records, and 
electronic pill bottle caps that make use of Microelectronic Event Monitoring Systems 
(Gonzalez et al., 2016; Mulcahy et al., 2003; Rosen et al., 2003). Blood glucose DSMB 
could be measured using log books tracking testing and blood glucose levels or by 
downloading blood glucose testing readings directly from an individual’s glucometer 
(Gonzalez et al., 2016; Gonder-Frederick et al., 2016; Mulcahy et al., 2003). Exercise 
DSMB could be measured using a pedometer or any of the number of exercise tracking 
technologies that have been developed recently and are becoming widely available 
(Gonzalez et al., 2016; Gonder-Frederick et al., 2016). Finally, diet DSMB could be 
measured using food diaries-- either paper-pencil or more sophisticated electronic ones 
(Gonzalez et al., 2016; Gonder-Frederick et al., 2016; Mulcahy et al., 2003).   
 There have been no longitudinal studies of the effects of cognitive functioning on 
DSMB completion. Longitudinal methods will be required to assess the dynamic nature 
of DSMB completion (Castellon et al., 2009) and to investigate the interacting effects of 
barriers to DSMB completion at the individual, interpersonal, community, and societal 
level (Johnson & Marrero, 2016). In addition, more studies of the top-down influences of 
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community and societal barriers on the interpersonal and individual barriers are required 
to influence policy in order to ensure that all individuals with T2DM have the opportunity 
and resources to successfully complete their DSMB and manage their T2DM.  
 In vivo studies of DSMB completion are required. A single study has investigated 
the relationship between a sham insulin injection skills test and performance on the Clock 
Drawing Test and the MMSE (Trimble et al., 2005). Poorer performance on the Clock 
Drawing Test was significantly associated with increased likelihood of making serious 
errors on the sham insulin injection task (p = .01) in a sample of 30 older adults. 
However, there was no significant association between performance on the task and 
performance on the MMSE (p > .05, Trimble et al., 2005). Future studies should 
investigate the relationships of multiple cognitive domains and abilities with in-lab 
performance on ecologically valid DSMB tasks such as the sham insulin injection task 
used by Trimble et al. and with other tasks necessary for successful DSMB completion. 
This methodology would be especially important to assess diabetes-related problem 
solving skills such as adjusting insulin doses in response to high or low blood sugar and 
changes in physical activity (Hills-Briggs et al., 2007; Mulcahy et al., 2003).  
These in-vivo studies would also serve the function of providing pilot data for the 
development of interventions to accommodate the effects of changes in cognitive 
functioning on the completion of DSMB. The goal of these interventions would be to 
increase and maintain successful DSMB completion in the face of cognitive deficits or 
declining cognitive functioning (Monette, 2012; Primozic et al., 2012).  Finally, once the 
relationships between cognitive functioning and DSMB have been further elucidated, 
interventions should be developed and validated to counter the impacts of cognitive 
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functioning on DSMB completion and T2DM adherence. This will require the continued 
efforts to train psychologists and neuropsychologists in the disease processes, 
psychosocial, and cognitive aspects of T2DM (Hunter, 2016).  
Conclusion  
 
 The present investigation sought to determine the impact of cognitive functioning 
on DSMB completion and diabetes-related and general QoL. In the prospective study, 
executive functioning objectively measured by phonemic verbal fluency and measured 
using self-report was significantly related to DSMB completion. Objective measures of 
processing speed and executive functioning along with self-report measures of executive 
functioning were significantly related to general QoL. In the archival study cognitive 
functioning as measured by the TICS was not significantly related to DSMB completion 
or impact of diabetes on life.  
 Much more research with varied methodologies is needed to conclusively 
determine the relationships between cognitive functioning, DSMB completion, and QoL. 
Future research is also needed to develop, validate, and implement interventions that can 
remove or accommodate the impact of cognitive deficits on DSMB completion in order 
to allow individuals with T2DM to continue to successfully manage the disease and 
prevent or delay further complications and cognitive impairment. Finally, further research 
is needed to address barriers to DSMB completion and T2DM treatment adherence at the 
individual, interpersonal, community, and societal levels in order to improve the overall 
poor levels of T2DM treatment adherence in the T2DM population as whole.  
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APPENDICES  
Appendix 1 
Demographic Questionnaire/ Interview  
Participant ID:_____________ 
Date (MM/DD/YYYY): ________________ D.O.B. (MM/DD/YYYY): 
_______________ 
Age: ___________ 
Gender: Man  Woman Other: _________________       
Prefer Not To Answer 
Ethnicity: ____________________________________________________ 
Birth Place (City, Province, Country): 
 ___________________________________________________ 
If NOT born in Canada, how many years have you lived in Canada?: 
_______ 
Primary language spoken day-to-day: 
_____________________________________________ 
Fluent in English if primary language is not English:       Yes  No 
Highest Education level attained (Years of education): 
_________________________________ 
Number of years of education in English: __________________________ 
Are you employed?:     
Yes      No                   Other:_______________________ 
If yes, what is your occupation? ________ 
If no, when was the last time you worked? ________________________ 
Current Marital Status: 
a) Single, never married 
b) Married 
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c) Cohabiting  
d) Divorced or separated  
e) Widowed or widower  
f) Other (please specify): _________________________ 
With whom do you live currently? (alone, spouse, other): 
_________________________ 
Do you smoke?: Yes  No 
If YES, on average, how many Cigarettes do you smoke per DAY: _______ 
Do you drink alcohol?: Yes  No 
If YES, on average how many drinks do you have per WEEK: ___________ 
Height: _______________ 
Weight: _______________ 
What is your currently prescribed T2DM treatment regimen?:  
a) Diet & exercise only  
b) Oral hypoglycemic medications: (types and dose) 
c) Insulin (types and dose): 
d) Oral hypoglycemic medications and insulin  
 
Please provide us with your current, most up-to-date medication list: 
Medication Name    Dose  Frequency  
___________________________    __________ ____________________ 
___________________________    __________ ____________________ 
___________________________    __________ ____________________ 
___________________________    __________ ____________________ 
___________________________    __________ ____________________ 
___________________________    __________ ____________________ 
___________________________    __________ ____________________ 
___________________________    __________ ____________________ 
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What was your most recent A1C?: ___________% 
When was it measured?: ____________________ 
When were you diagnosed with diabetes? (years since diagnosis): 
_______________ 
Do you have any complications from your diabetes?:  Yes  No 
If YES, what complications do you have: ____________________ 
Have you ever received a psychiatric diagnosis?:       Yes   No 
Have you ever taken medication for your mood or received psychotherapy?:                                              
                                         Yes   No  
If YES, please specify: __________________________________________ 
Have you been hospitalized in the PAST YEAR (Circle one)?:      Yes      No 
If YES, how many times in the past year: _________________ 
If YES, for what reason: ________________________________________ 
Have you ever been hospitalized specifically for hypoglycemia?:     Yes      
No 
Have you received the “Master Your Health” program?: 
    Yes   No 
Have you received any other diabetes education programs?: 
    Yes   No 
If YES, please specify the program: _______________________________ 
What is your current level of pain from 0-9, 0 being no pain and 9 being the 
most pain you have ever had? ____________ 
What is your chronic level of pain on average from 0-9, 0 being no pain and 
9 being the most pain you have ever had? ____________ 
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Do you take medication for of the following health conditions: 
High Blood Pressure     Yes   No 
High Cholesterol      Yes   No 
Hypothyroidism     Yes   No 
 
(circle point value for endorsement): 
a) Myocardial Infarction (heart attack, 1 point) 
 b) Congestive Heart Failure (1 point) 
c) Peripheral Vascular Disease (blood clots in legs, neuropathy, 1 
point) 
d) Cerebrovascular Disease (stroke, TIA, aneurysm, bleed, 1point) 
e) Peptic Ulcer Disease (acid reflux, 1 point) 
f) Diabetes Mellitus with end-organ damage (1 point) 
g) Moderate to Severe Chronic Kidney Disease (2 points) 
h) Hemiplegia (paralysis, 2 points) 
i) Liver Disease (mild, 1 point) 
j) Liver Disease (moderate to severe, 3 points) 
k) Chronic Obstructive Pulmonary Disease (1 point) 
 
Pre-testing glucometer reading: ______mmol/l 
Completion date of the testing appointment if hypoglycemia was reported 
(MM/DD/YYYY): _____________________ or  
did not participate after hypoglycemia was reported or  
Not Applicable (No hypoglycemia) 
Informant Measures Completed?  Yes  No 
If yes, relationship of informant to participant: ________________________ 
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Appendix 2 
Participant ID:_____________ 
Date (MM/DD/YYYY): ________________  
Diabetes Self-Management Behaviour Questionnaire 
The questions below ask you about your diabetes self-care activities during the past 7 days. If 
you were sick
1
 during the past 7 days, please think back to the last 7 days that you were not sick. 
Diet 
How many of the last SEVEN DAYS have you followed a healthful eating plan? 
0 1 2 3 4 5 6 7 
On average, over the past month, how many DAYS PER WEEK have you followed your eating 
plan? 
0 1 2 3 4 5 6 7 
Exercise 
On how many of the last SEVEN DAYS did you participate in at least 30 minutes of physical 
activity? (Total minutes of continuous activity, including walking). 
0 1 2 3 4 5 6 7 
On how many of the last SEVEN DAYS did you participate in a specific exercise session (such 
as swimming, walking, biking) other than what you do around the house or as part of your work? 
0 1 2 3 4 5 6 7 
Blood Sugar Testing 
On how many of the last SEVEN DAYS did you test your blood sugar? 
0 1 2 3 4 5 6 7 
On how many of the last SEVEN DAYS did you test your blood sugar the number of times 
recommended by your health care provider? 
0 1 2 3 4 5 6 7 
Foot Care 
On how many of the last SEVEN DAYS did you check your feet? 
0 1 2 3 4 5 6 7 
On how many of the last SEVEN DAYS did you inspect the inside of your shoes? 
                                                          
1
 In diabetes treatment regimens “sick days” represent the presence of any acute illness that can affect 
blood glucose levels and requires changes to the routine treatment regimen.  
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0 1 2 3 4 5 6 7 
Medications 
On how many of the last SEVEN DAYS did you take your recommended insulin injections? 
0 1 2 3 4 5 6 7        N/A 
On how many of the last SEVEN DAYS did you take your recommended number of diabetes 
pills? 
0 1 2 3 4 5 6 7        N/A 
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Please answer the following questions as accurately as possible based on how you managed your 
diabetes.  
How many days during the past week (last 7 days) … 
1. …did you miss taking your diabetes medications as prescribed? 
 
0 1 2 3 4 5 6 7 
2. …did you miss monitoring your blood sugar?  
 
0 1 2 3 4 5 6 7 
3. …did you eat foods not healthy for your diabetes?  
 
0 1 2 3 4 5 6 7 
4. …did you eat more food than you were supposed to? 
 
0 1 2 3 4 5 6 7 
5. …did you do at least some light physical activity (such as walking, light gardening)?  
 
0 1 2 3 4 5 6 7 
6. …did you do at least 30 minutes of moderate physical activity (such as pushing a vacuum 
cleaner, riding a bicycle, playing golf)?  
 
0 1 2 3 4 5 6 7 
7. …did you do at least 20 minutes of vigorous physical activity (such as running or 
participating in strenuous sports)?  
 
0 1 2 3 4 5 6 7 
8. During the past week, how much difficulty did you have with (0= no difficulty, 7= the 
most difficulty you have ever had):  
 
a. Monitoring your blood sugar? 
 
0 1 2 3 4 5 6 7 
 
b. Giving yourself your diabetes medications as your doctor instructed? 
 
0 1 2 3 4 5 6 7 
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c. Managing your weight? 
 
0 1 2 3 4 5 6 7 
 
d. Periods of uncontrolled eating? 
 
0 1 2 3 4 5 6 7 
 
e. Feeling hungry? 
 
0 1 2 3 4 5 6 7 
 
f. Food cravings? 
 
0 1 2 3 4 5 6 7 
 
g. Being physically active? 
 
0 1 2 3 4 5 6 7 
 
h. Coping with frustration and worry related to your diabetes? 
 
0 1 2 3 4 5 6 7 
 
9. During the past week (last 7 days), how frustrated have you been with trying to manage 
your diabetes (0= no frustration, 7= the most frustration you have ever had)? 
 
0 1 2 3 4 5 6 7 
 
10. During the past week (last 7 days), how worried have you been about your future health 
because of your diabetes (0= no worry, 7= the most worry you have ever had)? 
 
0 1 2 3 4 5 6 7 
 
11. Overall, how confident have you felt during the past week (last 7 days) about being able 
to manage your diabetes (0= no confidence, 7= the most confidence you have ever 
had)?  
 
0 1 2 3 4 5 6 7 
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12. How important is it for you right now to (0= not important, 7= the most important it 
has ever been):  
 
a. monitor your blood sugar? 
 
0 1 2 3 4 5 6 7 
b. take your diabetes medications as your doctor instructed? 
0 1 2 3 4 5 6 7 
c. manage your weight? 
 
0 1 2 3 4 5 6 7 
d. manage your diet? 
 
0 1 2 3 4 5 6 7 
e. manage your physical activity? 
 
0 1 2 3 4 5 6 7 
f. manage frustration and worry related to your diabetes? 
 
0 1 2 3 4 5 6 7 
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The following statements describe self-care activities related to your diabetes. Thinking about 
your self-care over the last 8 weeks, please specify the extent to which each statement applies to 
you on a 1-4 scale with 1= does not apply to me and 4= applies to me very much. If a question 
asks about a self-care activity that is not part of your diabetes treatment, please circle the N/A 
option. 
1. I check my blood sugar levels with care and attention. 
1 2 3 4  N/A 
2. The food I choose to eat makes it easy to achieve optimal blood sugar levels 
1 2 3 4   
3. I keep all doctors’ appointments recommended for my diabetes treatment.  
  1 2 3 4   
4. I take my diabetes medication (e. g. insulin, tablets) as prescribed.  
 1 2 3 4  N/A 
5. Occasionally I eat lots of sweets or other foods rich in carbohydrates.  
 1 2 3 4   
6. I record my blood sugar levels regularly  
1 2 3 4  N/A 
7. I tend to avoid diabetes-related doctors’ appointments 
 1 2 3 4   
8. I do regular physical activity to achieve optimal blood sugar levels.  
1 2 3 4   
9. I strictly follow the dietary recommendations given by my doctor or diabetes specialist.  
1 2 3 4   
10. I do not check my blood sugar levels frequently enough as would be required for achieving 
good blood glucose control.  
1 2 3 4  N/A 
11. I avoid physical activity, although it would improve my diabetes.  
 1 2 3 4   
12. I tend to forget to take or skip my diabetes medication (e. g. insulin, tablets).  
1 2 3 4  N/A 
13. Sometimes I have real ‘food binges’ (not triggered by hypoglycemia). 
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 1 2 3 4   
14. Regarding my diabetes care, I should see my medical practitioner(s) more often.  
 1 2 3 4   
15. I tend to skip planned physical activity.  
 1 2 3 4   
16. My diabetes self-care is poor. 
 1 2 3 4   
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Participant ID:_____________ 
Date (MM/DD/YYYY): ________________  
Diabetes Self-Management Behaviour Questionnaire (Informant) 
Please think of the individual you care for or live with who has diabetes and answer the following 
questions as accurately as possible.  
The questions below ask you about the diabetes self-care activities of the person with diabetes 
you care for or live with during the past 7 days. If they were sick during the past 7 days, please 
think back to the last 7 days that they were not sick. 
Diet 
How many of the last SEVEN DAYS have they followed a healthful eating plan? 
0 1 2 3 4 5 6 7 DK 
On average, over the past month, how many DAYS PER WEEK have they followed their eating 
plan? 
0 1 2 3 4 5 6 7  DK 
How many days during the past week (last 7 days) did they eat foods not healthy for diabetes? 
0 1 2 3 4 5 6 7  DK 
During the past week (last 7 days), how many days did they eat more food than they were 
supposed to? 
0 1 2 3 4 5 6 7  DK 
Exercise 
How many days during the past week (last 7 days), did they do at least some light physical 
activity (such as walking, light gardening)? 
0 1 2 3 4 5 6 7  DK 
How many days during the past week (last 7 days), did they do at least 30 minutes of moderate 
physical activity (such as pushing a vacuum cleaner, riding a bicycle, playing golf )?  
0 1 2 3 4 5 6 7  DK 
How many days during the past week (last 7 days), did they do at least 20 minutes of vigorous 
physical activity (such as running or participating in strenuous sports)?  
0 1 2 3 4 5 6 7  DK 
Blood Sugar Testing 
On how many of the last SEVEN DAYS did they test their blood sugar? 
0 1 2 3 4 5 6 7  DK 
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On how many of the last SEVEN DAYS did they test their blood sugar the number of times 
recommended by their health care provider? 
0 1 2 3 4 5 6 7  DK 
How many days during the past week (last 7 days) did they miss monitoring their blood sugar? 
0 1 2 3 4 5 6 7  DK 
Medications 
On how many of the last SEVEN DAYS did they take their recommended insulin injections? 
0 1 2 3 4 5 6 7 N/A 
On how many of the last SEVEN DAYS did they take their recommended number of diabetes 
pills? 
0 1 2 3 4 5 6 7 N/A 
How many days during the past week (last 7 days) did they miss taking their diabetes medications 
as prescribed?  
0 1 2 3 4 5 6 7 N/A 
1. Which of the following has their health care team (doctor, nurse, dietitian, or diabetes 
educator) advised them to do? 
Please check all that apply: 
____ a. Follow a low-fat eating plan 
____ b. Follow a complex carbohydrate diet 
____ c. Reduce the number of calories they eat to lose weight 
____ d. Eat lots of food high in dietary fiber 
____ e. Eat lots (at least 5 servings per day) of fruits and vegetables 
____ f. Eat very few sweets (for example: desserts, non-diet sodas, candy bars) 
____ g. Other (specify): ___________________________________________ 
____ h. They have not been given any advice about their diet by their health care team. 
 
2. Which of the following has their health care team (doctor, nurse, dietitian or diabetes educator) 
advised them to do? 
Please check all that apply: 
____ a. Get low level exercise (such as walking) on a daily basis. 
____ b. Exercise continuously for at least 20 minutes at least 3 times a week. 
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____ c. Fit exercise into their daily routine (for example, take stairs instead of elevators, park a 
block away and walk, etc.) 
____ d. Engage in a specific amount, type, duration and level of exercise. 
____ e. Other (specify): _____________________________________________ 
____ f. They have not been given any advice about exercise by their health care team. 
 
3. Which of the following has their health care team (doctor, nurse, dietitian, or diabetes 
educator) advised them to do? 
Please check all that apply: 
____ a. Test their blood sugar using a drop of blood from their finger and a color chart. 
____ b. Test their blood sugar using a machine to read the results. 
____ c. Test their urine for sugar. 
____ d. Other (specify): ___________________________________________________ 
____ e. They have not been given any advice either about testing their blood or urine sugar level 
by their health care team. 
 
4. Which of the following medications for their diabetes has their doctor prescribed? 
Please check all that apply. 
____ a. An insulin shot 1 or 2 times a day. 
____ b. An insulin shot 3 or more times a day. 
____ c. Diabetes pills to control their blood sugar level. 
____ d. Other (specify): ____________________________________________ 
____ e. They have not been prescribed either insulin or pills for their diabetes. 
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The following statements describe self-care activities related to the person with diabetes. 
Thinking of self-care over the last 8 weeks, please specify the extent to which each statement 
applies to this person on a 1-4 scale with 1= does not apply to them and 4= applies to them very 
much. If you are not sure that they complete (or do not complete) the self-care activity, please 
circle the do not know (DK) option.  
1. They check their blood sugar levels with care and attention. 
1 2 3 4  DK  
2. The food they choose to eat makes it easy to achieve optimal blood sugar levels 
1 2 3 4  DK  
3. They keep all doctors’ appointments recommended for their diabetes treatment.  
  1 2 3 4  DK  
4. They take their diabetes medication (e. g. insulin, tablets) as prescribed.  
 1 2 3 4  DK  
5. Occasionally they eat lots of sweets or other foods rich in carbohydrates.  
 1 2 3 4  DK 
6. They record their blood sugar levels regularly  
1 2 3 4  DK 
7. They tend to avoid diabetes-related doctors’ appointments 
 1 2 3 4  DK  
8. They do regular physical activity to achieve optimal blood sugar levels.  
1 2 3 4  DK 
9. They strictly follow the dietary recommendations given by their doctor or diabetes specialist.  
1 2 3 4  DK 
10. They do not check their blood sugar levels frequently enough as would be required for 
achieving good blood glucose control.  
1 2 3 4  DK 
11. They avoid physical activity, although it would improve their diabetes.  
 1 2 3 4  DK  
12. They tend to forget to take or skip their diabetes medication (e. g. insulin, tablets).  
1 2 3 4  DK 
13. Sometimes they have real ‘food binges’ (not triggered by hypoglycemia). 
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 1 2 3 4  DK  
14. Regarding their diabetes care, they should see their medical practitioner(s) more often.  
 1 2 3 4  DK  
15. They tend to skip planned physical activity.  
 1 2 3 4  DK  
16. Their diabetes self-care is poor. 
 1 2 3 4  DK 
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